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Abstract 
Cell biology and biochemical studies of ovine batten disease 
 
by 
Janet Boyu Xu 
 
The neuronal ceroid lipofuscinoses (NCLs, Batten disease) are a group of fatal inherited 
neurodegenerative lysosomal storage diseases of humans, which result in severe cortical 
atrophy, blindness, seizures, and the accumulation of fluorescent lysosome-derived 
organelles in neurons and most other cells throughout the body. Two naturally occurring of 
forms of NCL in sheep, CLN5 and CLN6, are used to study human disorders. A mutation in a 
soluble lysosomal protein (CLN5) causes NCL in Borderdale sheep and the South Hampshire 
sheep have a defective intracellular endoplasmic reticulum membrane protein (CLN6). The 
functions of these proteins are still unclear.  Generation of highly specific and sensitive 
antibodies to these proteins would be very useful for biological and functional studies. 
Studies described in this thesis used ovine CLN5 and CLN6 NCL models to establish the full 
length coding sequences of the genes and expression of the encoded proteins. Antibodies 
against ovine CLN5 and CLN6 were generated and used for characterisation studies of both 
proteins in vitro.  
The full length ovine CLN5 gene sequence was amplified using a two-step PCR and ligation 
strategy with internal overhanging primers. Ovine CLN5 exon 1 has an allelic variant, but it 
was not associated with the CLN5 sheep mutation. Recombinant ovine CLN5 and CLN6 
proteins were not expressed in Escherichia coli (E. coli) prokaryotic systems, perhaps 
because the gene sequences may be toxic to the host. 
Recombinant ovine CLN5 and CLN6 proteins were expressed successfully in eukaryotic 
mammalian cells using lentiviral vectors. The adenoviral antibodies against ovine CLN5 and 
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CLN6 specifically recognized ovine CLN5 and CLN6 as shown by immunocytochemistry, 
Western blotting and mass spectrometry. The rabbit anti-CLN5 antibodies specifically 
identified the ovine mature CLN5 glycosylated form with a molecular weight of 60 kDa in 
media and cells and a molecular weight of 35 kDa when deglycosylated by PNGase F. The 
rabbit anti-CLN6 antibodies specifically detected overexpressed ovine CLN6 at molecular 
weight of 27 kDa in cells by Western blotting. Mass spectrometry revealed that the CLN5 N-
signal sequence is cleaved off when it is mature. The deglycosylation study confirmed that 
CLN5 is a soluble glycosylated protein, containing high-mannose or complex type glycans at 
six out of eight predicted N-glycosylation sites. 
A lysosomal localisation of ovine CLN5 study was confirmed by rabbit anti-CLN5 antibodies 
labelling of the cells that also expressed the lysosomal associated membrane protein LAMP1, 
while ER intracellular localisation of ovine CLN6 was revealed by co-staining with rabbit anti-
CLN6 antibodies and an ER marker. The CLN5 antibodies also detected endogenous CLN5 
expression throughout the normal sheep and human brains. This study also provides 
evidence for the hypothesis of interactions between CLN5 and CLN6 in cultured and virally 
transduced neural cell lines using the anti-CLN5 and anti-CLN6 antibodies.  Co-expression of 
CLN6 and CLN5 up-regulated CLN5 expression in CLN5 affected cells.  
In conclusion, the work described in this thesis elucidates the capability of lentiviral system 
expression of CLN5 and CLN6 proteins, and proved the reliability of the generated adenoviral 
CLN5 and CLN6 antibodies. 
 
 
 
 
 
Keywords: Batten disease, neuronal ceroid lipofuscinosis, lysosomal storage disease, animal 
models, sheep, brain, CLN5, CLN6, proteins, antibodies. 
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Literature Review 
1.1 Overview of the neuronal ceroid lipofuscinoses 
The neuronal ceroid lipofuscinoses (NCLs, Batten disease) are a group of fatal 
neurodegenerative lysosomal storage diseases (LSD) of humans and other animals. Most are 
autosomal recessively inherited diseases. All forms share two definitive hallmarks; severe 
brain atrophy (progressive loss of neurons) and the accumulation of fluorescent lysosome-
derived organelles (storage bodies) in neurons and most other cells throughout the body 
(Palmer et al., 2015). Retinal degeneration is also a common feature. Affected children start 
life normally but then develop personality and behavioural changes, progressive visual 
failure, and mental and motor deterioration. They suffer nightmares, fits and seizures, and 
die between 7 years old and adulthood (Goebel et al., 1999; Mole et al., 2005; Mole et al., 
2011). The traditional estimate of incidence of 1 in 12,500 live births (Rider and Rider, 1988) 
was once thought to be pessimistic, but now seems realistic as a higher frequency becomes 
apparent with improved diagnosis. The causes and development of these devastating 
neuropathies are still poorly understood, and current treatment options mostly are limited 
to alleviating the symptoms. 
1.2 History of human NCLs 
The first clinical description of the NCLs was made by Dr. Otto Christian Stengel in 1826 
(Stengel, 1982). His article in the Norwegian Medical Journal reported a singular illness in 
four siblings, who were healthy until the age of six. Starting with sight decline, the disease 
course led to blindness, gradual loss of intellect and speech, followed by epileptic fits and 
death in the twenties. After almost a century of being undocumented, the disease was 
reported again by Batten in 1903 and by Vogt in 1905 (Hoffman, 1956). A number of reports 
of further childhood forms with progressive vision loss and mental retardation followed 
(Haltia, 2006). Despite the variation in the molecular genetics and clinical features, all the 
forms share unifying pathomorphological features, and for a long time were grouped as 
“amaurotic family idiocy” along with Tay-Sachs disease, before being recognised as a 
separate disease.  
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The field remained unclear until Zeman and Dyken introduced the new term neuronal 
ceroid-lipofuscinosis (NCL) in 1969, according to the histochemical and electron microscopic 
features of the storage material (Zeman and Dyken, 1969). The NCLs were then divided into 
four subtypes based on the ages of onset, the clinical features and the ultrastructure of the 
storage material (Haltia, 2003). These four types are infantile NCL (INCL), late-infantile NCL 
(LINCL), juvenile NCL (JNCL) and adult NCL (ANCL). In the late 1980s and 1990s, two major 
hydrophobic proteins were found to be specially stored in the NCL storage cytosomes: either 
subunit c of mitochondrial ATP synthase (Palmer et al., 1989; Palmer et al., 2015) or the 
sphingolipid activator proteins, SAPs A and D (Tyynelä et al., 1993). Since the first gene 
responsible for the INCL form was identified in 1995 (Vesa et al., 1995), a number of 
different genes have been discovered which underlined the different human NCLs. Currently, 
mutations in a total of 13 different genes are known to cause human NCLs and each gene is 
responsible for a form designated as CLNs 1-8 and 10-14 (NCL mutation database; 
http://www.ucl.ac.uk/ncl/mutation.shtml, 2017). There may be more yet to be discovered.  
1.3 Lysosomes and lysosomal storage diseases 
Lysosomes are acidic membrane bound organelles found in many eukaryotic cells (Vellodi, 
2005), and they contain different soluble digestive enzymes (Futerman and van Meer, 2004; 
Sleat et al., 2013). Over 60 lysosomal proteins were identified in earlier studies (Sleat et al., 
1996, 2005, 2007, 2008a), and more than 165 murine proteins may be lysosomal proteins 
(Sleat et al., 2013). Lysosomes break down macromolecules in the cells (i.e. proteins, 
carbohydrates, nucleic acids and lipids) to subunits such as sugars and amino acids that the 
cell can either utilize or excrete (Luzio et al., 2007). They act as a waste disposal system for 
the cell by digesting unwanted materials from the cytoplasm, and from outside the cells. 
Therefore the lysosome is a key organelle in the regulation of cellular homeostasis. All the 
lysosomal enzymes are optimally active at an acidic pH of 4.5-6 (Marshansky and Futai, 
2008).  Abnormal lysosomal functions consequent to loss of acidity or mutations in the 
lysosomal enzyme related genes can result in failures to fully catabolize or process 
macromolecules, which then accumulate in lysosomes; hence the description lysosomal 
storage diseases (LSDs) (Futerman and van Meer, 2004).    
The LSDs are a group of 50 inherited diseases (Futerman and van Meer, 2004; Platt et al., 
2012; Bailey, 2017) with a combined incidence estimated at around 1:5,000 live births (Fuller 
et al, 2006). The NCLs are LSDs, as they are recessively inherited and characterized by the 
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abnormal accumulation of material in lysosomes. NCLs are divided into two groups based on 
the composition of the storage bodies (Table 1.1): those storing sphingolipid activator 
proteins (saposins or SAPs A and D), including CLN1, CLN4 and CLN10; while storage of 
subunit c of mitochondrial ATP synthase is found in CLNs 2-3 and 5-8 (Palmer et al., 1992, 
2015; Haltia, 2006), where gene mutations result in specific subunit c accumulation. The 
reasons for these specific protein storage disorders remain unclear. 
1.4 Molecular genetic classification of NCLs 
The NCLs were historically classified into four types, INCL, LINCL, JNCL and ANCL, based on 
the ages of onset of clinical symptoms. Since then, extensive human molecular genetics and 
biochemical studies have increased our knowledge of the different genetic variants (Mole et 
al., 2004). Mutations in different NCL genes can cause a similar clinical phenotype, such as 
the LINCL-like forms, caused by deficiencies in CLN5, CLN6, CLN7 or CLN8 (Warrier et al., 
2013). Mutations in the same gene can also cause different disease courses (Kousi et al., 
2012; Warrier et al., 2013). In light of this, recent information on the NCL related genes and 
mutations, a new classification of the human NCLs has been developed that includes 13 
genes whose deficiencies result from a current total of 446 mutations 
(http://www.ucl.ac.uk/ncl/mutation.shtml, 2017). These classifications are based on the 
defective genes as well as the age of onset (Table 1.1). More mutations may be discovered. 
However, the more recently discovered variants (CLN11-14) do not always meet all the 
classification criteria (Palmer et al., 2013). 
Cases of this disorder are also classified into two groups based on the types of gene products 
(Table 1.1); soluble lysosomal proteins (CLN1, CLN2, CLN5, CLN10, and CLN13) or putative 
membrane bound proteins (CLN3, CLN6, CLN7, CLN8, CLN12 and CLN14).  
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Table 1.1 Genetic classification of the human NCLs 
(From Kousi et al., 2012; Cotman et al., 2013; Kollmann et al., 2013; Warrier et al., 2013) 
Gene/ 
NCL form 
Locus Major subtype NCL Gene 
product 
Protein type/ cellular 
localisation 
Storage 
proteins 
CLN1 1p32 Classic infantile PPT1 Soluble/lysosomal matrix SAP A and D 
CLN2 11p15 Classic late 
Infantile 
TPP1 Soluble/lysosomal matrix Subunit c 
CLN3 16p12 Classic juvenile CLN3 Membrane bound/lysosomal 
membrane 
Subunit c 
CLN4/ 
DNAJC5 
20q13.33 Adult (Parry 
disease) 
CSP Membrane bound/synaptic 
vesicles 
SAP A and D 
CLN5 13q21-32 Variant late 
infantile 
CLN5 Soluble/lysosomal matrix Subunit c 
CLN6 15q23 Variant late 
infantile 
CLN6 Membrane bound/ER 
membrane 
Subunit c 
CLN7 4q28.1-
28.2 
Variant late 
infantile 
MFSD8 Membrane bound/lysosomal 
membrane 
Subunit c 
CLN8 8p23 Late infantile, 
Northern epilepsy 
CLN8 Membrane bound/ER-Golgi 
membrane 
Subunit c 
CLN10 
(CTSD) 
11p15.5 Congenital Cathepsin D Soluble/lysosomal matrix SAP A and D 
CLN11/ 
GRN 
17q21 Adult Progranulin Extracellular  
CLN12/ 
ATP13A2 
1p36 Juvenile P-type ATPase Membrane bound/lysosomal 
membrane 
 
CLN13/ 
CTSF 
11q13 Adult Kufs type B Cathepain F Soluble/lysosomal matrix  
CLN14 7q11.21 Infantile KCTD7 Membrane bound/cytosolic 
membrane associated 
 
 
Abbreviations: CLN1 etc, ceroid lipofuscinosis, neuronal 1 etc; CSP, cysteine string protein; DNAJC5, DnaJ (Hsp40) 
homolog, subfamily C, member 5; ER, endoplasmic reticulum; KCTD7, potassium channel tetramerization 
domain-containing protein 7; MFSD8, major facilitator superfamily domain containing 8; PPT1, palmitoyl protein 
thioesterase I; SAP, sphingolipid activator protein; SCAR7, autosomal recessive spinocerebellar ataxia type 7; 
TPP1, tripeptidyl peptidase I.  
 
CLN1 
The gene CLN1 was first localised to human chromosome 1p32 (Jӓrvelӓ et al., 1991), and 
found to encode a functional enzyme, palmitoyl protein thioesterase 1 (PPT1) (Vesa et al., 
1995). PPT1 is a small glycoprotein postulated to be involved in the catabolism of lipid-
modified proteins during lysosomal degradation (Vesa et al., 1995). The crystal structure of 
PPT1 indicates that the CLN1 mutations affect catalysis, substrate binding or cause improper 
folding of the core, resulting in enzyme dysfunction (Bellizzi et al., 2000). Studies have 
suggested that the CLN1 protein is localised in synaptosomes and synaptic vesicles in 
neuronal cells, while it also acts as a soluble lysosomal protein targeted to lysosomes 
(Hellsten et al., 1996). 
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A major founder effect has caused a high incidence of a particular mutation of the CLN1 
gene in Finland, the cause of classical infantile NCL (INCL) (Vesa et al., 1995; Bellizzi et al., 
2000). Development of affected children is normal until 3-18 months of age, and they die 
between 6 and 15 years of age (Siintola et al., 2006). In addition, other mutations in the 
CLN1 gene are associated with LINCL, JNCL and ANCL variants (Das et al., 1998; Diggelen et 
al., 2001). A total of 67 disease-causing mutations have been described in the CLN1 gene 
(NCL Mutation Database, http://www.ucl.ac.uk/ncl/CLN1mutationtable.htm, 2017). 
CLN2 
CLN2, localised to chromosome 11p15 by homozygosity mapping, encodes the lysosomal 
enzyme tripeptidyl peptidase (TPP1) (Sleat et al., 1997). Mutations in it lead to a severe 
deficiency in TPP1 (Sleat et al., 1997; 2008b). Loss of TPP1 activity is associated with the 
specific accumulation of subunit c of ATP synthase (Palmer et al., 1992). Affected children 
show clinical symptoms from the age of 2-4 years. They suffer seizures, ataxia, 
developmental and mental retardation, visual impairment and speech loss before death in 
mid-childhood. Most of the published 116 mutations 
(http://www.ucl.ac.uk/ncl/CLN2mutationtable.htm, 2017) lead to the classical LINCL 
phenotype but a few cases with a juvenile NCL phenotype have been also reported (Sleat et 
al., 1997; Bessa et al., 2008).  
CLN3 
Mutations in CLN3 cause juvenile CLN3 disease, the most common subtype of NCL. First 
described were two separate mutations and a point mutation in the CLN3 gene (Lerner et al., 
1995). CLN3, mapped to chromosome 16p12 (Mitchison et al., 1994), encodes a putative 
lysosomal transmembrane protein with 6 transmembrane domains, both the N- and C- 
termini being in the cytosolic (Mao et al., 2003). Affected patients show progressive visual 
failure from the age of 5-10 years, followed by seizures and complete motor deterioration, 
with death occurring in the third decade or earlier (Munroe et al., 1997). Over 67 disease 
associated mutations have been reported, and most of the cases share prematurely 
truncated protein products (http://www.ucl.ac.uk/ncl/CLN3mutationtable.htm, 2017). 
CLN4 
CLN4 is autosomal-dominant adult onset NCL, first described in the 1970s, that is named 
Parry disease (Boehme et al., 1971). Following genetic analyses of affected ANCL families, 
 23 
researchers identified a unique heterozygous mutation in DNAJC5 encoding cysteine-string 
protein alpha (CSPα), and found a reduced amount of CSPα in neuronal cells of affected 
cases (Noskova et al., 2011). Another subtype, the autosomal recessive of ANCL, referred to 
as Kufs disease, affects individuals aged between 25 and 46 years, starting with progressive 
epilepsy, behaviour changes, and movement disorders (Noskova et al., 2011). The main 
clinical symptom is dementia, and patients die about 10 years after onset (Siintola et al, 
2006; Noskova et al., 2011). The CLN4/DNAJC5 gene was localised in 20q13.33, and two 
mutations in exon 3 have been reported from ANCL affected cases so far (Noskova et al., 
2011).  
2008).  
CLN5 
See section 1.6.  
CLN6 
See section 1.7.  
CLN7 
A variant form of LINCL originally detected in Turkish patients was referred as CLN7 (Wheeler 
et al., 1999). Patients show clinical features from the age of 2 to 7 years, with rapid visual 
loss, mental and motor regression, seizures, and all die prematurely (Kousi et al, 2012). The 
CLN7 protein is encoded by MFSD8 (major facilitator superfamily domain 8-containing gene), 
localised on chromosome 4q28.1-q28.2 (Siintola et al., 2007). CLN7 patients have been 
diagnosed in many populations since then, including Pacific Islanders (Kousi et al., 2012)  and 
a total of 38 mutations have been reported so far 
(http://www.ucl.ac.uk/ncl/CLN7mutationtable.htm, 2017). 
CLN8 
CLN8 which maps to chromosome 8p23 is the causative gene for Northern epilepsy, also 
called progressive epilepsy with mental retardation (EPMR) (Ranta et al., 1999). It encodes a 
putative membrane protein predicted to have five transmembrane domains, and to reside in 
the ER and ER-Golgi intermediate compartments in non-neuronal cells, while localized 
outside the ER in neurons (Lonka et al., 2000). The function of the CLN8 protein remains 
unclear. A total of 31 mutations identified in CLN8 
(http://www.ucl.ac.uk/ncl/CLN8mutationtable.htm, 2017) cause two distinct diseases, EPMR 
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and late infantile variant NCL (Kousi et al., 2012). The CLN8 vLNCL form has an earlier onset 
(from 2-7 years) and more a rapid disease course than the EPMR form (from 5-10 years).  
CLN10 (CTSD) 
A mutation in the well-known cathepsin D gene (CTSD) was found to cause a naturally 
occurring ovine congenital NCL disease (Tyynelä et al., 2000) and a similar disease was later 
reported in humans (Siintola et al., 2006). The CTSD gene is localised to chromosome 
11p15.5, and mutations that entirely abolish CTSD activity result in the most severe NCL, 
congenital NCL, CLN10 (Tyynelä et al., 2000; Siintola et al., 2006b). CTSD is an aspartyl 
protease, a soluble lysosomal protein. A total of 10 mutations have been reported in 
patients (Siintola et al., 2006b; Hersheson et al., 2014; Doccini et al., 2016; 
http://www.ucl.ac.uk/ncl/CLN10CTSDmutationtable.htm, 2017). The onset in new born 
babies includes respiratory insufficiency and seizures that may have begun before birth. 
Death occurs within hours to weeks of birth. Patients have smaller brains and a firmer gyral 
pattern than normal following a developmental delay occurring between the 30th and 32nd 
week of gestation (Kousi et al., 2012). Patients with later onset forms (early school age or 
even later) present with ataxia, blindness, loss of speech, and motor dysfunction (Kousi et 
al., 2012). 
CLN 11-14 
The recently identified CLNs 11-14 do not meet all the clinical or neuropathological criteria 
for NCL classification and mutations in some of the genes implicated are associated with 
other diseases. Thus, there is less certainty about their inclusion into the NCL family (Palmer 
et al., 2013). 
CLN11: CLN11 disease, caused by a mutation in the progranulin gene (GRN), was reported to 
cause an adult onset NCL in a single -family (Smith et al., 2012). The affected patients 
presented with rapidly progressive visual failure and seizures. GRN is on chromosome 
17q21.32, and encodes progranulin, a secretory glycoprotein of unknown function.  
CLN12: Mutations in ATP13A2 have been found to cause Kufor-Rakeb syndrome, a rare 
Parkinsonism disorder (Dehay et al., 2012), and also a juvenile onset NCL (CLN12) in a single 
family with learning difficulties (Bras et al., 2012). ATP13A2 encodes a lysosomal type 5 P-
type ATPase predicted to have 10 transmembrane domains (Dehay et al., 2012). 
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CLN13: Mutations in the cathepsin F (CTSF) gene have been discovered to cause an 
autosomal recessive dementia with adult onset NCL (CLN13), Kufs Type B (Smith et al., 
2013).  
CLN14: The CLN14/KCTD7 gene encodes the potassium channel tetramerization domain – 
containing protein 7 (Kousi et al., 2012; Farhan et al., 2014), a highly conserved protein that 
is located in the cytoplasm and expressed in the brain. Mutations in KCTD7 have been 
described in INCL as well as in infantile progressive myoclonic epilepsy (Van Bogaert et al., 
2007; Kousi et al., 2012).  
1.5 Animal models of NCL 
The first description of an animal form of NCL was from English setters (Koppang, 1962, 
1970). Since then spontaneous forms of NCL were discovered in other breeds of dogs (Jolly 
et al., 1994; Melville et al., 2005; Palmer et al., 2011), as well as in cats (Bildfell et al., 1995), 
sheep (Jolly and West, 1976; Jolly et al., 1980; Cook et al., 2002; Jolly et al., 2002), goats (Fisk 
and Storts, 1988), cattle (Harper et al., 1988; Hafner et al., 2005), horses (Url et al., 2001), 
pigs (Cesta et al., 2006), ferrets (Nibe et al., 2011) and mice (Bronson et al., 1998; Ranta et 
al., 1999; Gao et al., 2002; Cooper et al., 2006; Shacka, 2012).  
Colonies of animal models in which all affected individuals have the same mutation are 
particularly valuable tools for determining the pathophysiology of disease and for validating 
therapeutic strategies. The work described in this thesis is based on the natural occurrence 
of the two forms of NCL in sheep, CLN5 and CLN6. Sheep have a large human-like brain and 
human-like physiology, and their longer life expectancy than rodent have allows for 
investigations of the long-term effects of treatments. Because of their relevance to humans, 
the findings of studies in sheep have been world leading. There is a rapidly growing demand 
for large animal model studies.  For instance these have recently become mandatory for the 
US Federal Drug Agency approval of therapeutic drugs.  Being domestic production animals, 
sheep are bred for easy care and are used to human handling, making them ideal for this 
purpose and remarkably cost effective compared with the alternatives, particularly when 
managed in a New Zealand pastoral environment.  An initiative is underway to ensure that 
the strategies, skill-sets and facilities developed in these studies become available for other 
investigations, as this utilisation of pastoral sheep is a growing niche area for research. 
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1.6 CLN5 
1.6.1 Human CLN5 
CLN5 NCL first described as a Finnish variant late infantile neuronal ceroid lipofuscinosis, was 
mapped to chromosome 13q22 (Savukoski et al., 1998). Later studies identified CLN5 
mutations in a variety of populations and also causative of juvenile and adult forms (Cannelli 
et al., 2007; Xin et al., 2010; Kousi et al., 2012). The gene consists of four exons, spanning 
over 13 kb of genomic DNA. The human CLN5 coding sequence contains four possible ATG 
initiation sites. Initially, the first ATG was suggested as the initiator of translation which 
would yield a 407 amino acid protein (about 47 kDa) containing two transmembrane 
domains (Savukoski et al., 1998).  In subsequent protein expression experiments, CLN5 was 
expressed as a 60 kDa glycoprotein that was shifted to 38 KDa after deglycosylation with 
PNGase F (Isosomppi et al., 2002). It was then concluded that the fourth ATG in humans is 
the major initiation site. A SignalP V2.0 program (http://www.cbs.dtu.dk/) predicted that the 
human CLN5 polypeptide undergoes proteolysis of the N-terminal signal peptide, resulting in 
a theoretical molecular weight of 36.6 kDa protein (Isosomppi et al., 2002).  
So far, 36 different CLN5 mutations are known to occur in humans. The most common 
mutation among patients with Finnish vLINCL is a 2 bp deletion in exon 4 (c.1175delAT), 
resulting in a truncated protein (http://www.ucl.ac.uk/ncl/CLN5mutationtable.htm, 2017).  
As the mutant protein showed defective intracellular lysosomal targeting, Isosomppi et al. 
(2002) suggested that the pathogenesis of this type of CLN5 may be associated with 
defective lysosomal trafficking and prevention of its normal biological function.  
The CLN5 protein does not share significant homology with other known proteins and its 
function is still unclear. CLN5 encodes a soluble lysosomal glycoprotein with eight putative 
N-glycosylation sites (Isosomppi et al., 2002; Sleat et al., 2006a). Localisation studies have 
suggested that various N-glycosylation sites of CLN5 have different effects on folding, 
trafficking and the lysosomal function of CLN5 (Moharir et al., 2013).   
1.6.2 CLN5 animal models 
Naturally occurring CLN5 NCLs have been found in cattle (Houweling et al., 2006), sheep 
(Jolly et al., 2002), Border Collie dogs (Melville et al., 2005) and Golden Retriever dogs 
(Gilliam et al., 2015), with disease courses matching human CLN5. A CLN5 knock-out mouse 
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model has been generated by deletion of exon 3 (Kopra et al., 2004). However, these mice 
are not characterised by the severe brain atrophy seen in humans, sheep and dogs.  
Studies on sheep models of NCLs offer significant benefits. The clinical progression in sheep 
is more similar to that of human NCL patients than that in mice. Domestic sheep are easy to 
maintain and manage. In New Zealand, Borderdale sheep have been found with a naturally 
occurring NCL (Jolly et al., 2002). The affected sheep present with blindness from 10 months 
of age, have a tendency to walk in circles when disturbed, and move toward humans rather 
than away from them (Jolly et al., 2002). The causes of blindness are atrophy of the occipital 
cortex and loss of photoreceptors from the retina. 
 
 
Figure 1.1  A schematic diagram of ovine CLN5 with the location of the known mutation indicated by the 
black arrow 
The naturally occurring form of CLN5 in Borderdale sheep results from a single substitution at a consensus 
splice site, causing a deletion of exon 3 and a truncated putative protein (Frugier et al. 2008). 
 
The accumulation of subunit c of mitochondrial ATP synthase was detected in the affected 
Borderdale sheep and the cause of disease traced to a mutation in CLN5 (Frugier et al., 
2008). A flock of these sheep has been established for research, which is particularly 
relevant to the human CLN5 late infantile form but also soluble enzyme forms of NCLs in 
general. The ovine CLN5 cDNA has been sequenced (NM_001082595), and has a single start 
codon that aligns best with the third ATG of the human CLN5 sequence (Frugier et al., 2008). 
CLN5 is located on sheep chromosome 10, contains four exons (Figure 1.1), and encodes a 
predicated 361 amino acid protein. The mutation in Borderdale sheep causes a nucleotide 
substitution at a consensus splice site in the ovine CLN5 gene (c.571+1G>A) with subsequent 
excision of exon 3 (Figure 1.1) yielding a truncated putative protein (Frugier et al., 2008). 
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1.7 CLN6 
1.7.1 Human CLN6 
Human CLN6 is located on chromosome 15q21-q23 (Wheeler et al., 2002), and has a 
predicted open reading frame of 933 nucleotides in seven exons which span a genomic 
region of approximately 23 kb (Gao et al, 2002). It encodes a highly conserved non-
glycosylated, 311 amino acid protein, with a putative N-terminal cytoplasmic domain, seven 
predicted transmembrane domains, followed by a C-terminus (Gao et al., 2002; Heine et al, 
2004; Mole et al., 2004). It is thought to be localised in the ER (Mole et al., 2004).  
Raising antibodies against peptide fragments of the CLN6 sequence has proved to be 
problematic but it has been reported that antisera raised against CLN6 detected a 27-30 kDa 
band (Heine et al, 2004; Mole et al., 2004). The CLN6 sequence has not been assigned to any 
family of proteins. It is highly conserved across mammalian species, human CLN6 being 92% 
identical to the sheep gene (Tammen et al., 2006), and 90.3% to the mouse gene (Gao et al., 
2002). The majority of the differences were in exon 1. No function has yet been assigned for 
the CLN6 protein, and it is still unclear how defects in, or absence of, CLN6 leads to 
lysosomal dysfunction (Heine et al, 2004; Mole et al., 2004). However, it has been suggested 
that CLN6 plays a role in endocytosis of lysosomal proteins. A number of mutant CLN6 
polypeptides are transported to lysosomes, may be via the endosomal compartment. The 
endocytic pathway is reduced in cultured CLN6 deficient fibroblasts (Heine et al, 2004). It has 
also been reported that mutant CLN6 proteins are degraded 3-20 fold faster that wild type 
ones (Kurze et al., 2010). 
The majority of mutations in CLN6 result in variant late infantile NCLs (vLINCL; MIM# 
601780). To date, 71 disease-causing mutations have been identified from 20 countries 
(http://www.ucl.ac.uk/ncl/CLN6mutationtable.htm, 2017). Ages of onset range from 18 
months to 8 years, the majority being between 3 and 5 years (Mole et al., 2005). Symptoms 
are developmental mental retardation followed by speech impairment, seizures, ataxia, 
motor delay and visual loss. After deteriorating rapidly, most affected children die between 
the ages of 5 and 12 years.  
CLN6 mutations have also been reported in NCLs with teenage and juvenile onsets (Andrade 
et al., 2012; Faruq et al., 2013) and Kufs disease Type A (Arsov et al., 2011).  The teenage 
onset patients showed progressive myoclonus epilepsy; whereas the juvenile onset patients 
 29 
presented with cerebellar ataxia with seizures. The CLN6 Kufs disease Type A patients are 
quite different from the other CLN6 patients (Arsov et al., 2011).  The age of onset is 
between 30 and 50 years with progressive myoclonus epilepsy and loss of intellect, but not 
visual loss. It is unclear why different mutations in CLN6 lead to different disease phenotypes 
and there are no effective treatments for CLN6 patients.  
1.7.2 CLN6 animal models 
Naturally occurring NCLs have been diagnosed in animals and localized to CLN6, including 
the nclf mouse (Bronson et al., 1998; Gao et al, 2002; Wheeler et al., 2002), the New Zealand 
South Hampshire (SH) sheep, and the Australian Merino sheep (Jolly and West, 1976; Jolly et 
al., 1980; Tammen et al., 2001, 2006; Cook et al., 2002). Both affected sheep breeds have 
also been called OCL sheep, and provide excellent large animal models for studies of CLN6 
disease progression and for testing treatments.  
CLN6 affected SH sheep develop clinical symptoms between 10 and 14 months of age, 
notably blindness. The course of the disease is similar to the CLN5 form in Borderdale sheep, 
but brain atrophy is less severe and the sheep die by the age of 2 years (Jolly et al., 1982, 
1989, 2002). CLN6 affected Merino sheep develop clinical symptoms between 7 and 12 
months of age, with similar disease progression to that seen in SH sheep (Tammen et al., 
2001; Cook et al., 2002; Palmer et al., 2011). The accumulated storage material, subunit c of 
mitochondrial ATP synthase was first identified in the SH sheep model (Palmer et al., 1989) 
and proved to be a major descriptor of this disorder in humans and other animal models 
(Palmer, 2015).  
Linkage studies positioned the genetic lesion in the SH sheep to ovine chromosome 7q13–
15, homologous to the human CLN6 location on chromosome 15q21–23 (Broom et al., 
1998). The Merino NCL has also been linked to the same region on chromosome 7 (Tammen 
et al., 2001). Ovine CLN6 (NM_001109984) contains seven exons (Figure 1.2). A missense 
mutation (c.184C>T) causes CLN6 disease in Merino sheep, whereas affected South 
Hampshire sheep have a large 5’UTR exon 1 deletion (see comments on Figure 1.2) and 
reduced levels of CLN6 mRNA (Tammen et al., 2006). A silent polymorphism (c.822G>A) was 
also found in both New Zealand SH and Australian Merino sheep (Tammen et al., 2006).  
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Figure 1.2  A schematic diagram of the ovine CLN6 with the locations of the known mutations and 
polymorphism indicated by black arrows 
The naturally occurring form of CLN6 in South Hampshire sheep results from a single base insertion and a major 
401 base deletion from the 5’ UTR of the gene to intron 1 (Mohd Ismail, 2014). A single substitution in exon 2 
(c.184C>T) results in ovine CLN6 in Australian Merino sheep (Tammen et al., 2006). 
1.8 N-glycosylation and lysosome protein trafficking pathways 
Proteins can be post-translationally modified by the addition of oligosaccharides to form 
glycoproteins, in a process called glycosylation. N-linked glycosylation refers to the 
attachment of oligosaccharides (known as glycans) to the amide nitrogen on the side chain 
of asparagine (Asn). Both secreted and membrane-bound proteins in eukaryotes can 
undergo N-glycosylation. Addition of an N-glycan to a protein has several roles (Imperiali and 
O'Connor, 1999; Shental-Bechor and Levy 2009; Sinclair and Elliott, 2005). Firstly, adding 
glycans can enhance the solubility and stability of proteins in the ER-Golgi membranes and 
on the outside of cell membrane. Secondly, N-glycans can signal trafficking. They can 
determine when to transport a protein to the Golgi apparatus or to target it for degradation, 
for instance, in case of major folding defects.  
N-linked glycosylation begins in the ER and continues in the Golgi apparatus in eukaryotes 
(Stanley et al., 2009). Biosynthesis starts with the addition of a large oligosaccharide 
precursor from dolichol to which it is attached by a diphosphate linkage (Figure 1.3). Dolichol 
is a lipid molecule, embedded in the phospholipid bilayer of the ER membrane and acts as a 
carrier for the oligosaccharide. The transferred glycan is a branched oligosaccharide, 
containing three glucose (Glc), nine mannose (Man), and two N-acetylglucosamine (GlcNAc) 
residues (Figure 1.3, in the red rectangle). Five of its 14 residues are essentially core in the 
structures of all N-linked oligosaccharides, being two GlcNac and three Man residues (Figure 
1.3, in the purple rectangle). 
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Figure 1.3 Glycan processing in ER and Golgi membranes 
Modified from Drickamer and Taylor (2006).  
 
As a nascent polypeptide moves into the lumen of the ER, the entire glycan is transferred 
from the dolichol carrier to an asparagine residue on the polypeptide (Figure 1.3). The 
asparagine must be located within the consensus sequence, Asn-X-Ser/Thr where X is any 
amino acid except proline (Drickamer and Taylor, 2006). Not all Asn-X-Ser/Thr sequences 
become glycosylated. For instance, the rapid folding of a segment of a protein containing an 
Asn-X-Ser/Thr sequence may prevent the transfer of a glycan to it. 
After attachment the glycan is used as a label molecule in the folding process (Drickamer and 
Taylor, 2006). The majority of glycoproteins require at least one glycosylated residue in 
order to achieve proper folding in the ER. Once the protein is folded correctly, three glucose 
and one mannose residues are removed from the oligosaccharide chains. This initial 
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trimming process acts as a quality control step to monitor folding. Without proper folding 
the glucose residues are not removed and the glycoprotein does not leave the ER.  
Properly folded glycoproteins are transferred from the ER to the cis-Golgi network where the 
glycans are modified to three mature types: high mannose, complex and hybrid (Drickamer 
and Taylor, 2006) (Figure 1.3). High mannose glycans have just two GlcNac with many 
mannose residues, often almost as many as in the precursor oligosaccharides before 
attachment. Complex type glycans contain almost any number of the other types of 
saccharides (mainly combinations of mannose, GlcNac, N-acetylgalactosamine, fucose and 
sialic acid residues). Hybrid type glycans contain mannose residues on one side of the 
branch, while on the other side a GlcNac initiates a complex branch. The structure of each 
type is different in different proteins and only some examples of the process are depicted in 
Figure 1.3.  
The high-mannose glycans (Figure 1.3, in the black square) can have one or more mannose 
residues that are phosphorylated on their 6-carbon atoms, forming mannose-6-phosphate 
residues (M6P). These phosphorylated glycans bind to M6P receptors in the trans-Golgi at a 
slightly acidic pH (≈ 6.5 – 7) and are trafficked via the M6P-dependent pathway (Figure 1.4). 
They are then collected via the cytosolic tails of the M6P receptors and transferred by 
clathrin-coated vesicles to late endosomes (LE), where the M6P receptors disassociate as the 
pH decreases (5.5) and are then dephosphorylated. Lysosomal membrane proteins (Figure 
1.4, labelled with black arrows) are not phosphorylated. Instead their cytosolic tails bind as 
do the tails of M6P receptors. These glycoproteins are transported to the lysosomes, while 
the M6P receptors recycle back to the trans-Golgi network. M6P receptors are also found on 
the plasma membrane.  
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Figure 1.4 The mannose 6 phosphate (M6P) pathway, a major route for lysosomal proteins to lysosomes 
Lysosomal proteins migrate from the ER to the cis-Golgi apparatus where mannose residues are 
phosphorylated. The phosphorylated proteins bind to M6P receptors in the trans-Golgi, and form vesicles that 
fuse with late endosomes, where the proteins dissociate from the M6P receptors and are then 
dephosphorylated. The receptors are recycled back to the Golgi apparatus or transferred to the plasma 
membrane. The cargo proteins fuse with a lysosome. Some of secreted lysosomal proteins are taken up into 
the cells by M6P receptors on the plasma membrane and transported to the early endosome, the late 
endosome and finally to the lysosome (used with permission from D. Palmer). 
1.9 Production of polyclonal antibodies 
Highly specific and sensitive antibodies are invaluable for biological studies and clinical 
diagnoses. They are traditionally produced by immunization of a suitable animal, such as a 
mouse, rabbit or goat, with an antigen. This induces B-lymphocytes (antigen-binding cells) to 
produce antibody-secreting plasma cells specific for the antigen via the injected host’s 
humoral immune response. In general, polyclonal antibodies are produced from a range of 
B-cells that show heterogeneity in the amino acid sequences of the antigen-binding 
immunoglobulin and bind to different epitopes on the antigen. Monoclonal antibodies arise 
from specific B-cell clones in culture.  
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1.9.1 Expression of recombinant protein via Escherichia coli (E. coli) 
prokaryotic systems 
The immunizing antigen can be a peptide, a purified recombinant protein, or a semi-purified 
cell homogenate injected together with a highly immunogenic adjuvant. In this study, the 
planned antigens were to be recombinant proteins. The first choice for the expression of 
recombinant proteins is typically an E. coli prokaryotic system. Production of proteins in this 
bacterial strain is well established, simple and usually provides high yields. The progressive 
fundamental understanding of transcription, translation, and protein folding in E. coli have 
made the bacterium more user-friendly than eukaryotic protein expression systems. 
However, it is not always possible to generate appropriate antigens, and it is time consuming 
to do so. 
1.9.2 Expression of protein in eukaryotic mammalian cells by using lentiviral 
vectors 
An alternative production method is to use eukaryotic mammalian cell expression systems, 
which have the ability to perform comprehensive post-translational modifications and to 
secrete glycoproteins. One of the most popular stable mammalian cell lines is from human 
embryonic kidney (HEK293) cells. HEK293 cells produce biologically functional proteins with 
native structures and similar post-translational modifications to those in the human body.  
Vectors derived from lentiviruses, a family of complex retroviruses derived from the human 
immunodeficiency virus (HIV-1), are commonly used to transfer genes of interest for 
expression in mammalian cells (Brooks et al., 2002). Recombinant lentiviral vectors have 
transferred genes under tightly controlled promoters to a variety of tissues, including the 
brain (Jakobsson et al., 2003). Safety is important when using these viruses and the vectors 
are highly modified so as to be unable to cause virulent infections or to self-replicate. 
A recombinant lentiviral vector is generated using four plasmids (Figure 1.5). The first 
plasmid functions as a packaging signal and promoter, and integrates the transgene into the 
host genome. The gene of interest (ovine CLN5, or CLN6 coding sequence in the current 
study) is inserted into the plasmid and replaces the structural viral genes (such as gag, pol, 
and env). The structural genes responsible for virus assembly, infection into host cells, and 
regulation of promoter transgene expression are supplied separately in another three 
plasmids. Since about 60% of the HIV-1 genome has been removed, the HIV-1 virus is not 
able to be reconstituted, ensuring that it is safe to use (Trono, 2000). This mature lentiviral 
 35 
package uses receptor-mediated cell entry and once it is inside the host cell (e.g. human 
embryonic kidney cell, HEK293), the transgene plasmid is transcribed to two single strand 
RNAs (ssRNA) that assemble with the three viral proteins (Figure 1.5). Post transfection, the 
mature viruses (lentiviral CLN5 and CLN6) are exported into the cell culture media, and then 
extracted and purified.  
 
 
Figure 1.5 Recombinant lentiviral vector production and transduction of HEK293 cells 
The lentiviral plasmids are transfected in cultured HEK293 cells. Each cell that receives all four plasmids will 
transcribe the promoter transgene plasmid from the LTRs. This creates two copies of ssRNA that assemble with 
the viral proteins. The assembled mature virus particles bud off from the cell surface and are exported to the 
cell culture supernatant from which they can be extracted and purified by centrifugation. Purified virus is 
pipetted directly onto cells of interest, such as sheep neural cells, and are taken up in a process known as 
transduction. 
 
Advantages of lentiviral vectors are their ability to mediate potent transduction of large 
cloning sequences, up to 10 kb, and their efficient integration into chromosomes to allow 
stable and prolonged transgene expression in dividing and non-dividing cells (Vodicka, 2001; 
Palfi et al., 2014). The major use of lentiviral vectors is to infect non-dividing cells, such as 
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neurons. Several animal model studies have shown that lentiviruses are able to transduce 
different cell types in the brain, resulting in high and long term transgene expression in vivo, 
suggesting their suitability in gene therapy studies (Kordower et al., 1999; Brooks et al., 
2002; Haskell et al., 2003; Dahl et al., 2015). Lentiviruses are utilized in the laboratory to 
transfer genes into dividing cells in vitro to express target proteins for functional analysis.  
1.9.3 Specific antibody generation using adenoviral vectors 
Adenoviruses are medium-sized (90–100 nm) naked viruses consisting of a nucleocapsid and 
a linear double-stranded DNA genome. Over 51 different types are found in humans. When 
these viruses infect a host cell, they introduce their DNA into the host. The genetic material 
of adenoviruses is not incorporated into the host genetic material, but is left free in the 
nucleus, and the instructions in this extra DNA molecule are transcribed just like any other 
gene. The only difference is that these extra genes are not replicated when the cells undergo 
division so daughter cells do not have the extra gene. 
Adenoviral vectors are widely used gene transfer tools to promote targeted gene expression 
in many tissues, such as muscle, eye, brain, liver and lung (Daly, 2004; Rein et al., 2006). 
They have several advantages (Danthinne and Imperiale, 2000). Firstly they can infect a wide 
range of dividing and non-dividing cells. Secondly, they are easily purified in high titres. 
Thirdly, they can accommodate up to 37 kb of foreign genomic DNA. Fourthly, their genome 
rarely integrates into the host chromosome. In addition, it has been suggested that 
adenoviral vectors could be a good adjuvant for antibody generation. They shuttle the target 
gene to overexpress an antigen in vivo, overcoming the frustrating process of protein 
generation, purification and multiple injections into hosts (Anderson et al., 2000). This is a 
simple, rapid way to generate antibodies without the need for preparation of the protein or 
peptide of interest, for instance TPP1 antibodies (Haskell et al., 2003). In this thesis, the 
coding sequences of the target genes (ovine CLN5 and CLN6) were cloned into adenoviral 
shuttle plasmids (pVQAd CMV K-NpA) by colleagues at the Unviersity of Otago (Dr. Stephanie 
Hughes, Dunedin, New Zealand) using standard techniques (Figure 1.6) and the shuttle 
plasmids transfected into HEK293 packing cells. Adenoviruses were amplified by cell 
passaging and purified adenoviral vectors were then injected into rabbits and mice.  
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Figure 1.6 Generation of antibodies using adenoviral vectors                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
The cDNA encoding the protein of interest is cloned into an adenoviral shuttle plasmid which is transfected into 
HEK293 cells together with an adenoviral packaging plasmid. Adenovirus containing the target sequencing is 
amplified by serial passaging of HEK293 cells and purified. Adenoviral particles are injected into the host 
animals via a single injection into a rabbit or a mouse. Sera containing antibodies are collected (modified from 
Hughes et al., 2014b). 
1.10 Neural cells in the central nervous system 
The central nervous system (CNS) consists of a wide range of cell types that work together to 
receive, transmit and react to information and to coordinate the activities of body parts. 
Neurons, or nerve cells, localized in the brain and spinal cord of the CNS, process and 
transmit information via electrical and chemical signals, and connect to form neural 
networks. A typical neuron has three main structures; a soma (the cell body), dendrites and 
an axon. The cell body contains the nucleus which stores the genes of the cell. Dendrites are 
thin structures that start from the soma, are highly branched, and receive signals from other 
neurons. Axons are long cables extending from the soma that carry electrical signals away 
from the cell body toward other neurons. Neurons vary in size, shape and length. 
There are many possible sub-classifications of neurons. Researchers have categorized 
neurons by function (Kandel, 2000). Sensory neurons collect information from sensory 
organs (such as the skin, eyes and nose) and send signals to the CNS (Figure 1.7 A). Motor 
neurons send signals from the CNS and form synapses with muscles to transmit commands 
for muscle contractions (Figure 1.7 B). Interneurons form neuron-neuron interconnections in 
the nervous system (Figure 1.7 C).  
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Figure 1.7 Overview of some neuron types 
(A) Sensory neurons transform physical stimuli into electrical activity in cells. (B) Motor neurons carry 
commands from the brain to muscles and glands. (C) Interneurons convey signals from one brain region to 
another. (D) Pyramidal cells with somata like pyramids constitute the majority of neurons in the cerebral 
cortex. (E) Cerebellar Purkinje cells have extensively ramified dendritic trees. (F) Cortical basket neurons are 
inhibitory interneurons with extensive dendritic trees for contacting other neurons (modified from Stahl et al., 
2008).  
 
Neuronal cells are also classified based on location, shape and the pattern of dendrites 
(Stahl, 2008). Pyramidal cells have triangular shaped somata (Figure 1.7 D). Most neurons in 
the cerebral cortex are pyramidal neurons, especially those in the frontal cortex. Purkinje 
cells, located in the cerebellum, have extensively branched dendrites (Figure 1.7 E). A 
specific, recognizable feature of Purkinje neurons is the expression of calbindin (Whitney et 
al., 2008). Basket cells contain highly ramified dendritic trees. They are interneurons present 
in the cortex, hippocampus and cerebellum (Figure 1.7 F) (Wang et al., 2002; Stahl, 2008). 
The hippocampal basket cells are also parvalbumin-expressing cells. 
1.11 Experimental rationale 
1.11.1 Research objectives 
The neuronal ceroid lipofuscinoses are the most common group of inherited 
neurodegenerative diseases that affect children. Naturally occurring animal models, e.g. 
sheep, are used to study human neurological disorders, and supply more reliable 
information than small animal models (Pinnapureddy et al., 2015). Two NCL proteins, CLN5 
and CLN6, have been studied for two decades, but their functions are still unclear. 
Generation of highly specific and sensitive antibodies to these proteins would be very useful 
for biological and functional studies. In the studies described in this thesis, the naturally 
occurring ovine models of CLN5 and CLN6 NCL were used to establish the full length coding 
sequences of the genes and expression of the encoded proteins. Antibodies against ovine 
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CLN5 and CLN6 were generated and used for characterisation studies of both proteins in 
vitro.  
1.11.2 Research aims  
The first aim of this study was to clone full length ovine CLN5 and CLN6 gene sequences into 
an expression vector (e.g. pRUN vector or Gateway cloning vectors), and attempt 
recombinant protein expression in E. coli. The CLN5 exon 1 allelic variants were also tested. 
These results are described in Chapter 2. 
The second aim was to use lentiviral vectors expressing full length CLN5 and CLN6 coding 
sequences under the control of the MND promoter. These vectors were packaged and 
transduced into HEK293FT cells, and the over-expressed recombinant CLN5 and CLN6 
proteins produced from these cell lines used to test the specificity of antibodies. Adenoviral 
anti-CLN5 and CLN6 antibodies were generated and characterised by immunocytochemistry, 
Western blotting and mass spectrometry, described in Chapter 3. 
The third aim was to visualise cellular and regional CLN5 and CLN6 expressions in the ovine 
CNS, and to examine the correlations between these two proteins, described in Chapter 4. 
Chapter 5 provides a general discussion and conclusion, as well as suggesting future 
directions for this research.  
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Generation of full length ovine CLN5 and CLN6 constructs 
for recombinant protein expression 
2.1 Introduction 
Two unique sheep models of Batten disease are being used to develop gene therapy 
strategies for these devastating neurodegenerative diseases of children. CLN5 Batten disease 
in Borderdale (BD) sheep is caused by a defect in a soluble lysosomal protein, whereas the 
CLN6 form in South Hampshire (SH) sheep is caused by a defect in a membrane protein. 
Despite the two proteins having quite different cellular residences and presumed functions, 
the clinical developments of these two forms of Batten disease are similar. However, the 
functions of the CLN5 and CLN6 proteins are still unclear. They have not been purified and 
generation of the two proteins would be very useful for biological and functional studies. 
This study aimed to clone full length ovine CLN5 and CLN6 gene sequences into an 
expression vector (e.g. pRUN or Gateway cloning vectors) for recombinant protein 
expression in E. coli. 
The pRUN vector is a high copy number expression plasmid closely related to the pET vector 
family. It was modified from a pMW172 plasmid with more restriction sites in the polylinker. 
The pMW172 expression vector was generated based on the original pET vector containing a 
modified polylinker and has been used to express segment 1 of gelsolin (Way et al., 1990). In 
the present study, CLN5 and CLN6 sequences were initially cloned into pRUN vector, and 
overexpression in the host E. coli strain C43 (DE3) was attempted. C43 (DE3) is a mutant 
strain of BL21 (DE3) (Miroux and Walker, 1996), frequently used to overcome toxicity 
associated with overexpressing some recombinant proteins using the bacteriophage T7 RNA 
polymerase expression system (Dumon-Seignovert L et al., 2004). An alternative Gateway 
cloning expression system was also used in attempts to generate ovine CLN5 and CLN6 
recombinant proteins. Recombinant transcripts are also controlled by the T7 polymerase 
promoter. 
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2.2 Animal samples and methods 
2.2.1 Animal samples 
CLN5 BD and CLN6 affected SH sheep have been developed and are maintained under 
standard New Zealand pastoral conditions on Lincoln University farms. All animal procedures 
were carried out in compliance with the New Zealand Animal Welfare Act (1999) and were 
approved by the Lincoln University Animal Ethics Committee.  
For the CLN5 exon 1 study, six BD genomic DNAs (genotyped by Dr. Nadia Mitchell) were 
obtained from 2 affected (CLN5-/-), 1 heterozygote (CLN5+/-) and 3 controls (CLN5+/+). For the 
ovine CLN5 genotyping study, a total of 351 sheep genomic DNA samples were investigated, 
including 42 CLN5-/-, 82 CLN5+/- and 80 CLN5+/+ Borderdale samples, and 69 from CLN5+/+ 
South Hampshire sheep. Blood samples from Merino, Kelso ranger, Kelso maternal, 
Coopdale, Romney and Coopworth sheep on FTA paper matrix cards (Whatman, Middlesex, 
UK) were kindly donated by Professor Jon Hickford, Lincoln University.  
For the bovine CLN5 study, a total of 30 Devon cattle DNA samples, including 2 CLN5-/-, 12 
CLN5+/- and 16 CLN5+/+ controls, were kindly provided by Dr. Imke Tammen, University of 
Sydney, Australia. For the human CLN5 study, 53 anonymous mixed age human oral DNA 
samples were kindly provided by Professor Martin Kennedy, University of Otago, 
Christchurch. The two normal human brain tissues used were obtained from Professor 
Richard Faull, the Huntington Brain Bank, University of Auckland, Auckland. 
2.2.2 Genomic DNA extraction 
2.2.2.1 Genomic DNA extraction from brain 
DNA was extracted from brain frontal lobes using an Axyprep Multisource Genomic DNA 
Miniprep Kit (Axygen, USA). Brain tissues were frozen in liquid nitrogen prior to processing. 
Tissue (20 mg) was processed through the Axyprep spin column. The OD260 and the 260/280 
ratio of each sample were measured spectrophotometrically (Nano Drop, Germany). The 
concentration of DNA (ng/µl) was calculated from 50 × OD260 of each sample. Purified DNA 
samples were stored at -20°C until required for PCR. 
2.2.2.2 Genomic DNA exaction from blood on FTA cards 
DNA from each blood sample was purified using a two-step washing procedure (Zhou et al. 
2006). A 1.2 mm blood disc was punched from an FTA card (Whatman), placed into a PCR 
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tube, washed with 200 μl of 20 mM NaOH, 30 min, and equilibrated in 200 μl TE buffer, 5 
min. After removal of the TE buffer, the disc containing genomic DNA was air-dried 
overnight, and placed in 500 μl of ddH2O at 4°C. 
2.2.2.3 RNA extraction and complementary DNA synthesis of ovine CLN5 
Borderdale RNA from each blood sample was exacted by Dr. Nadia Mitchell using a PureLink 
Total RNA blood kit (Invitrogen, NZ). Single stranded cDNA was synthesised from (450 ng) of 
total RNA in 20 µl PCR reactions using Superscript III reverse transcriptase (Invitrogen, NZ).   
2.2.3 PCR 
2.2.3.1 Primers  
The design of all the primers used here were based on the sequence information in the 
National Centre for Biotechnology Information (NCBI) GenBank using the DNAMAN 4 
programme (©fLynnon Biosoft). The published mRNA sequences used were ovine CLN5 
(NM_001082595), ovine CLN6 (NM_001040289.1), bovine CLN5 (NM_001046299.1) and 
human CLN5 (NM_006493). The information for each specific primer pair and their 
generated PCR products is shown in Table 2.1 and Table 2.2, and the locations of the 
designed primers on their mRNA sequences are provided in Appendix, A.1. All specific 
primers were synthesised and supplied lyophilized (Invitrogen, NZ). Each primer was diluted 
with TE (10 mM Tris-HCl, pH 8.0, 1 mM EDTA) to a stock concentration of 50 µM and stored 
at -20°C. 
2.2.3.2 PCR using Platinum Pfx Taq DNA polymerase 
Platinum pfx Taq DNA polymerase (Invitrogen, NZ) was used to generate full length CLN5 
and CLN6 coding sequences. A standard 50 μl PCR reaction was performed with template 
DNA (~100ng), 0.25 μM of each primer, 200 μM of each dNTP, 1.5 mM MgSO4, 2.5 units of 
Platinum pfx Taq DNA polymerase (Invitrogen, NZ), 2× PCR enhancer solution, and 1× the 
amplification buffer supplied with the polymerase. Amplifications were carried out in a 
Thermo cycler (Eppendorf, Hamburg, Germany). The PCR cycles were: 94°C for 2 min, 35 
cycles of 94°C, 15 sec, 55°C, 30 sec and 68°C, 1 min, followed by 72°C, 5 min. Ovine CLN5 
exon 1 sequence was generated using primer sets of CLN5_TOPO_For 2 (forward) and 
CLN5_GSP2 (reverse) and the full ovine CLN5 sequence using primer sets of CLN5_TOPO_For 
2 (forward) and CLN5_3’UTR-R5 (reverse) (Table 2.1).  
 
Table 2.1 CLN5 primer sequences and PCR product information 
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PCR product names Primer names Primer sequences 5’- 3’ Product 
sizes 
Sheep CLN5 exon 1 F: CLN5_TOPO_For2 
R: CLN5_GSP2 
CACCATGGCGCAGGCGGGGGGTGCCGG 
ACAGTCACTTTGGAACTGGCCAACG 
430bp 
Sheep CLN5 exons 2-
4 stop 
F: CLN5_Ex2F 
R: CLN5_TOPO_Revstop 
ACGCTTCTCCTTCCGTCCGGAAC 
TTATAAACCAGAGAGTGTTCTG 
907bp 
Sheep CLN5 exons 2-
4  
F: CLN5_Ex2F 
R: CLN5_3’UTR-R5 
ACGCTTCTCCTTCCGTCCGGAAC 
TGTTAGCTTTCTGCCCCAAGG 
1012bp 
Sheep CLN5 exon 1 
(fragment A) 
F: CLN5_TOPO_For2 
R: CLN5_Exons 1-
2Rlong 
CACCATGGCGCAGGCGGGGGGTGCCGG 
CGGAAGGAGAAGCGTTTGTAGGGCACCGGCCACT 
205bp 
Sheep CLN5 exon 2-4 
(fragment B) 
F: CLN5_Exons 1-2Flong 
R: CLN5_3’UTR-R5 
GCCGGTGCCCTACAAACGCTTCTCCTTCCGTCCGGAAC 
TGTTAGCTTTCTGCCCCAAGG 
1021bp 
Sheep CLN5 F: CLN5_TOPO_For2 
R: CLN5_3’UTR-R5 
CACCATGGCGCAGGCGGGGGGTGCCGG 
TGTTAGCTTTCTGCCCCAAGG 
1199bp 
Sheep CLN5his F: CLN5_TOPO_For2 
R: CLN5_His_R 
CACCATGGCGCAGGCGGGGGGTGCCGG 
TTAGTGGTGGTGGTGGTGGTGTAAACCAGAGAGTGTTCT 
1104bp 
Sheep CLN5his BamH 
I/HindIII 
F: CLN5_F_BamH I 
R: CLN5_R_HindIII_his 
TATTATCGGGATCCATGGCGCA 
AGCCCAAGCTTTTAGTGGTGGT 
1129bp 
Sheep CLN5his exons 
2-4  BamH I/ HindIII 
F: CLN5_ex2-4F_BamH I 
R: CLN5_R_HindIII_his 
GGTTATCGGGATCCAAACGCTT 
AGCCCAAGCTTTTAGTGGTGGT 
952bp 
Sheep CLN5151-207 F: CLN5_F151-207 
R: CLN5_R151-207 
CACCATATCCCGGCGCCAGT 
CCTAATCTGGTTCCGGACGG 
68bp 
Sheep CLN5656-717 F: CLN5_F656-717 
R: CLN5_R656-717 
CACCATAAGCCCGAAAAAGGAG 
CCCGCCTACCTTAACACAAAT 
78bp 
Sheep CLN5myc F: CLN5_TOPO_For2 
R: CLN5_mycR 
CACCATGGCGCAGGCGGGGGGTGCCGG 
TCACAGATCCTCTTCTGAGATGAGTTTTTGTTCTAAACCAG
AGAGTGTTCT 
1120bp 
Cattle CLN5 exon1 F: 5’UTRF7 
R: I1R2 
AGCCGAGTGGATCGAGCGCT 
GCCAGGACGCAACTTCCTAC 
437bp 
Human CLN5 exon1 F: H1F2 
R: H1R1 
CATAAAAGATGACGCCCCAGGTC 
GACCCCAACCCCGACAGTGC 
470bp 
 
Table 2.2 CLN6 primer sequences and PCR product information 
PCR product names Primer names Primer sequences 5’- 3’ Product 
sizes 
Sheep CLN6 F: CLN6_OF 
R: CLN6_WTOR 
CACCATGGAGGCTGCGGCGCGGAG 
TTGGCTGCTGACGTGGAGGGTG 
972bp 
Sheep CLN6his F: CLN6_OF 
R: CLN6_His_R 
CACCATGGAGGCTGCGGCGCGGAG 
TCAGTGGTGGTGGTGGTGGTGGTATTGGCTGCTGACGTG 
951bp 
Sheep CLN6his BamH 
I/HindIII 
F: CLN6_F_BamH I 
R: CLN6_R_HindIII_his 
TATATCGGGATCCATGGAGGCT 
ATCCCAAGCTTTCAGTGGTGGT 
978bp 
Sheep CLN6 exon 2-7 F: CLN6_Ex207F 
R: CN6_Ex2-7R 
CACCCACAGCTCCGTCAAGGC 
TCAGTGGTGGTGGTGGTGGTG 
874bp 
 
Notes: Start and stop codons are in bold. Bases highlighted in grey refer to enzyme cutting sites: BamH I 
(GGATCC) and HindIII (AAGCTT). The 6× His tags are in boxed, and the myc tag is underlined. 
 
The full ovine CLN6 coding sequence was also amplified with Platinum pfx Taq DNA 
polymerase, using CLN6 genomic DNA from normal SH sheep for the DNA template (~100 
ng), and primer sets, CLN6_OF (forward) and CLN6_WTOR (reverse) (Table 2.2) in a 50 μl PCR 
reaction.  The PCR cycles were 2 min at 94°C, followed by 35 cycles of 94°C, 15 sec; 68°C and 
2 min, with a final extension of 72°C, 5 min.   
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2.2.3.3 PCR using Taq DNA polymerase 
Qiagen Taq DNA polymerase (Qiagen, Hilden, Germany) was used for most sequence 
amplifications. A standard 20 μl PCR reaction was performed with template DNA (~100ng), 
0.25 μM of each primer, 125 μM of dNTPs, 2.5 mM MgCl2, 1 unit of Taq DNA polymerase 
(Qiagen) and 2 μl 10× PCR buffer. The cycles consisted of 95°C, 5 min, followed by 35 cycles 
of 95°C, 30 sec; 55°C, 30 sec, and 72°C, 90 sec, and a final extension of 72°C, 5 min.  This PCR 
programme was used to generate the ovine CLN5 exons 2-4 sequence (section 2.3.6.3), the 
bovine CLN5 exon 1 sequence (2.3.6.4) and the target insert of CLN6 exons 2-7 for cloning 
(2.2.6.1). The specific primer sets used to generate each PCR product are listed in Table 2.1 
and Table 2.2.  
2.2.3.4 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to analyse PCR products and plasmid DNAs. Unless 
otherwise specified, 1.5 % (w/v) agarose gels were used. Electrophoresis was performed in 
Tris acetate EDTA (TAE) buffer (40 mM Tris base, 20 mM acetate, 1 mM EDTA, pH 8.0) with 
ethidium bromide dye (0.2 μg/ml), 100 V, 20 min. DNA was visualised under UV light and 
photographed with a GelDoc XR (Bio-Rad, USA) imaging system.  
2.2.3.5 Purification of PCR products  
Amplified PCR products were gel-purified using an AxyPrep DNA gel extraction kit (Axygen, 
NZ). 
2.2.3.6 Direct sequencing of DNA fragments 
Mixtures containing 6 ng of PCR product and 5 pmol of forward or reverse primers were 
diluted in ddH2O to 15 µl and sent to the Allan Wilson Centre Genome Service, Massey 
University, NZ, for sequencing on a Big Dye terminator v3.1 sequencer. The resulting 
sequences were analysed using GeneScan (http://genes.mit.edu/GENSCAN.html) and 
aligned to the specific target sequences published on NCBI using GeneDoc 2.6.02 from the 
GeneDoc HomePage (http://www.psc.edu/biomed/genedoc/). 
2.2.3.7 PCR – single strand conformational polymorphism (SSCP) 
PCR-SSCP was used to genotype ovine CLN5 genomic DNA sequences. PCR amplification was 
performed in a 50 μl PCR reaction containing the extracted genomic DNA, generated in 
section 2.2.3.2, with Platinum pfx Taq DNA polymerase, previously described in section 
2.2.3.3. Directly after PCR, a 0.7 μl aliquot of each amplicon was mixed with 7 μl of loading 
dye (98% formamide, 10 mM EDTA, 0.025% bromophenol blue, 0.025% xylene) for SSCP 
analysis. After denaturation at 95°C, 5 min, samples were cooled on ice and loaded onto 16 × 
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18 cm, 14% acrylamide vertical gels (acrylamide: bis-acrylamide 37.5:1, Bio-Rad) which were 
polymerized with 0.01% (v/v) N,N,N’N’-tetramethylethylenediamine (TEMED) and 0.05% 
(w/v) ammonium persulphate. Gels were run in Protean II cells (Bio-Rad), 390 V, 19 h, 12°C, 
in TBE buffer (45 mM Tris, 45 mM boric acid, 1 mM EDTA), then fixed and stained in 10% 
ethanol, 0.5% acetic acid and 0.2% silver nitrate for 5 min (Byun et al., 2009). They were 
rinsed with ddH2O, 3 min, then developed with a warm solution (55°C) of 3% NaOH and 0.1% 
formaldehyde until dark bands appeared on a yellow background (5 - 10 min). Development 
was terminated with a solution of 10% ethanol and 0.5% acetic acid, and gels were kept in 
ddH2O. 
2.2.4 Cloning ovine CLN5 and CLN6 coding sequences into pRUN vector 
An empty pRUN plasmid (2587 bp) was kindly provided by Mike Runswick and Professor 
John Walker, MRC, Mitochondrial Biology Unit, Cambridge, UK. Purified CLN5 and CLN6 PCR 
fragments containing a 6× Histidine (His) tag at C-terminus were cloned into BamH I-HindIII 
cleaved pRUN vector, and overexpression of CLN5 and CLN6 proteins in the host E. coli strain 
C43 (DE3) attempted as follows. The 6× His tag was cloned into the target gene sequence to 
allow purification of expressed recombinant proteins by binding to Ni affinity 
chromatography columns.  
2.2.4.1 Generation of full length CLN5, full length CLN6 and CLN5 exons 2-4  
sequences with a 6× His tag as target inserts 
The full CLN5 target insert was amplified from the CLN5+/+ cDNA (as described in section 
2.2.2.3), using Platinum Taq polymerase (Invitrogen) and the primer sets of CLN5_Topo_For 
2 (forward) and CLN5_His_R (reverse) which contained a 6× His in-frame tag sequence at the 
C terminus, named as CLN5his (Figure 2.1). To allow directional cloning of the target insert 
into pRUN, two restriction enzyme cutting sites with 5-8 extra bases were introduced onto 
the 5‘ (BamH I, GGTACC) and 3’ (HindIII, AAGCTT) of the CLN5his sequence by a second PCR 
with CLN5_F_BamH I (forward) and CLN5_R_HindIII_his (reverse) primers (Table 2.1) using 
the reaction programme and cycles described in section 2.2.3.2. 
The full CLN6 target insert of was generated in the same manner. It was amplified from the 
CLN6+/+ cDNA, using Qiagen Taq polymerase and the primers CLN6_OF (forward) and 
CLN6_His_R (reverse (Table 2.2) which contained a 6× His in-frame tag sequence at the C 
terminus, named as CLN6his (Figure 2.1). Two enzyme cutting sites were then added into the 
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CLN6his sequence by a second PCR with CLN6_BamH I (forward) and CLN6_R_HindIII_his 
(reverse) primers (Table 2.2) as described in section 2.2.3.3. 
An alternative CLN5 target insert (excluding exon 1) was also amplified using CLN5his as the 
template and the primers CLN5_ex2-4F_BamH I (forward) and CLN5_R_HindIII_his (reverse) 
as described in section 2.2.3.2. All three PCR products were gel purified and sequenced prior 
to cloning. 
2.2.4.2 DNA ligation and bacterial transformation 
The three purified target insert DNAs, encoding the full length CLN5 and CLN6 genes, and the 
CLN5 gene excluding exon 1, were cloned into linearized pRUN and transformed into C43 
(DE3) competent E. coli cells as follows. All steps were carried under sterile conditions. 
Double restriction enzyme digestions were carried out on the target inserts and the pRUN 
vector, to generate sticky ligation sites. The DNAs (~350 ng), were digested in a 25 µl 
solution containing 1.5 µl of HindIII enzyme (New England Biolabs, UK), 3 µl of digestion 
buffer and ddH2O, 37°C, 1 h; followed by digestion in 1.5 µl of BamH I enzyme (New England 
Biolabs, UK) and 3 µl of digestion buffer for another 1.5 h. All the digested DNAs were 
confirmed by agarose electrophoresis. For DNA ligation, each enzyme-digested target insert 
(10 µl) was added to 5 µl of 10× ligation buffer, 1 µl T4 ligase (New England Biolabs, UK), 5 µl 
of linearized vector at a molar ratio of PCR product: vector of 2:1, and the finial volume 
adjusted to 25 µl with ddH2O. This ligation reaction was mixed gently and incubated at room 
temperature, 1 h. The generated plasmid DNAs were named as pRUN CLN5his, pRUN 
CLN6his and pRUN CLN5his exons 2-4 (Figure 2.1). A reference reaction containing only 
pRUN vector was included as a negative control. 
For E. coli transformation, the full ligation reaction was added to a vial of E. coli TOP10 
competent cells (Invitrogen, NZ), incubated on ice, 1 h, heat-shocked at 42°C, 45 sec, and 
immediately chilled on ice, 1 min. Room temperature SOC medium (Super Optimal Broth, 
250 µl, Invitrogen, NZ) was added to the vial containing DNA and E. coli cells, and incubated, 
with horizontal shaking, 37°C, 200 rpm, 1 h. The transformation mixture (50 µl) was spread 
on an LB-agar plate (1% w/v tryptone, 0.5% w/v yeast extract, 1% w/v NaCl, 1.5% w/v agar, 
pH 7.5) supplemented with 100 µl/ml ampicillin, which was incubated overnight, 37°C, to 
produce colonies. A reference plate spread with 50 µl of component cells was included as a 
negative control.  
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Figure 2.1 pRUN constructs for recombinant protein expression 
(a) pRUN CLN5his, (b) pRUN CLN6his and (c) pRUN CLN5his exons 2-4 
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2.2.4.3 Plasmid DNAs purification 
Single colonies of E. coli TOP 10 cells transformed with the different plasmid DNAs were 
inoculated into 3 ml of LB medium (Sigma, NZ) containing 100 µg/ml of ampicillin, followed 
by vigorous shaking, 250 rpm, overnight, 37°C. The cells were harvested by centrifugation, 1 
min, 12,000 g, 4°C, and the plasmid DNAs purified from the cell pellets using Axygen Plasmid 
Mini kits (Axygen, NZ). The concentrations of plasmid DNA were tested using a Nano Drop 
spectrophotometer (ND-1000, 3.3.0, USA) and the size of the plasmid DNA was checked by 
restriction endonuclease digestion and agarose gel electrophoresis as described in section 
2.2.4.4. The purified plasmid DNAs were labelled as pRUN CLN5his, pRUN CLN6his and pRUN 
CLN5his exons 2-4 (Figure 2.2). 
2.2.4.4 Restriction endonuclease digestion of plasmid DNA 
ApaI (New England Biolabs, UK) restriction endonuclease was used to digest the purified 
pRUN CLN5his plasmid DNA, BglII was used to digest the purified pRUN CLN6his and BamH I 
was used to digest pRUN CLN5his exons 2-4. Plasmid DNAs (1 µg) were digested in 20 µl 
reactions containing digestion buffer (2 µl) and 10 units of the restriction enzyme, 37°C, 
overnight, then inactivated by incubation at 65°C, 15 min. The digested plasmid DNAs were 
analysed on agarose gels as previously described in section 2.2.3.4.  
2.2.5 Recombinant protein expression in E. coli 
2.2.5.1 Protein expression 
The successful constructs, pRUN CLN6his and pRUN CLN5his exons 2-4 , were subsequently 
expressed in the E. coli strain C43 (DE3). LB medium, 3 ml, supplemented with ampicillin 
(100 µg/ml) was inoculated with a single colony and incubated in an orbital incubator, 250 
rpm, overnight, 37°C. A 25 µl aliquot was added to 50 ml of fresh LB medium containing 
ampicillin (100 µg/ml), and the cells grown at 37°C until the OD600nm = 0.6. Expression of 
recombinant protein was induced by adding isopropyl β-D-1-thiogalactopyranoside (IPTG, 1 
M stock solution) to a final concentration of 1 mM. The cells were then incubated with 
vigorous shaking at 37°C for an additional 5.5 h. Half ml samples from each of the bacterial 
cells were collected and harvested before induction and 5.5 h after induction. The remaining 
bacterial cells were pelleted and stored at -20°C. Alternative protein expression conditions 
were also tested, including lower cell growth temperatures, 30°C or 25°C, and a decrease in 
the IPTG concentration to 0.5 mM.  
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Cell samples were harvested by centrifugation 10 min, 5000 rpm, 4°C. Each cell sample pellet 
was treated with 200 µl of 2× protein sample buffer (4% SDS, 300 mM mercaptoethanol, 
20% glycerol, 0.004% bromophenol blue, 500 mM Tris-HCl pH 6.8), boiled, 10 min, and 
particulates pelleted, 5 min, 14,000 rpm, 4°C. Supernatants were transferred to fresh tubes. 
As CLN6 is an insoluble protein, it may be in the inclusion bodies in the CLN6 cells. An extra 
step was performed for cells transformed with pRUN CLN6his clones. Pellets were treated 
with 5 ml of 8 M urea, 10 mM sodium phosphate, pH 8.0 and centrifuged again, 5 min, 
14,000 rpm, 4°C to pellet insoluble cellular debris. The resulting supernatant was collected. 
To test protein expression, the solubilised fractions from each clone were subjected to SDS-
PAGE electrophoresis. 
2.2.5.2 SDS-PAGE electrophoresis 
Prior to SDS-PAGE, BCA protein assays were used to determine protein concentrations using 
Biorad DC protein assay kits (Bio-Rad, NZ). Sample fractions and the corresponding pre-
induced samples of each construct were separated by SDS-PAGE in a Bio-Rad Mini cell 
electrophoresis system (Bio-Rad laboratories, Hercules, CA, USA). Protein samples (30 µg) 
were loaded onto 10% acrylamide gels, and electrophoresis was carried out at 80 V, 20 min, 
followed by 120 V for another 1.5 h. Apparent molecular weights of proteins were 
determined by comparison with the visible blue bands of Precision plus protein standard 
markers (7 µl, Bio-Rad, NZ). Immediately following electrophoresis, gels were stained with a 
solution of 42% methanol, 16% acetic acid containing 0.1% Commassie blue R250 overnight 
and destained with several changes of 40% methanol and 10% acetic acid until the 
backgrounds were clear. 
2.2.6 Generation of CLN5 and CLN6 recombinant proteins using the Gateway 
cloning expression system 
An alternative cloning system was also tested. Usually, the generation of a recombinant 
protein expression construct via Gateway technology involves two steps. First, the gene of 
interest is inserted into an “entry” vector, pENTR™//D-TOPO (Invitrogen, NZ). Secondly, the 
resultant constructs are re-cloned into a “destination” vector, pDEST17 (Invitrogen, NZ), 
which contains an N-terminal 6× His tag used for protein purification.  
2.2.6.1 Generation of protein expression constructs 
To generate CLN5 target inserts, two small polypeptide cDNAs corresponding to ovine CLN5 
amino acids 51-69 (named as CLN5151-207) and 218-239 (named as CLN5656-717) were 
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generated by separate PCRs (Figure 2.2 a and b) using the standard processes described in 
sections 2.2.3.2 and 2.2.4.1. The full length CLN6 target insert was amplified from CLN6+/+ 
cDNA by PCR (Figure 2.2 c). All target inserts contained ‘CACC’ at the N terminus for 
directional cloning. The specific primer sets used were shown in Table 2.1 and Table 2.2.  
PCR amplicons of the target inserts were purified and sub-cloned into pENTR/D/TOPO 
(Figure 2.2) and transformed into TOP10 competent E. coli cells as described in section 
2.2.4.2, except that the transformation mixture was spread onto LB-agar plates 
supplemented with 50 µl/ml kanamycin (Invitrogen, NZ). Plasmid DNA from randomly 
selected clones for each gene were extracted and analysed by direct sequencing. The chosen 
constructs were re-cloned from pENTR/D/TOPO into the His tag containing pDEST17 vector 
(Figure 2.2) using Gateway LR Clonase II Enzyme Mix (Invitrogen, NZ), and transformed into 
C43 (DE3) cells. Plasmid DNA for the three constructs pDEST17 CLN5151-207, pDEST17 CLN5656-
717 and pDEST17 CLN6 exons 2-7 (Figure 2.2) was extracted, confirmed by restriction 
digestion and glycerol stocks of C43 (DE3) bacterium containing positive clones were 
prepared and stored frozen.  
2.2.6.2 Expression of CLN5 polypeptides and CLN6 protein 
The general processes were as described in section 2.2.5.1. To generate CLN6 protein, E. coli 
C43(DE3) clones containing the pDEST CLN6 exon 2-7 construct were grown at 37°C. When 
the cell densities reached an OD600nm = 0.6, IPTG was added to a final concentration of 1 mM 
or 0.5 mM and cells incubated at 37°C for an additional 4 h. Each bacterial cell sample was 
collected and harvested before induction and 1 h, 2 h, 3 h and 4 h after induction. Cells were 
also inducted by 1 mM IPTG and incubated at 20°C for an additional 23 h and cells samples 
harvested before induction, and 6 h and 23 h after induction.  
To generate two small CLN5 polypeptides, both of the expression constructs pDEST17 
CLN5151-207 and pDEST17 CLN5656-717 were transformed into one C43 (DE3) cell, and grown at 
37°C. The cells containing the CLN5 polypeptide sequences were induced by 1 mM IPTG and 
incubated at 37°C for additional 5 h. Cell samples were collected before induction, and 2 h 
and 5 h after induction. Solubilized fractions were analysed by SDS-PAGE as described in 
sections 2.2.5.1 and 2.2.5.2.  
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Figure 2.2 Gateway constructs for recombinant protein expression 
(a) pDEST17 CLN5151-207, (b) pDEST17 CLN5656-717 and (c) pDEST17 CLN6 exons 2-7. Genes of interest were PCR-
amplified using forward primers containing a 5’-CACC-overhang and their specific reverse primers (Table 2.1 
and Table 2.2). The resulting PCR products were cloned directionally into a pENTR/D/TOPO and subsequently 
re-cloned into pDEST17 expression vectors. 
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2.2.7 Clone the CLN5 coding sequence into pCR4-TOPO vector 
The full length ovine CLN5 coding sequence, both with and without a myc tag, was cloned 
into pCR4-TOPO (Invitrogen, Carlsbad, CA, USA), and used to generate lentiviral vectors 
which express CLN5 protein in HEK293FT cells (described in Chapter 3) 
2.2.7.1 Addition of a myc tag to the CLN5 coding sequence 
The full CLN5 sequence with a myc tag (CLN5myc) was generated by PCR using Platinum Taq 
polymerase (Invitrogen) with the primers CLN5_Topo_For 2 (forward) and CLN5_mycR 
(reverse) (Table 2.1) containing a C-terminal myc tag sequence (section 2.2.3.2). The 
product, CLN5myc, was gel purified and sequenced using the CLN5_mycR reverse primer. 
2.2.7.2 Generation of CLN5 protein expression constructs 
The two purified PCR products, encoding full length CLN5 (1199 bp, Appendix A.2.1) and 
CLN5myc (1120 bp, Appendix A.2.2), were cloned into pCR4-TOPO (3957 bp) and 
transformed into TOP10 E. coli cells as follows. All steps were carried under sterile 
conditions. For each PCR product, 5 µl, was first added to 0.2 µl of 10 mM dATP, 1 μl 10× PCR 
buffer, 5 units of Taq DNA polymerase (Qiagen), and incubated at 70°C, 30 min to generate a 
poly-A tail. For DNA ligation, the poly-A-tailed PCR products (2 µl) were added to 1 µl of salt 
solution and 1 µl of TOPO vector at a molar ratio of PCR product: vector of 1:1, and the final 
volume was adjusted to 6 µl with ddH2O. This ligation reaction was mixed gently and 
incubated, room temperature, 30 min, then subsequently transformed to E. coli as 
previously described (section 2.2.4.2). Positive clones of pCR4-TOPO CLN5 (Figure 2.3 a) and 
pCR4-TOPO CLN5myc (Figure 2.3 b) were selected. The plasmid DNAs were extracted, and 
confirmed by EcoRI (New England Biolabs, UK) restriction digestion as previously described 
(section 2.2.4.5). 
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Figure 2.3 pCR4-TOPO CLN5 constructs 
(a) pCR4-TOPO CLN5, (b) pCR4-TOPO CLN5myc 
2.3 Results 
2.3.1 Generation of full length ovine CLN5 and CLN6 coding sequences 
Attempts to clone the full length cDNA of ovine CLN5 in one reaction were unsuccessful, 
possibly due to the disjunction in GC/AT ratios. Ovine CLN5 exon 1 sequence contains a 
much higher percentage of G/C bases (around 80%) compared with exons 2-4. To overcome 
this, a two-step PCR and ligation strategy was used to generate full length ovine CLN5. In 
brief, the CLN5 exon 1 (section 2.2.3.2) and exons 2-4 (section 2.2.3.3) were amplified 
separately and then the isolated gene fragments joined using a two-step hybrid PCR with 
internally overhanging primers. Full length ovine CLN6 cDNA was successfully generated in 
one amplification reaction (section 2.2.3.3). 
2.3.1.1 The presence of allelic variants in exon 1 of ovine CLN5  
Amplifications of exon 1 in genomic DNA from a number of sheep produced two distinct PCR 
products, 426 bp (the predicted size) and a smaller 406 bp product (Figure 2.4). The 426 bp 
band was obtained from both affected (CLN5-/-) and control (CLN5+/+) sheep samples, while 
the 406 bp band was detected from one control and a heterozygote (CLN5+/-) sheep. Each 
amplified PCR product was gel purified and sequenced (sections 2.2.3.4- 2.2.3.6) to 
determine which sequence was the published sheep CLN5 exon 1. 
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Figure 2.4 PCR products of the ovine CLN5 exon 1 
PCR products were run on 1.5% agarose gels and examined under UV-light. The primers used in the reactions 
are listed in Table 2.1. A 426 bp PCR product (allele a) was observed in samples S1, S2, S4 and S5; while a 406 
bp PCR product (allele b) was revealed in sample S6. Sample 3 had both PCR products (alleles a and b). M refers 
to the 1 kb Plus DNA ladder (Invitrogen, NZ). 
 
The two nucleotide sequences were aligned with the published sequence of ovine CLN5 exon 
1 and the first part of intron 1 (NM_001082595). The 426 bp fragment (allele a) was identical 
to the published ovine CLN5 sequence (Figure 2.4 and Figure 2.5 a). The 406 bp allele variant 
(allele b) had five changes compared to the published sequence; two polymorphisms, one 
deletion and two non-sense changes (Figure 2.5 a, indicated in black or green arrows). 
Protein sequence alignment of the a and b alleles revealed three amino acid differences 
(Figure 2.5 b, indicated in green arrows), which arose from the two polymorphisms and one 
deletion shown in the nucleotide sequence alignment. The first replacement in the allele b 
sequence (Pro23Leu) resulted from a C to T transition at nucleotide 68, the second 
(Ala44Thr) from a G to A transition at nucleotide 130 and the deletion of an Arg (Arg47del) 
from a GGC deletion at nucleotide position 138.  
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Figure 2.5 Sequence alignment of published ovine CLN5 exon 1 and two allelic variants a and b.  
(a) DNA sequence (NM_001082595). ATG is the start codon of exon 1, and CAA is the stop codon of the exon 1. 
(b) Protein sequence. Black arrows indicate silent changes in nucleotides. Green arrows indicate changes in 
both nucleotides and amino acids. 
 
2.3.1.2 Generation of the ovine CLN5 exons 2-4  sequence 
Amplification of exons 2-4 from genomic DNA templates produced a single band with the 
expected size of 1012 bp (Figure 2.6). The sequence aligned 100% with the published CLN5 
coding sequence (NM_001082595).  
 
       
 
 
 
Figure 2.6 PCR product of the ovine CLN5 exons 2-4 
5 µl PCR product run on a 1.5% agarose gel and examined 
under UV light. A 1021 bp PCR product was generated from 
the CLN5_Ex2F and CLN5_3’UTR_R5 primer sets (Table 2.1). 
M refers to the 1 kb Plus DNA ladder (Invitrogen). 
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2.3.1.3 Generation of the full length ovine CLN5 coding sequence  
The full length ovine CLN5 coding sequence was generated by a two-step hybrid PCR (Figure 
2.7). Two DNA fragments with internal overlaps of the exon 1-exon 2 boundaries (A and B) 
were amplified separately, then the two isolated fragments joined in a second PCR (Figure 
2.7).  After the first PCR, a single 205 bp band (Figure 2.8 a) of the CLN5 exon 1 sequence 
fragment (A) and a single 1021 bp band (Figure 2.8 b) of the CLN5 exons 2-4  sequence 
fragment (B) were revealed by agarose gel electrophoresis. After the second PCR, a 
sequence fragment with expected size of 1199 bp (Figure 2.8 c) was observed. Each PCR 
product was sequenced, and aligned 100% with the published CLN5 coding sequence 
(NM_001082595).  
 
 
 
Figure 2.7 Generation of the full length ovine CLN5 coding sequence using a two-step hybrid PCR 
The first cycle consisted of two separate PCRs. Fragment A was amplified using CLN5 exon 1 (generated as in 
section 2.2.3.2) as a DNA template, Platinum Taq polymerase (Invitrogen) and primer sets of CLN5_TOPO_For 2 
(forward) and CLN5_Exon 1-2R long (reverse, overhanging R), designed from the 3’ end sequence of exon 1, 
followed by a corresponding overhanging sequence homologous to the 5’ end sequence of exon 2 (Table 2.1 
and section 2.2.3.2). The fragment B was amplified with CLN5 exons 2-4  (generated as in section 2.2.3.3), 
Qiagen Taq polymerase and primer sets of CLN5_Exon 1-2F long (forward, overhang F), generated with an 
overhanging sequences homologous to the 3’ end sequence of exon 1, and the 5’ end sequence of exon 2 and 
CLN5_3’UTR-R5 (reverse) (section 2.2.3.3). A second PCR ligated the two separate PCR products (A and B, 
containing internal overlaps over the exon 1-exon 2 boundaries) and amplified the resultant product using the 
primer sets of CLN5_TOPO_For 2 (forward) and CLN5_3’UTR-R5 (reverse) to obtain the full length coding 
sequence (section 2.2.3.2) 
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Figure 2.8 PCR amplifications of ovine CLN5  
(a) CLN5 exon 1 with overhanging 205 bp, (b) CLN5 exons 2-4  with overhanging 1021 bp, and (c) full length 
CLN5 1199 bp. PCR products were run on 1.5% agarose gels and examined under UV light. The primers used in 
the reactions are listed in Table 2.1. M refers to the 1 kb Plus DNA Ladder. 
 
2.3.1.4 Generation of the full ovine CLN6 coding sequence 
The full length of ovine CLN6 sequence was amplified using forward CLN6_OF and reverse 
CLN6_WTOR primers (Figure 2.1) and using CLN6 complementary DNA from normal South 
Hampshire sheep as a template. A single PCR fragment of the expected size of 972 bp was 
apparent (Figure 2.9). 
 
 
 
 
2.3.2 Cloning ovine CLN5 and CLN6 coding sequences into pRUN for 
recombinant protein expression 
The CLN6 coding sequence containing a 6×His tag was easily generated and cloned into 
pRUN. However, sequencing of the CLN5his clones showed some random nucleotide base 
changes in exons 2 to 4 (Figure 2.10, indicated with underlines), which result in changes to 
two amino acids (Figure 2.10, indicated by black arrows). The change in the CLN5his clones 1 
Figure 2.9 The full length ovine CLN6 PCR products  
PCR products were run on a 1.5% agarose gel and examined 
under UV light. The primers used are listed in Table 2.2. A 972 
bp PCR product was observed. M refers to the 1 kb Plus DNA 
ladder. 
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and 2 (Val87Met) resulted from a G to A transition at nucleotide 259. Another change in the 
CLN5his clones 2 and 3 (Leu1140Pro) resulted from a T to C transition at nucleotide 419. 
These changes could arise because the ovine CLN5 gene sequences are toxic to the host 
during E. coli replication, causing mutated CLN5 gene sequences to be amplified instead of 
normal ones. Other studies involving toxic proteins in E. coli are discussed in section 2.4.2. 
Sequencing showed that only one of the 8 CLN5his exons 2-4 clones had an identical protein 
sequence to the published ovine CLN5 (NP_001076064).  Subsequently, these clones of 
pRUNCLN5his exons 2-4 and the pRUNCLN6his were transformed into C43 (DE3) E. coli cells 
specifically selected for protein expression. 
 
 
 
Figure 2.10 Sequence alignment of different pRUN CLN5his clones 
Only the variable regions are shown in the three CLN5his clones (1, 2 and 3). A dash indicates identity with the 
‘true’ pRUNCLN5his construct sequence (top). Silent changes in nucleotides are underlined, and arrows indicate 
changes in both nucleotides and amino acids. All the changed nucleotides are labelled with the numbers below 
referring to their positions. 
2.3.3 pRUN-driven CLN5 and CLN6 protein expression was not successful 
SDS-PAGE electrophoresis did not reveal any differences between all samples collected 
before and after induction (Appendix A.3.1), indicating that the target recombinant CLN5 
and CLN6 proteins were not expressed in detectable quantities.  Alternative protein 
 59 
expression conditions were also tested, including a decrease in the cell growth temperature 
down to 25°C or 30°C after IPTG induction, and a decrease in the IPTG final induction 
concentration to 0.5 mM. Again no exogenous protein expression was detected by SDS-
PAGE.  
 
Figure 2.11 SDS-PAGE gel analysis of recombinant CLN6 
For each protein sample, 30 μg, was run on a 12% acrylamide gel which was stained with Commassie blue. C43 
(DE3) cells containing the CLN6 protein expression construct pDEST17 CLN6 exons 2-7 were grown at 37°C and 
then induced with 0.5 mM or 1 mM IPTG and incubated at (a) 37°C for 5 h or (b) 20°C for 23 h. The samples for 
analysis were collected just before the induction and (a) 1 h, 2 h, 3 h and 4 h post-induction or for (b) 6 h and 
23 h post-induction incubation. MW refers to Precision plus protein standard. 
2.3.4 Expression of the ovine CLN5 and CLN6 proteins by the Gateway 
expression system 
Similar protein bands were visible on Coomassie stained polyacrylamide gels from CLN6his 
ex2-7 sample fractions from before and after IPTG induction (Figure 2.11), indicating that 
recombinant CLN6 protein was not expressed in detectable amounts. Any expression of 
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recombinant CLN5 proteins was minimal, as exogenous bands of the expected molecular 
weights of peptides were not detected on the gels. (Appendix A.3.2). 
2.3.5 Cloning the full length CLN5 coding sequence into a pCR4-TOPO vector  
Successful cloning of the full length ovine CLN5 sequence with and without a myc tag into 
pCR4-TOPO vector was confirmed by EcoRI restriction digestion. Two DNA fragments of the 
expected size of 3936 bp (vector) and 1217 bp (insert) (Figure 2.12) were observed from 
EcoRI digested pCR4-TOPO CLN5 plasmid DNA (5153 bp, generated as in section 2.2.7.2). 
Two DNA fragments with expected sizes of 3936 bp and 1238 bp (Figure 2.12) were revealed 
from EcoRI digested pCR4-TOPO CLN5myc plasmid DNA (5074 bp, generated as in section 
2.2.7.2). Each plasmid DNA aligned 100% with the published CLN5, with and without myc 
sequences.  
 
 
 
Figure 2.12 EcoRI digested pCR4-TOPO CLN5 and pCR4-TOPO CLN5myc plasmid DNAs 
Undigested and EcoRI digested plasmid DNA were run on 1% agarose gel and examined under UV light. (a) 
Two bands of 3936 bp and 1217 bp were generated from pCR4-TOPO CLN5 DNA (5153 bp) after EcoRI 
digestion. (b) Two bands of 3936 bp and 1138 bp were generated from pCR4-TOPO CLN5myc DNA (5074 bp) 
after EcoRI digestion. M refers to the 1 kb DNA ladder (Axygen, NZ). 
 
Subsequently, these successful clones were used for protein expression in a eukaryotic 
system (described in Chapter 3). The plasmid DNA of constructs pCR4-TOPO CLN5 and pCR4-
TOPO CLN5myc were sent to Dr. Stephanie Hughes (Viral Vector Facility, University of Otago) 
for cloning into lentiviral vectors, which were then used to produce CLN5 proteins (see 
Chapter 3).   
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2.3.6 Genotyping the CLN5 exon 1 
2.3.6.1 PCR-SSCP analysis of ovine CLN5 exon 1 
Amplification of the sheep exon 1 revealed two alleles (a and b) (see section 2.3.1.1). The b 
allelic sequence (406 bp) have five bases changes compared with the published a allele (426 
bp) sequence (NM_001082595). PCR amplification of exon 1 of ovine CLN5 from affected (n 
= 42), heterozygotes (n = 82) and unrelated control (n = 227) sheep blood genomic DNA also 
generated these two amplicons (426 bp and 406 bp) shown on agarose gels (Figure 2.13 a). 
The resultant three allelic patterns were revealed as follows. The aa alleles contained the 
426 bp fragment, the bb alleles contained the 406 bp fragment, and the ab alleles contained 
both. No other bands were detected. Subsequently these PCR products were subjected to 
single strand conformation polymorphism (SSCP) analyses for DNA polymorphism detection. 
Because different ssDNAs fold differently, any base changes will be detected by the 
appearance of new bands, revealed by silver staining. Three SSCP patterns were observed, 
representing the three allele possibilities, aa, bb and ab (Figure 2.13 b). Variant aa had three 
dense bands, while variant bb had one major dense band. 
Frequencies of the observed allele patterns were calculated across the sheep genotypes 
(Figure 2.13 c). All 42 affected sheep CLN5-/- PCR amplicons revealed only a single band of 
426 bp in agarose gels (Figure 2.13 a) and a reproducible aa band pattern on SSCP analysis 
(Figure 2.13 b).  Allele a aligned 100% with the published ovine CLN5 sequence (Figure 2.5 a). 
Thus, all the affected sheep samples contained only aa alleles. The bb allele was not found in 
the 82 heterozygotes tested (Figure 2.13 c). All three allele possibilities were detected in 227 
controls, aa, bb or ab, the overall control allele ratio being 17: 53: 30. Thus the aa alleles 
were present in the affected sheep samples, and in controls (38 out of the 227 normal 
sheep), therefore these allelic variations are not associated with the CLN5 disease.  
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Figure 2.13 Genotyping the PCR product of the ovine CLN5 exon 1 
(a) PCR of ovine CLN5 exon 1. Three allelic variants in ovine CLN5 exon 1 were detected - a 426 bp PCR product 
(aa allele), a 406 bp PCR product (bb allele) and a PCR product containing alleles a and b. (b) Single strand 
conformational polymorphism of the ovine CLN5 exon 1 gene. Sheep DNA samples representative of the three 
unique SSCP patterns corresponding to three allelic sequences, aa, bb and ab, are shown. Amplicons were 
separated on 14% SSCP gels at 390 V, 19 h, 12°C. (c) The percentages of different CLN5 exon 1 alleles in New 
Zealand sheep. 
 
2.3.6.2 Sequencing the ovine CLN5 exons 2-4  
Since allelic variations were found in ovine CLN5 exon 1, the rest of the CLN5 coding 
sequence (exons 2-4) was also examined. The CLN5 exons 2-4 were amplified from nine 
genomic DNA samples containing exon 1 alleles aa, bb or ab. A single 907 bp band was 
present in all the tested samples (Figure 2.14). All these PCR products were sequenced and 
found to be the same as the published ovine CLN5 coding sequence.  
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2.3.6.3 Examination of the bovine CLN5 exon 1 
The unexpected occurrence of allelic variants in exon 1 of ovine CLN5 led to an examination 
of other species. PCR amplifications of bovine CLN5 exon 1 from CLN5 affected Devon cattle 
(n = 2), heterozygotes (n = 12) and controls (n = 16) DNA generated a single expected 
fragment (437 bp) (Figure 2.15), which aligned 100% with the published bovine CLN5 coding 
sequence (NM_001046299). Unlike ovine CLN5 exon 1, direct sequencing of random bovine 
samples did not reveal any sequence variant changes in exon 1. 
 
 
 
2.3.6.4 Examination of the human CLN5 exon 1 
 
 
The possibility of allelic variation in human CLN5 was also explored. A single band of the 
expected size (470 bp) was detected in all the CLN5 exon 1 PCR amplicons from human 
samples; 53 anonymous human oral samples and 2 normal human brain tissue samples 
Figure 2.16 PCR amplification of 
human CLN5 exon 1 
PCR products were run on 1.5% 
agarose gels. A 470 bp PCR 
product was amplified by using 
the H1F2 and H1R1 primers.  
Figure 2.15 PCR amplification of 
the bovine CLN5 exon 1 
PCR products were run on 1.5% 
agarose gels. A 437 bp PCR product 
was amplified by using of the 
5’UTRF7 and I1R2 primers. 
Figure 2.14 PCR amplification of the ovine CLN5 
exons 2-4  
5 μl of each PCR product was run on 1.5% agarose 
gels and examined under UV-light. A 907 bp PCR 
product resulted from the use of the CLN5_Ex2F 
and CLN5_TOPO_Revstop primers from animals 
containing exon 1 alleles aa, bb and ab.  
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(Figure 2.16). Direct sequencing confirmed that all amplified sequences aligned with the 
published human CLN5 sequence (NM_006493), and revealed nucleotide substitutions in 
four locations (Figure 2.17, indicated by black underlines). The first involved a C to T 
substitution at nucleotide 4, resulting in an Arg to Cys change. The second also involved a C 
to T substitution at nucleotide 61, resulting in a change of Pro to Ser. The others 
substitutions were silent. However, all were located before the third ATG, which has been 
identified as the true start codon of the human CLN5 (Isosompii et al., 2002, Frugier et al., 
2008). There were no sequence variants present in the human CLN5 exon 1 coding regions 
from all the tested samples, if the initiation site of human CLN5 is the third ATG.  
 
Figure 2.17 DNA sequence alignment of the human CLN5 exon 1 
Only variable regions are shown. A dash indicates identity with the top sequence, which is the published 
human CLN5 coding sequence (NM_006493). The third ATG is the start of exon 1, and CAA is the end of exon 1. 
2.3.7 Bioinformatics of the CLN5 interspecies comparison  
The published CLN5 ovine protein sequence (NM_001082595) was aligned to human 
(NM_006493), cattle (NM_001046299), dog (NM_00001011556), mouse (NM_001033242), 
predicted pig (XP_005668529), partial rabbit (XP_002712979) and chicken (XP_417005) 
sequences published on NCBI using Genedoc software (Figure 2.18).  An inter-species 
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comparison showed that the GC-rich exon 1 is highly variable between species (in the pink 
box), whereas the rest of the coding sequence (starting from WPVPY…) is strongly 
homologous. Alignment of ovine CLN5 protein sequences also revealed a very high degree of 
homology to bovine (96%), and less homology to the pig (88%), dog (87%), human (84%), 
rabbit (80%), mouse (77%) and chicken (72%) CLN5 sequences. 
All the above species had an N-terminal hydrophobic region corresponding to amino acids 
75-91 of the human CLN5 polypeptide (Holmberg et al., 2004), marked by a green line 
(Figure 2.18). The human CLN5 polypeptide is predicted to contain an N-terminal signal 
sequence, which is cleaved between amino acids 95 and 96 after entering the ER (Isosompii 
et al., 2002; Vesa et al., 2002). Mouse CLN5 also contains a signal sequence (Holmberg et al. 
2004). A signal peptide prediction program SignalP V4.1 
(http://www.cbs.dtu.dk/services/SignalP/) was used to predict the signal sequence cleavage 
sites (Figure 2.18, highlighted in yellow) in all the eight species. These were observed at 
almost the end of exon 1. The above predicted N-terminal signal sequences mediate 
targeting proteins to the ER in a signal recognition particle (SRP)-dependent manner. Signal 
sequences have a tripartite structure, consisting of a hydrophobic core region (h-region or 
single alpha-helix, Figure 2.18, marked by a green line) flanked by an n- (containing short 
positively charged amino acids) and a c-region that contains a signal peptidase (named 
cleavage site, Figure 2.18, marked by yellow highlight). 
2.4 Discussion 
2.4.1 Difficulties associated with cloning the full length ovine CLN5 
Amplification of the full length ovine CLN5 cDNA in one PCR reaction had not been done 
before.  Previous studies relied on several pairs of primers which amplified the exons and 
introns separately to produce the ovine CLN5 sequence (Frugier et al, 2008). All CLN5 
mutation studies of other species, including humans (Bessa et al., 2006), cattle (Houweling 
et al, 2006), and dogs (Melville et al, 2005), also used several short PCR reactions to produce 
sequences. 
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Figure 2.18 Alignment of human, sheep, cattle, dog, mouse, pig, rabbit and chicken CLN5 polypeptides 
Black arrows indicate the four possible human initiation sites (M), the third of which has been identified as the 
actual initiation site (Isosompii et al., 2002), being the start codon of exon 1 of the other seven protein 
sequences. The end of exon 1 (Y) of all eight fragments is indicated by a red arrow.  Pink regions indicate exon 1 
of all species. Black or grey backgrounds indicate amino acids conserved in all or several species. The 
hydrophobic region of the predicted signal sequence is marked by a green line. The amino acids N-terminal to 
the predicted cleavage sites are highlighted in yellow. The predicted cleavage sites of human, sheep, dog, pig 
and rabbit protein sequences were glycine (G), aspartic acid (D) in cattle, arginine (R) in mouse and serine (S) in 
chicken.  Modified from Frugier et al. (2008). 
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Difficulties in obtaining the full length cDNA in one PCR are likely caused by the disjunction in 
GC/AT ratios. CLN5 exon 1 sequence contains a much higher percentage of G/C bases 
(around 80% in ovine) compared with exons 2-4. GC-rich DNA sequences are more stable for 
PCR than sequences with a low GC content; the higher the GC content, the higher the 
melting point of the DNA. Increasing the melting temperature could separate the GC rich 
regions, but results in very low product yields or even no PCR product (Strien et al., 2013), 
especially for whole coding sequence amplification perhaps, because the Taq enzyme begins 
to denature more rapidly after several of cycles.  
To overcome this, a two-step PCR and ligation strategy was used here to generate the full 
length ovine CLN5. First, the GC rich CLN5 exon 1 and the lower GC content exons 2-4 
sequences were amplified separately (Figure 2.4, Figure 2.6 and Figure 2.7). Two separate 
PCRs were used to ensure that the two parts of the ovine CLN5 coding sequence amplified 
correctly, and to produce adequate amounts DNA for templates for the next PCR. Second, 
the complementary internal overhanging forward primer (38 bp) and the internal 
overhanging reverse primer (34 bp) were quite long, which would assist annealing. The 
forward one was generated with an overhanging sequence homologous to the 3’ end 
sequence of exon 1, followed by the 5’ end sequence of exon 2; whereas the reverse one 
was designed from the 3’ end sequence of exon 1, followed by a corresponding overhanging 
sequence homologous to the 5’ end sequence of exon 2. After the exon 1 and exons 2-4 
products were amplified separately using these overhanging primers, the two resultant 
fragments contained sequences with complementary ends at 3’ end of the exon 1 fragment 
and 5’ end of the exons 2-4 fragment (Figure 2.7), which helped Taq and primers to amplify 
the full coding sequence successfully in the final PCR reaction. 
2.4.2 Attempted expression of recombinant proteins with pRUN and Gateway 
vectors 
None of the attempts to produce recombinant proteins in prokaryotic systems were 
successful. These failures to express either CLN5 or CLN6 recombinant proteins may have 
been because of the toxicity of the target proteins, which might have caused bacterial cell 
death. The C43 (DE3) stain used in this study is originally a mutant strain of E. coli BL21 
(DE3), and was developed to overcome the toxicity associated with overexpressing 
recombinant proteins using the T7 RNA polymerase expression system (Miroux and Walker, 
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1996). It has previously been shown to improve the stability of plasmids in culture during the 
expression of toxic proteins (Dumon-Seignovert and Vuillard, 2004).  
In this study, the CLN5 clones produced only a few colonies on the agar plates, and all 
contained mutant CLN5 sequences (Figure 2.10). This may result from the CLN5 messenger 
RNA being toxic for C43 (DE3) cells causing growth inhibition. Previous studies also 
suggested that protein toxicity may arise when the recombinant protein performs an 
unnecessary function, which interferes with the normal proliferation and homeostasis of the 
host, resulting in a slower growth rate and cell death (Dong et al., 1995). However, the CLN5 
mutant amplified messenger RNAs were clearly not too toxic to C43 (DE3) cells, as mutated 
CLN5 colonies were generated. 
To help overcome this problem, an alternative method, expression of the full length CLN5 
and CLN6 proteins in a eukaryotic expression system using mammalian cells (human 
embryonic kidney, HEK293) was attempted. Protein expression in bacteria can result in 
higher yields and lower costs, but the lack of chaperones, specific co-factors and post-
translational modifications may cause loss of function, mis-folding, and thus affect protein-
protein interactions (Wurm, 2004). Using a mammalian cell expression system could address 
these drawbacks. The details of protein expression using full length CLN5 and CLN6 coding 
sequences transfected into HEK293 cells are described in Chapter 3.  
2.4.3 CLN5 exon 1 allelic variants are not disease associated 
PCR-SSCP analysis detected variants in the ovine CLN5 exon 1 (Figure 2.13), but not in exons 
2-4 (Figure 2.14). One allelic variant sequence (allele b) was only observed in heterozygote 
and control sheep. All the affected sheep had the published sequence (allele a), but this was 
also found in 38 unaffected sheep. Thus, this allelic variation is not associated with the CLN5 
disease. This was the only variant detected in the current tested samples, but more variants 
may be found in other sheep.  
In order to gain some idea of exon 1 variants in other species, bovine and human CLN5 exon 
1 sequences were also tested for possible allelic variations, and their association with NCL 
(Figure 2.15 and Figure 2.16). Naturally occurring CLN5 in cows (Houweling et al., 2006) 
presents with a disease course matching that of ovine CLN5, the causative mutation being a 
single base duplication (662dupG) in bovine CLN5. This mutation causes a frame-shift and a 
premature truncated protein (Arg221GlyfsX6). There are no CLN5 exon 1 sequence changes 
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reported in cattle, and the random bovine samples tested in the current research did not 
have any variants in exon 1. 
Human CLN5 shows 84% sequence similarity to the sheep gene, the greatest difference 
being in exon 1 (Figure 2.18). The human CLN5 coding sequence contains four possible ATG 
initiation sites. Initially, the first ATG was suggested as the initiator (Savukoski et al., 1998), 
and then the fourth ATG was considered the major initiation site, leading to a 38 kDa protein 
(Isosompii et al., 2002). Later studies suggested that the human CLN5 polypeptide has an N-
terminal signal sequence, which is cleaved off between amino acids 95-96 (Isosompii et al., 
2002; Vesa et al., 2002). After the full alignment of human, mouse, canine, bovine and ovine 
CLN5 cDNA sequences, it was concluded that the third human ATG is the conserved start 
codon (Frugier et al., 2008). Previously, variants have been reported in the human CLN5 
exon 1. Only one silent nucleotide change (72A>G) in exon 1 was found in a JNCL patient 
who had a mutation in exon 4 which caused a Phe361Leufs (Xin et al., 2010). Direct 
sequencing of 55 random human samples in this study revealed nucleotide substitutions in 
four locations in exon 1, two of which involved translation changes (Figure 2.17, Arg11Cys 
and Pro33Ser), however all the changes are located before the real start of the human CLN5. 
Naturally occurring CLN5 in dogs (Melville et al., 2005) have a mutation which results in a 
frame-shift and prematurely truncated protein (Arg221GlyfsX6). The disease in affected 
Border Collie dogs (Melville et al., 2005) and Australian Cattle Dogs (Kolicheski et al., 2016) is 
caused by a single nucleotide change at 619 bp in exon 4 of the CLN5 coding sequence. This 
transition results in replacement of Gln209 with a stop codon. No other sequence changes 
have been reported in dog CLN5 exon 1. 
2.4.4 The relationship between CLN5 exon 1 allelic variants and mutant CLN5 
clones 
Inter-species comparison revealed that the CLN5 exon 1 is highly variable between species, 
whereas the rest of the coding sequence is highly conserved (Figure 2.18). All of the species 
studied have a predicted N-terminal signal sequence, which typically directs the newly 
synthesized protein to the endoplasmic reticulum and is cleaved off either during or after 
completion of translocation to generate a free signal peptide and a mature protein. Signal 
sequences are variable in length and amino acid composition, and variability of the signal 
sequence affects interactions with the translocon or efficiencies of the targeting protein 
insertion into the ER membrane (Hegde and Bernstein, 2006). In this study, all the CLN5 
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clones generated had DNA sequences containing only the aa allele variant in exon 1, and 
PCR-SSCP analysis found that all the affected sheep samples contained only aa alleles, not bb 
or ab alleles (Figure 2.13 c). Signal sequence binding is mediated primarily by the signal 
recognition particle and the hydrophobic region, then further translation directs the signal 
sequence-ribosome-mRNA complex to the SRP receptor. This study found that the 
differences between the a and b alleles were three amino acid changes in this hydrophobic 
region (Figure 2.18). 
2.5 Conclusion 
Successful expression of full length recombinant ovine CLN5 and CLN6 proteins in an E. coli 
prokaryotic system is unlikely. Without the expressed proteins, the originally planned study 
could not be carried out. The plan of the study was to generate CLN5 and CLN6 antibodies by 
inoculation of recombinant proteins as antigens into chickens, to subsequently produce IgY 
antibodies. Therefore, CLN5 and CLN6 protein expression experiments were attempted in 
eukaryotic systems (Chapter 3). 
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Expression of CLN5 and CLN6 proteins in mammalian cells 
and characterisation of polyclonal antibodies raised 
against these proteins 
3.1 Introduction 
Highly specific and sensitive antibodies are critical tools for biological research and 
diagnostics, however this is a time-consuming and often frustrating process. Traditionally, 
polyclonal antibodies that are raised against proteins are generated by injection of a peptide 
or purified protein (as antigen) together with an immunogenic adjuvant (e.g. Freund’s 
adjuvant) into a host animal. Antigens are commonly generated by synthesising antigenic 
peptides or by purifying recombinant proteins or fragments from E. coli. Even when this is 
possible some putative antigens remain difficult, particularly ones like lysosomal proteins 
that are often highly conserved and have a close association with the MHC II- antigen 
presentation system. One way around this has been to clone the sequences for the antigens 
of interest into the mycobacterium, Bacillus of Calmette–Guérin (BCG), which acts as an 
inbuilt adjuvant and vehicle for in vivo protein expression.  This system has been used to 
produce immunity against many antigens, including the endosome-dwelling parasite, 
Leishmania major (Abdelhak et al 1995).   
However, neither of the CLN5 or CLN6 proteins could be expressed in prokaryotic E. coli 
systems (Chapter 2). Bacterial expression systems have no capacity to perform eukaryotic 
post-translational modifications such as glycosylation and proper folding (Palomares et al., 
2004). As an alternative, recombinant protein expression in mammalian cells has been 
developed. Human embryonic kidney (HEK293) cells provide a popular mammalian 
heterologous expression system with reliable growth and transfection characteristics 
(Graham et al., 1977, Thomas and Smart, 2005). HEK293FT cell lines, suitable hosts for 
lentiviral production, are derived from HEK293 cells, and can bind to the SV40 large T 
antigen which can increase protein production (ThermoFisher Scientific, growth and 
maintenance of the 293FT cell line guide).  
Lentiviruses, a family of complex retroviruses, are often used to derive vectors for gene 
therapy. Use of lentiviral vectors has been considered one of the most efficient methods of 
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gene delivery for lysosomal disorders, showing persistent transgene expression in mouse 
models (Brooks et al., 2002; Haskell et al., 2003; Linterman et al., 2010).  Lentiviral vectors 
can generate recombinant target proteins quickly and efficiently, under tight promoter 
control (Brooks et al., 2002; Sands and Davidson, 2006). Strong CLN6 expression resulted 
from using a lentiviral vector containing the ovine CLN6 coding sequence fused with a myc 
tag at the C-terminus into sheep neural cell cultures (Linterman et al., 2011). 
Adenoviral vectors provide another widely used gene transfer tool, and can produce a good 
adjuvant for antibody generation, when used to overexpress the target antigen in vivo (Rein 
et al, 2006). This is a straightforward method for generating antibodies against soluble and 
membrane proteins, as the protein purification step can be eliminated. Rabbits and mice are 
the most widely used animals. Previous studies have used adenoviral-based techniques to 
generate CLN2 (TPP1) antibodies by injecting a recombinant adenovirus into rabbits (Haskell 
et al., 2003) and similarly CLN3 antibodies have been raised in mice (Tecedor et al, 2013). 
In the study described in this chapter, lentiviral vectors expressing the full length CLN5 and 
CLN6 coding sequences under the control of the MND promoter were packaged and 
transduced into HEK293FT cells, and the over-expressed recombinant CLN5 and CLN6 
proteins with no tags produced from these stable cell lines were used to test the specificities 
of antibodies. Full length CLN5 and CLN6 sequences without tags were packed into 
adenoviral expression vectors, transduced in HEK293FT cells for protein expression, and 
used as antigens injected into rabbits and mice to raise antibodies. The specificities and 
sensitivities of these antibodies were characterised by immunocytochemistry, Western 
blotting and mass spectrometry. 
3.2 Methods 
3.2.1 Generation of stable HEK293FT cell lines by lentiviral transduction for 
CLN5 and CLN6 recombinant protein expression 
3.2.1.1 Lentiviral constructs 
Four plasmids, pCR4-TOPO CLN5 and pCR4-TOPO CLN5myc (generated as in section 2.3.5), 
pcDNA3.1D TOPO CLN6 and pcDNA3.1D TOPO CLN6myc (generated by Dr. Nadia Mitchell), 
were used to generate lentiviral vectors. Lentiviral vectors expressing these transgenes were 
produced with Batten Animal Research Network (BARN) collaborators, led by Dr. Stephanie 
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Hughes at the Otago Viral Vector Facility, University of Otago, under approval from ERMA 
New Zealand (GMD03091). 
In short, HIV-1 derived lentiviral plasmids (Meyerrose et al., 2008) expressing ovine CLN5 
(NM001082595) and ovine CLN6 (NM001040289), fused with, or without C-terminal myc 
tags under the control of the myeloid sarcoma virus U3 element (MND), were packaged 
(Zufferey et al., 1998). HEK293FT cells (Life Technologies, Carlsbad, CA, USA) were 
transfected with plasmids containing the NCL transgenes, packaging and VSV-G envelope 
genes (Zufferey et al., 1998) in serum-free OptiMEM serum media (OptiMEM, GIBCO, 
Invitrogen, NZ) containing Lipofectamine-2000 (Invitrogen, NZ) (Linterman et al., 2011). The 
medium was recovered 48 hours post-transfection, concentrated, resuspended in PBS 
containing 40 mg/ml lactose, and viral vectors were stored at -80C in cryogenic vials. These 
functional viral vectors were named LVMNDCLN5myc, LVMNDCLN5, LVMNDCLN6myc and 
LVMNDCLN6. A viral vector, called LVMNDGFP, encoding a GFP (green fluorescent protein) 
reporter gene was used as a positive control for transduction.  
3.2.1.2 HEK293FT cell culture 
The lentiviral vectors (3.2.1.1) were used to generate stable cell lines in HEK293FT cells. A 
cryovial of HEK293FT cells was transferred into a T25 flask (Nunc, NZ) containing 5 ml of pre-
warmed Dulbecco’s modified Eagle medium (DMEM, GIBCO, Invitrogen, NZ), and incubated 
at 37°C in a humidified atmosphere containing 5% CO2. Once cells reached 70-80% 
confluence the culture medium was removed and the cells were rinsed with Dulbecco’s 
phosphate buffered saline solution (dPBS, GIBCO, Invitrogen, NZ). Cells were disassociated 
from the bottom of the flask with 0.05% trypsin EDTA (1.5 ml, Tryple E, Invitrogen, NZ), 5 
min, 37°C, followed by 3.5 ml of pre-warmed DMEM complete medium to terminate the 
trypsin reaction. Cell counts were determined using a haemocytometer after the addition of 
trypan blue dye (Sigma Aldrich, NZ) at a 1:1 ratio. Healthy live cells were round and clear, 
whereas the dead cells were filled with the blue dye. The HEK293FT cells were then 
passaged into either flasks or plates at the desired density. 
3.2.1.3 Transduction of lentiviral vectors and generation of HEK293FT cell lines 
To obtain stable, long-term CLN5 and CLN6 expression, HEK293FT cells were transduced with 
the lentiviral vectors generated in 3.2.1.1. The cells were grown in T75 flasks (Nunc, NZ) until 
40% confluence, and maintained in half changed media. Each vial of the five concentrated 
viruses was removed from the freezer and thawed to room temperature. Transduction was 
 74 
achieved by direct administration of virus to the media at an estimated multiplicity of 
infection (MOI) of 100 (viral transduction units/cell), followed by gentle mixing, and a further 
24 h incubation, 37°C. The five generated cells lines were named as 293FT LVMNDCLN5myc, 
293FT LVMNDCLN5, 293FT LVMNDCLN6myc, 293FT LVMNDCLN6, 293FT LVMNDGFP. When 
70% confluence was reached, the generated cells were dislodged (as described in section 
3.2.1.1). Half of the cell suspensions were frozen in DMEM containing 10% DMSO (Sigma, 
NZ) and aliquoted into several vials (2×106 cells/vial), stored at -80°C overnight, and then 
transferred to liquid nitrogen for long term storage as stocks. The remaining cells were 
repeatedly passaged in DMEM, and incubated for 24 h in OptiMEM media before 
immunocytochemistry, Western blotting and mass spectrometry.  
3.2.1.4 Immunolocalisation of myc tagged CLN5 and CLN6 proteins 
Cells of 293FT LVMNDCLN5myc and 293FT LVMNDCLN6myc (3.2.1.3) were plated onto poly-
L-lysine treated 6-well plates (Nunc, NZ) at 9×105 cells/well and maintained until 70% 
confluence. 293FT LVMNDGFP cells were used as a transduction control, allowing detection 
of virus transduction success by the detection of GFP under the fluorescent microscope. The 
cells were washed briefly in dPBS, and fixed in 4% paraformaldehyde (PFA), 15 min. The 
plates were used immediately or sealed with Parafilm (Sigma Aldrich, NZ), wrapped in foil 
and stored at 4°C.  
After a brief wash in dPBS, the cells were incubated with 300 µl/well blocking buffer, 3% 
normal goat serum (NGS, Sigma, NZ) in PBST (PBS, pH7.4, containing 0.2% Triton X-100), 30 
min, room temperature, followed by incubation with mouse anti-myc (ab18185, Abcam, 
Cambridge, UK) diluted 1:1000 in blocking buffer, 4°C, overnight. Cells were washed, 3 × 30 
min, with PBST before incubation with the secondary antibody, goat anti-mouse Alexa 594 
conjugated antibody (A11005, Invitrogen, NZ) diluted 1:1000 in blocking buffer, room 
temperature, 4 h. Unbound antibody was removed with another 3 × 30 min washes with 
PBST, and the cells were refreshed in 0.1 M sodium phosphate buffer (PB) pH 7.2. Cells were 
mounted on glass, with ProLong Gold antifade reagent (P36930, Invitrogen, NZ), cover-
slipped, and images taken with an Olympus IX71 inverted fluorescent microscope fitted with 
a DP71 camera using the 40× and 60× objectives.  For long term storage, the borders of 
coverslips and slides were sealed with nail varnish and the slides stored at 4°C in a lightproof 
slide box. 
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3.2.1.5 Extraction of CLN5 and CLN6 proteins, with or without myc tag, from 
HEK293FT cells 
All the generated cells (3.2.1.3) were plated as previously described in section 3.2.1.4. The 
cells were incubated until 70% confluence in DMEM, then for 24 h in serum-free OptiMEM. 
Proteins were extracted from both media and cells for Western blot analysis. To extract 
CLN5myc and CLN5 proteins, media generated from 293FT LVMNDCLN5myc and 293FT 
LVMNDCLN5 cells were collected and concentrated 25- fold through a 10 kDa cut-off 
centrifugal filter device (Amicon Ultra 0.5, Millipore, Thermo Fisher) by centrifugation, 30 
min, 17,000 g, 4°C. To test for CLN5 in cells, the cells were lysed with 100 µl of protein lysis 
buffer (4% w/v SDS, 20% v/v glycerol, 100 mM Tris pH 6.8) on ice, 20 min, boiled, 5 min, then 
gently homogenised by passing 5-10 times through a 25 gauge needle on a 1ml syringe. 
293FT LVMNDGFP cells, as a negative control, were lysed as above. 
Media generated from 293FT LVMNDCLN6myc and 293FT LVMNDCLN6 cells were collected, 
and centrifuged as above. The stable cells were lysed using ice-cold 1% n-dodecyl-β-D-
maltoside (DDM, Glycon Biochemicals, Luckenwalde, Germany) in 0.5 M Tris pH 7.4 and kept 
on ice, 20 min. The supernatant was collected by centrifugation, 30 min, 17,000 g, 4°C. 
Protease inhibitors, phenylmethyl-sulphonyl fluoride (PMSF 1 mM, Sigma, NZ) and EDTA (1 
mM) were added to all media and cell lysis buffers. Aliquoted samples for Western blotting 
and immunocytochemistry were stored at -80°C.   
3.2.1.6 SDS-PAGE electrophoresis and Western blotting 
The general process of SDS-PAGE is described in section 2.2.5.2. To prepare protein samples 
for loading, 30 µg of lysed cells or 10 µl of concentrated media were dissolved in protein 
sample buffer (protein lysis buffer with freshly added 200 mM DTT and 200 mM 
bromophenyl blue) and denatured at 70°C, 10 min. The proteins were separated on 10% 
poly acrylamide gels (80 V, 20 min, followed by 120 V, 1.5 h) and then transferred to Hybond 
PVDF membranes (GE Healthcare, UK), 100 V, 1 h, in a BioRad Mini Trans-Blot on ice using 
ice-cold transfer buffer and a cooling unit. The membranes were blocked in TBST (TBS, 0.1 M 
Tris-HCl, pH 7.2, 0.05% Tween 20), containing 5% skim milk powder, 1 h. This and all 
subsequent steps were carried out on a shaking platform, 40 rpm, followed by 3×10 min 
washes in TBST. Membranes were incubated in the primary antibody (1:2000 diluted in 
TBST) overnight, 4°C, washed, then incubated in the secondary antibody (sheep anti-mouse 
HRP, NXA931, GE Healthcare, UK, 1:10,000 diluted in TBST), 2 h. After washing in TBST, 3×10 
min, antigens were detected by chemiluminescence (ECL), 5 min, using ECL-Plus reagents 
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(GE Healthcare, UK) and protein bands visualised using a Fujifilm LAS-3000 imager (Fuji, 
Valhalla, NY).  
3.2.2 Optimisation of CLN5 and CLN6 antibodies generated from adenoviral 
vectors in stable cell lines 
3.2.2.1 Generation of polyclonal CLN5 and CLN6 antibodies 
The rabbit and mouse sera raised against CLN5 and CLN6 were produced by the laboratory 
of Dr Stephanie Hughes at University of Otago and ViraQuest Inc., North Liberty, USA, under 
approval from ERMA New Zealand (GMD 200732). In summary, the coding sequences of full 
length ovine CLN5 and CLN6 (sourced as in section 3.2.1.1) were cloned into adenoviral 
shuttle plasmids under the control of the CMV promoter. The shuttle plasmids containing 
the target genes were then transfected into HEK293FT packing cells. Adenoviruses 
containing CMVCLN5 and CMVCLN6 were amplified by serial passages on HEK293FT cells and 
purified, then injected into New Zealand white rabbits in a single ear vein injection or into 
Swiss Webster mice with a single injection into the tail vein. The rabbits were pre-bled 
before inoculation and blood collected 30 and 50 days post-injection.  Mice were bled two 
months post-injection. Sera prepared post-coagulation were stored at -20°C. 
3.2.2.2 Characterisation of anti-CLN5 and anti-CLN6 sera by Immunocytochemistry 
The general methods for characterisation of anti-CLN5 and anti-CLN6 sera are described in 
section 3.2.1.4. 293FT LVMNDCLN5 and 293FT LVMNDCLN6 cells were plated onto poly-L-
lysine treated 24-well plates (Nunc, NZ) at 4×104 cells/well and maintained until 70% 
confluent. The cells were fixed, blocked, and treated with primary rabbit anti-CLN5/CLN6 or 
mouse anti-CLN5/CLN6 antibodies at dilutions of 1:500 and 1:1000 in blocking buffer 
overnight, 4°C. Cells were washed 3 × 30 min with PBST before incubation with goat anti-
rabbit Alexa 488 (green, A11008, Invitrogen, NZ) or goat anti-mouse Alexa 488 (green, 
A11001, Invitrogen, NZ) conjugated secondary antibodies, diluted 1:1000 in blocking buffer, 
4 h. Following immunolabelling, cell nuclei were stained with 4’, 6-diamidino-2-phenylindole 
(DAPI, 1 mg/ml stock, Sigma Aldrich, NZ), diluted to 1:10,000 in PBS, 5 min, and washed with 
PBS. Cell media were then replaced with 0.1 M PB before the cells were mounted onto glass, 
cover-slipped with ProLong Gold antifade reagent, and imaged with a fluorescence 
microscope. The green (488 nm) or red (594 nm) fluorescence channels were used to 
compare the staining intensities at each dilution, thus to determine the optimal antibody 
concentrations. Appropriate negative controls (without primary antibodies) were included in 
all staining methods. 
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3.2.2.3 Western blot analysis of anti-CLN5 and anti-CLN6 antibodies 
The general processes for Western blot analysis of anti-CLN5 and anti-CLN6 antibodies are 
described in section 3.2.1.6. CLN5 and CLN6 protein samples from the 293FT LVMNDCLN5 
and 293FT LVMNDCLN6 cells (3.2.1.3) were extracted and quantified. Two 10% SDS gels 
were prepared. One gel was loaded with 30 µg of CLN5 lysed cells and 10 µl of CLN5 
concentrated media, and the other gel was loaded with 30 µg of CLN6 cells dissolved in 
DDM. Each set of samples was duplicated on each gel and transferred to PVDF membranes. 
Each membrane was blocked, and cut in half vertically. The halves were incubated 
separately overnight, 4°C, in one of the four primary antibodies (1:500 dilution of rabbit anti-
CLN5, mouse anti-CLN5 and mouse anti-CLN6; 1:1000 dilution for rabbit anti-CLN6). 
Following 3 × 10 min washes with TBST, each blot was incubated with donkey anti-rabbit 
HRP (NXA934, GE Healthcare, UK) or donkey anti-mouse HRP (NXA931, GE Healthcare, UK) 
(1:5000 dilution for CLN5 and 1:10,000 dilution for CLN6), 2 h. Washing steps were carried 
out as above, before 5 min ECL detection.   
3.2.2.4 Mass spectrometry analysis of ovine CLN5 and CLN6 proteins using anti-CLN5 
and anti-CLN6 antibodies raised in rabbits 
Mass spectrometry was used to identify the ligands to which the rabbit anti-CLN5 and anti-
CLN6 adenoviral antibodies bound to the SDS-gel bands from stably transduced HEK293FT 
cell lines. SDS-PAGE gels of proteins from these cells were stained with colloidal Coomassie 
blue G-250 (Sigma Aldrich, St. Louis, MO, USA). However, the yields of proteins at the 
anticipated molecular weights were too low to result in clearly stained bands. In order to cut 
the correct spot of the gels for mass spectrometry, protein bands were identified by 
Western blotting of parallel gel lanes and the equivalent areas cut from the Coomassie 
stained gel.  
Concentrated CLN5 media, 50 µl and 170 µg of CLN6 cell samples (as used in section 3.2.2.3) 
along with the protein marker were loaded onto half of a 10% SDS-PAGE gel for colloidal 
Coomassie blue G staining (Figure 3.6). Concentrated CLN5 media, 10 µl and 30 µg of CLN6 
lysed cells were similarly loaded onto the other half of this gel for Western blotting. 
Immediately following electrophoresis, the gel was cut in half. The half with the protein 
marker was fixed overnight in 50% (v/v) ethanol and 3% phosphoric acid (v/v). After 3× 30 
min washes with distilled water, the gel was equilibrated in 34% methanol (v/v), 3% 
phosphoric acid (v/v) and 17% (w/v) ammonium sulphate, 1 h, before the addition of 0.025 g 
Coomassie blue G-250 powder. Equilibrium staining was achieved after 1 day, and 
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terminated with three 3× 30 min washes with distilled water. The second half of the gel was 
Western blotted, and bands were detected with rabbit antisera raised as described in 
section 3.2.2.3.  
Areas were cut out from the Coomassie stained gels at the appropriate sites of CLN5 and 
CLN6 as indicated from the Western blotting and processed for mass spectrometry at the 
Centre for Protein Research, University of Otago. Briefly, the gel areas were digested with 
sequencing grade modified trypsin (Promega, Madison, WI, USA) using a robotic workstation 
for automated protein digestion (DigestPro Msi, Intavis AG, Cologne, Germany). Eluted and 
dried peptides were analysed by liquid chromatography-coupled LTQ-Orbitrap mass 
spectrometry (Thermo Scientific, San Jose, CA, USA). Raw data were processed through 
Proteome Discoverer software v1.3 (Thermo Scientific, San Jose, CA, USA) and a Mascot 
search engine (Matrix Science; http://www.matrixscience.com/), searching against the 
SwissProt amino acid sequence database, which contains the predicted ovine CLN5 and CLN6 
sequences.  
3.2.2.5 Post-translational CLN5 
To study CLN5 glycosylation, CLN5 protein was deglycosylated by two enzymes; 
endoglycosidase H (Endo H, New England Biolabs, Ipswich, MA, USA) and peptide N-
glycosidase F (PNGase F, New England Biolabs). Concentrated CLN5 protein media, 2 µl, was 
mixed with 1 µl of 10× glycoprotein denaturation buffer and 9 µl of water. Each reaction mix 
was denatured at 100°C, 10 min, before incubation with 50 units of Endo H or 125 units of 
PNGase F according to the instructions, 37 °C, 1 h. Control samples were similarly incubated 
in appropriate buffers without the addition of the glycosidases. Digested protein samples 
and controls were separated by SDS-PAGE and visualised by immunoblotting for mass 
spectrometry. 
3.3 Results 
3.3.1 Lentiviral-mediated expression of ovine CLN5myc and CLN6myc 
proteins 
In an initial experiment, recombinant lentiviral expression vectors containing ovine CLN5 and 
CLN6 cDNA sequences fused to a C-terminal myc tag were used to generate transduced 
HEK293FT cell lines and express the proteins for molecular analyses. Expressions of CLN5myc 
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and CLN6myc were indicated by immunocytochemistry for the myc-tag. Molecular masses of 
the expressed myc tagged proteins were confirmed by Western blotting. 
3.3.1.1 Immunocytochemistry of expressed CmvLN5myc and CLN6myc proteins 
A GFP control virus was transduced into HEK293FT cells to check transduction efficiency. 
Fluorescence microscopy detected GFP expression and confirmed transduction (Figure 3.1 
a). Anti-myc antibody staining of transduced HEK293FT cells containing myc tagged CLN5 
(Figure 3.1 b) or CLN6 (Figure 3.1 c) was revealed by red immunofluorescence in the 
cytoplasm. Anti-myc staining was not visible in non-transduced HEK293FT cells. These results 
indicated that the cell lines transduced with the CLN5myc and CLN6myc lentiviral expression 
vectors expressed recombinant protein within the cells. 
 
a                                                        b                                                         c  
 
 
Figure 3.1 Immunofluorescent images of proteins expressed in transduced HEK293FT cells 
(a) GFP expression (b) CLN5myc and (c) CLN6myc expression. Lentiviral transduction was detected with anti-
GFP (green, 1:500) or mouse anti-myc (red, 1:1000). The scale bar represents 200 µm for CLN5myc (b) and 100 
µm for CLN6myc (c) and GFP (a) cells.  
 
3.3.1.2 Western blotting of expressed CLN5myc and CLN6myc proteins  
The protein samples used for Western blotting of expressed CLN5myc and CLN6myc proteins 
were CLN5myc from cells and concentrated media, CLN6myc from cells and concentrated 
media, and GFP from cells (as a negative control). Western blotting using the mouse anti-
myc antibody revealed a single prominent immunoreactive band of 29 kDa in cell extracts 
from CLN6myc transduced cells (Figure 3.2). The size of this band is similar to that of the 
human CLN6myc protein transiently expressed in BHK21 cells (Mole et al. 2004). However, 
no such band was evident in the CLN6myc media indicating that the CLN6myc protein was 
not secreted. CLN5 was detected by the anti-myc antibody in both CLN5myc media (secreted 
fractions) and CLN5myc cell extracts at apparent molecular weights of approximately 60 kDa 
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(Figure 3.2), similar to the full length human CLN5 protein found in media of overexpressing 
BHK cells (Isosomppi 2002). This size is consistent with the anticipated mass of the CLN5myc 
tag construct, and also similar to that of the mature human CLN5 protein (Sleat et al. 2006) A 
strongly stained CLN5myc band was observed in the media, but the band from the 
solubilized CLN5myc cells was faint, indicating that most of the synthesised CLN5myc was 
secreted into the media.  
 
 
 
Figure 3.2 Western blot of LVMNDCLN5myc, LVMNDCLN6myc and LVMNDGFP expressing HEK293FT cells 
Thirty microgram protein aliquots of each cell sample and 10 µl of CLN5myc and CLN6myc media samples were 
resolved on a 10% SDS-PAGE; proteins were transferred to a PVDF membrane and subsequently treated with 
1:2000 mouse anti-myc and 1:10,000 donkey anti-mouse HRP. A pre-stained Precision Plus protein marker 
(2.2.5.2) was used to determine molecular weight.  
 
The negative control cells, expressing GFP, did not contain bands with molecular masses of 
either 60 kDa or 29 kDa, as expected, since they were not transduced with either CLN5myc 
or CLN6myc. However, an endogenous myc band was observed around 35 kDa in all of the 
cell samples indicating that HEK 293FT host cells may contain a myc endogenous tag 
immune-reactive protein.  
3.3.2 Detection of CLN5myc and CLN6myc using antisera generated from 
adenoviral viral vectors 
Packaged adenoviral viral vectors containing CLN5 and CLN6 cDNAs were injected into 
rabbits in an attempt to raise antibodies, and sera were collected from their blood (3.2.2.1). 
Western blotting was used to test these putative anti-CLN5 and CLN6 antisera by 
determining if they stained the recombinant CLN5 and CLN6 myc tagged proteins 
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characterised above. The putative sheep CLN5 sera raised in rabbits detected protein bands 
of approximately 60 kDa in the CLN5myc media (Figure 3.3 a), similar to that previously 
found by mouse anti-myc staining of the CLN5myc samples (Figure 3.2). The putative sheep 
CLN6 antisera raised in rabbits strongly stained a 29 kDa band in CLN6myc cell extracts 
(Figure 3.3 b), the same sized band as observed in the same cell extracts by staining with the 
anti-myc (Figure 3.2). These results indicated that the sheep CLN5 and CLN6 antisera 
detected the CLN5myc and CLN6myc proteins.  
 
 
 
Figure 3.3 Western blots of rabbit anti-CLN5 and anti-CLN6 antibodies in LVMNDCLN5myc and 
LVMNDCLN6myc expressing HEK293FT cells 
Protein samples and markers were loaded as for in Figure 3.2. The blot containing CLN5myc proteins was 
treated with 1:500 CLN5 antisera and 1:5,000 donkey anti-rabbit HRP, and the CLN6myc blot was treated with 
1:1000 CLN6 antisera and 1:10,000 donkey anti-rabbit HRP. 
 
3.3.3 Detection of CLN5 and CLN6 proteins without myc tags using antibodies 
generated from adenoviral vectors 
The ovine CLN5 and CLN6 proteins without myc tags were also expressed in the generated 
293FT LVMNDCLN5 and 293FT LVMNDCLN6 cell lines (generated as described in section 
3.2.1.3). The expressed CLN5 and CLN6 proteins were used to examine the specificity of 
ovine CLN5 and CLN6 antisera raised in rabbit and mouse by immunocytochemistry and 
Western blotting. 
3.3.3.1 Optimisation of immunocytochemistry  
It is important that immunocytochemistry staining is of high quality, to enable detection in 
antiserum positive cells clear of background fluorescence. In this study, dilutions of 1:500 
 82 
and 1:1000 were tested for each of the primary antibodies; rabbit anti-CLN5, rabbit anti-
CLN6, mouse anti-CLN5 and mouse anti-CLN6. Cells that received antibodies at a dilution 
factor of 1:500 stained clearly; while the 1:1000 dilutions required higher exposure times, 
increasing background which impaired the clarity of the cells (Appendix A.4). Cells incubated 
with only secondary antibodies (as a negative control) did not show any staining. 
Subsequently the 1:500 dilution factor was chosen as the optimal antibody dilution for 
further immunochemistry experiments.  
3.3.3.2 Immunocytochemical analysis of adenovirally derived anti-CLN5 and anti-CLN6 
antibodies 
A study was conducted to detect untagged CLN5 and CLN6 protein using the adenoviral 
antibodies raised in rabbits and mice. LVMNDCLN5 cells showed bright and clear punctuate 
green staining with both rabbit anti-CLN5 (RαCLN5) and mouse anti-CLN5 (MαCLN5) 
antibodies at a dilution of 1:500 (Figure 3.4 i and iii) and the LVMNDCLN6 cells also stained 
clearly with both the rabbit anti-CLN6 (RαCLN6) and mouse anti-CLN6 (MαCLN6) antibodies 
at this dilution (Figure 3.4 ii and iv). DAPI stained the nuclei of all the cells. Merged images 
showed that most of the cells stained by DAPI were also labelled by the individual primary 
antibodies, indicating a high efficiency of transduction of the generated 293FT LVMNDCLN5 
and 293FT LVMNDCLN6 cells.  These results indicate that all of the antibodies identified the 
target cells containing CLN5 or CLN6 proteins. Since much more antisera were obtained from 
rabbits than mice, the anti-rabbit antibodies were used for most of the subsequent 
immunochemistry tests. 
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Figure 3.4 Immunofluorescent images of CLN5 and CLN6 protein expression in HEK293FT cells 
CLN5 proteins were detected with (i) rabbit anti-CLN5 (RαCLN5) or (iii) mouse anti-CLN5 (MαCLN5) antibodies; 
CLN6 proteins were detected with (ii) rabbit anti-CLN6 (RαCLN6) or (iv) mouse anti-CLN6 (MαCLN6) antibodies. 
Green: anti-CLN5 or anti-CLN6, blue: DAPI stained cellular nuclei, merged images: right column. The scales bars 
represent 200 µm for i and 100 µm for ii, iii and iv. 
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3.3.3.3 Western blotting with adenovirally derived anti-CLN5 and anti-CLN6 antibodies 
raised in rabbits 
A band with a molecular weight of 60 kDa was detected by Western blotting with rabbit anti-
CLN5 (1:500) of CLN5 transduced cells and concentrated media, a size consistent with that of 
the mature protein (Figure 3.5 a) (Sleat et al., 2006b). This indicated that the rabbit anti-
CLN5 antibodies recognise the full CLN5 protein. Two extra bands of slightly lower molecular 
weights were also revealed, which could be truncated forms of CLN5. The same pattern of 
CLN5 protein bands was detected with the mouse anti-CLN5 antibody (1:500), but the 
staining was not as intensive as with rabbit anti-CLN5. No staining was detected in GFP cells 
samples (negative control) or in CLN6-transduced cells (not shown).  
Similarly, both rabbit and mouse anti-CLN6 antibodies detected a protein in CLN6-
transduced cells with a molecular weight of 27 kDa (Figure 3.5 b) demonstrating the utility of 
the antibodies for ovine CLN6 proteins. Again, no signal was detected in GFP cells or in CLN5-
transduced cells (not shown). Both blots using mouse anti-CLN5 and anti-CLN6 antibodies 
had darker backgrounds and two extra bands from lysed cell membrane samples.  
 
 
 
Figure 3.5 Western blot of (a) LVMNDCLN5 and (b) LVMNDCLN6 expressing HEK293FT cells 
Protein bands were detected using rabbit anti-CLN5 and CLN6 or mouse anti-CLN5 and CLN6 antibodies by 
enhanced chemiluminescence exposed for 100 sec. Cell samples (30 µg) and CLN5 concentrated media (10 µl) 
were resolved by 10% SDS-PAGE. Proteins were then transferred to a PVDF membrane, treated with primary 
antibodies and donkey anti-rabbit/mouse HRP (1:5000 for CLN5 blot; 1:10,000 for CLN6 blot).  
3.3.4 Mass spectrometry 
Identity of protein exacted from gel fragments was confirmed by mass spectrometry. 
Coomassie blue staining from either the CLN5 or CLN6 transduced cells did not reveal bands 
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at the anticipated molecular weights, suggesting that the amount of the protein expressed 
was too little to stain with Coomassie (Figure 3.6). 
To overcome this, the CLN5 and CLN6 proteins samples were also detected with either rabbit 
anti-CLN5 or anti-CLN6 antibodies on Western blotting. A single band of each protein was 
identified by Western blotting, indicating the likely location of the protein on the Coomassie 
blue stained gels (Figure 3.6, in red rectangles) which were subsequently cut for trypsin 
digestion and mass spectrometry. Trypsin specifically cleaves proteins at the carboxyl side of 
arginine and lysine residues that are not followed by a proline, resulting in small tryptic 
fragments. The tryptic peptide fragments were analysed by mass spectrometry (MS) using 
MS/MS ion search.  
 
                                   
 
Figure 3.6 Coomassie blue staining and Western blotting of LVMNDCLN5 and LVMNDCLN6 expressing 
HEK293FT cells 
Proteins were separated by SDS electrophoresis. Half of each gel was stained with Coomassie blue (left) and 
the other half was labelled with rabbit anti-CLN5 or rabbit anti-CLN6 for Western blot analysis (right). The 
equivalent areas on the Coomassie blue stained gel at the expected molecular weights for CLN5 and CLN6 (in 
the red squares) were cut and submitted for mass spectrometry. 
 
3.3.4.1 CLN5 sequence 
In silico, digestion of ovine CLN5 by trypsin using the online peptide analysis of ExPASy 
(http://web.expasy.org/peptide_mass/) resulted in 27 peptide sequences of four or more 
amino acids (Table 3.1, T1-T27 and Figure 3.8, marked in orange lines). The mass 
spectrometry analysis identified 13 tryptic peptides, all of which were consistent with the 
predicted ovine CLN5 sequences, at an expected protein coverage of 42.2% (Table 3.1, 
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labelled with “Yes” and Figure 3.8, highlighted in grey). The longest identified fragment 
(RQWP……IGFR) matched the predicted peptides from T5 to T11, which includes all of exon 
2, several amino acids from the C terminus of exon 1 and the N terminus of exon 3. The 
remainder of the identified fragments matched the peptides T16, T18, T19, T22, T23 and 
T27, located in exon 4. The identified sequences in mass spectrometry started from the 53rd 
amino acid, but not at the predicted signal sequence (Figure 3.8, marked in a green box, 
amino acids 1-46, peptides T1-T4). Thus, the ovine CLN5 protein includes residues 53-361, 
producing a 308 amino acid mature protein. 
 
Table 3.1 The predicted trypsin digested ovine CLN5 peptide sequences 
 Mass Position Predicted trypsin digested peptide sequences Identified peptide 
sequences (MS) 
T1 1260.5902 1-14 MAQAGGAGAGAWGR  
T2 842.4115 16-25 GAGAGAGPER  
T3 529.2881 26-29 APWR  
T4 2222.1716 30-52 WAPALLWLAAATAAAAAAGDPSR  
T5 917.4879 54-60 QWPVPYK Yes 
T6 1684.7788 62-75 FSFRPEPDPYCQAK Yes 
T7 1540.7538 76-89 YTFCPTGSPIPVMK Yes 
T8 1107.5316 90-98 DDDVIEVFR Yes 
T9 1117.6040 99-107 LQAPVWEFK Yes 
T10 1015.5571 108-116 YGDLLGHLK Yes 
T11 1059.5404 117-125 IMHDAIGFR Yes 
T12 678.3668 126-131 STLTEK  
T13 5670.4685 132-178 NYTMEWYELFQLGNCTFPHLRPEMNAPFWCNQG
AACFFEG IDDNHWK 
 
T14 1850.9680 179-196 ENGTLVLVATISGGMFNK  
T15 2230.0298 203-221 QDNETGIYYETWTVQASPK  
T16 1164.4666 227-235 WFESYDCSK Yes 
T17 534.3398 236-239 FVLR  
T18 540.2664 240-243 TYEK Yes 
T19 963.5145 244-252 LAELGADFK Yes 
T20 896.4472 254-260 IETNYTR  
T21 2591.2664 261-284 IFLYSGEPTYLGNETSVFGP TGNK  
T22 729.4869 285-291 TLALAIK Yes 
T23 1527.7994 293-304 FYYPFKPHLSTK Yes 
T24 2013.1531 305-321 EFLLSLLQIFDAVVIHR  
T25 2237.0452 322-337 EFYLFYNFEYWFLPMK  
T26 591.3500 338-342 SPFIK  
T27 1344.7158 343-353 ITYEEIPLPNRKNRTLSGL Yes 
 
A search of the identified CLN5 fragment peptides against the universal data base using 
protein blast software (https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins) revealed 
that the peptide sequence of KEAEKWFESYDCSK (Figure 3.8, T16) did not align with any 
other confirmed protein sequence. The other identified peptide fragments were observed in 
bovine CLN5 sequence (NP_001039764.1), except that the first peptide fragment 
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(RQWP……IGFR) (T5-11) also found in pig (XP_005668529) CLN5. Thus, the rabbit anti-CLN5 
antibodies bind to the ovine CLN5 sequence specifically, after the CLN5 signal sequence has 
been cleaved off to produce a mature protein. 
The inferred molecular mass of the sheep CLN5 was 41.3 kDa from mass spectrometry, 
smaller than the 60 kDa stained band in Western blotting. That the size difference could 
arise from cleavage of the signal peptide and post-translational N-glycosylation is explored 
below. 
3.3.4.2 Post-translational modification of ovine CLN5 
CLN5 is heavily glycosylated and cleaved into a mature soluble protein (Sleat et al., 2006a).  
In this study, CLN5 secreted from 293FT CLN5 cells was subjected to deglycosylation with 
Endo H and PNGase F. Endo H releases high-mannose type oligosaccharides bound to Asn by 
cutting after the first N-acetylglucosamine (GlcNAc) residue of the oligosaccharide chain, 
leaving one sugar moiety on Asn (Figure 3.7 a) (Leonard et al, 1990). Endo H treatment 
resulted in the single 60 kDa band becoming three bands with molecular weights of 
approximately 46 kDa, 42 kDa and 38 kDa (Figure 3.8, bands 1, 2, and 3).  PNGase F removes 
complex type N-linked oligosaccharides by cutting immediately after the Asn, and does not 
leave a sugar moiety (Figure 3.7 b). The modification converts the asparagine to aspartic 
acid. Therefore, the PNGase F treated CLN5 samples migrated faster than Endo H treated 
samples. The PNGase F deglycosylation resulted in a single band (Figure 3.7 c, band 4) of 
approximately 35 kDa, consistent with the deglycosylated protein with the signal sequence 
removed. The size reduction from 60 kDa to 35 kDa confirms that the ovine CLN5 was 
glycosylated. 
A search of the ovine CLN5 protein using NetNGlyc 1.0 Server software 
(http://www.cbs.dtu.dk/services/NetNGlyc/)  indicated eight potential N-glycosylation sites 
as recognized by the sequence Asn – X – Ser/Thr. These were located at Asn (N) 132, 145, 
180, 205, 257, 273, 283 and 355 of ovine CLN5 (Figure 3.8, highlighted in blue). To determine 
which of the these eight N-glycosylation sites are utilized, the four Endo H and PNGase F 
deglycosylated protein bands (Figure 3.7 c, SDS gel in red squares) were excised and 
analysed separately by mass spectrometry. All the deglycosylated tryptic peptides (Figure 
3.8, purple lines) were then mapped individually with ovine CLN5 peptide fragments 
(highlighted in grey). The six putative N-glycosylation sites (indicated by pink arrows), N 180, 
205, 257, 273, 283 and 355 were identified from Endo H and PNGase F treated peptides, but 
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not from untreated CLN5 peptide fragments. This implies that those six potential 
glycosylation sites of the ovine CLN5 protein are N-glycosylated. The other two N residues 
(N132 and N145, indicated by question marks) were not identified in any peptide sequences. 
Whether or not those two are real N-glycosylation sites and function in CLN5 post-
translation modification is still not clear. 
             
 
Figure 3.7 CLN5 deglycosylation 
(a, b) Structures of N-linked oligosaccharide deglycosylated with Endo H or PNGase F. The abbreviations used 
are: M=mannose, G=galactose, GlcNAc=acetylglucosamine, Asn= asparagine, Thr=threonine, Ser=serine, and 
S=sialic acid. The red dashed lines indicate the enzyme cutting positions. (c) Coomassie blue stain and Western 
blot of EndoH or PNGase F deglycosylated LVMNDCLN5 expressing HEK293FT cells. As before protein bands 
were separated on an SDS gel, half of which was stained with Coomassie blue, and the other half labelled by 
Western blotting with the rabbit anti-CLN5 antibodiesfor Western blotting. The Coomassie blue stained bands 
at the molecular weights expected for CLN5 and CLN6 in the red rectangles were excised and submitted for 
mass spectrometry analysis. 
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Figure 3.8 Alignment of the normal sheep (N), affected Borderdale (A) and deglycosylated (M) CLN5 protein 
sequences 
The predicated signal sequence (residues 1-46) is marked in a green box. The asparagine residues of the eight 
predicated glycosylation sites are highlighted in blue. All the trypsin digested fragments from the sheep CLN5 
sequence identified by mass spectrometry are highlighted in grey, while those from Endo H or PNGase F 
deglycosylation are marked with purple lines. The 27 trypsin digest fragments (T1-T27) predicted by ExPASy are 
marked in orange lines. The CLN5 mutation in affected Borderdale sheep is a splice site mutation causing a 
frame shift which changes residue 116 through to a premature termination at triplet 126 (*). 
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3.3.4.3 CLN6 sequence 
In silico trypsin digestion of the ovine CLN6 sequence using the online peptide analysis, 
ExPASy (http://web.expasy.org/peptide_mass/) resulted in 12 possible peptide fragments 
(Table 3.2, T1-T12 and Figure 3.9, marked by pink lines). Two matching peptide sequences 
were identified by mass spectrometry in the current study. One was LIFSGYQNHLSVR (Figure 
3.9, in grey background), which matched the predicted tryptic T7 peptide sequence (Table 
3.2), and the other, HPGAAGGSGARPGASFLQAR, matched the predicted T2 tryptic peptide 
sequence (Table 3.2 and Figure 3.9, in grey background). The identified matched peptide 
sequences started from amino acid 9 (H), suggesting that CLN6 is unlikely to contain a signal 
sequence.  
 
Table 3.2 The predicted trypsin digested ovine CLN6 peptide sequences 
Mass Position Predicted trypsin digested peptide sequences Identified peptide 
sequences (MS) 
648.3133 1-6 MEAAAR  
1864.9524 9-28 HPGAAGGSGARPGASFLQAR Yes 
557.3042 29-33 HSSVK  
7716.9398 34-99 
ADEAAGTAPFHLDLWFYFTLQNWVLDFGRPIAMLVFPLEWFPLNKPS 
VGDYFHMAYNIITPFLLLK 
 
530.3296 100-103 LIER  
2842.5283 111-136 SLIYVSIITFIMGASIHLVG DSVNHR  
1533.8172 137-149 LIFSGYQNHLSVR Yes 
713.4192 150-155 ENPIIK  
5655.7321 156-201 NLKPETLIDSFELLYYYDEY LGHSMWYIPFFLILFMYFSG CFTPTK  
5347.8592 202-249 AESSMPGAALLLVVPSGLYYWYLVTEGQLFILFIFTSFAMLALVLHQK  
4096.2502 253-287 LFLDSNGLFLFYSFALALLLVALWVAWLWNDPVLR  
2616.2809 290-311 YPGVIYVPEPWAFYTLHVSSQY  
 
A search of the identified CLN6 fragment peptides against the universal database using 
protein blast software (https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins) revealed 
that the peptide sequence of HPGAAGGSGARPGASFLQAR is unique, as it did not align with 
any other sequence. The other identified peptide LIFSGYQNHLSVR also aligned with pig CLN6 
(NP_001230543.1) and bovine CLN6 (NP_001103454.1) only. These results establish that the 
area of the gel where the CLN6 antibody binds contains the CLN6 protein, thus confirming 
that the rabbit anti-CLN6 antibodies specifically bind to ovine CLN6.  
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Figure 3.9 Sheep CLN6 protein sequence 
The peptide sequences determined by mass spectrometry have a grey background. All the trypsin digested 
fragments (T1-T12) from sheep CLN6 sequence are marked with pink lines. Trypsin cuts the C-terminal side of K 
and R unless the next residue is P. 
 
3.4 Discussion 
3.4.1 Lentiviral-mediated expression of CLN5 and CLN6 recombinant proteins  
Several expression systems are used for the generation of recombinant proteins. The 
expression of some proteins, such as secreted glycosylated proteins, in prokaryotic systems 
can be challenging, as some are toxic to the bacterial host cells. To overcome this, lentiviral 
vectors have been developed to generate recombinant proteins in mammalian cells (Gaillet 
et al., 2010; Tang et al., 2015). In this study, lentiviral vectors expressing CLN5 and CLN6 
coding sequences fused with a C-terminal myc tag under the control of the MND promoter 
were used to transduce HEK293FT cells for protein expression. The immunocytochemistry 
(Figure 3.1) and Western blotting (Figure 3.2) results indicate the effectiveness of lentiviral-
mediated over-expression of recombinant CLN5myc and CLN6myc.  
3.4.2 Adenoviral antibodies 
As mentioned above, the original plan for generation of antibodies was inoculation of the 
expressed recombinant proteins fused to myc tags into chickens and subsequent production 
of IgY antibodies. However, the C-terminal myc used here, along with CLN5 modifications, is 
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unstable within the lysosome (Pelham, 1988). As myc tagged proteins are different from 
untagged proteins in their protein folding and glycosylation, full length ovine CLN5 and CLN6 
recombinant proteins without tags were deemed more appropriate sources for antibody 
generation (Figure 3.4 and Figure 3.5). In addition, even though production of IgY antibody 
from egg yolk has been well developed, successfully generating chicken CLN5 and CLN6 
antibodies could be difficult because of the limitation of the antigens. Traditionally, to raise 
an antibody from one chicken would require two injections of total 200-400 µg of antigens 
(Brunda et al., 2006), and at least two or three chickens. Here, lentiviral vector mediated 
recombinant ovine CLN5 and CLN6 proteins have been expressed, but the amounts of the 
proteins were too low to be visible on SDS-PAGE gels (Figure 3.7 c). Therefore, producing 
enough antigen for injection into chickens would be problematic. Further more extensive 
protein purification and multiple boosting would be required, and it would take several 
months to raise antibodies. 
Hence, an alternative method was to produce sheep antibodies by injection of adenoviral 
vectors expressing CLN5 and CLN6 proteins into rabbits and mice. These adenoviral 
antibodies were well characterised on overexpressed ovine CLN5 and CLN6 cells by 
immunocytochemistry (Figure 3.4) and Western blotting (Figure 3.5).  
3.4.2.1 CLN5 
The adenoviral CLN5 antibodies successfully recognised ovine CLN5. A mass spectrometric 
study using the antibody identified 13 tryptic ovine CLN5 peptides out of the 27 peptide 
fragments predicted by online peptide analysis (Table 3.1 and Figure 3.8). One of the 
identified peptide sequences (KEAEKWFESYDCSK) did not align with any other sequence 
among the universal data. This confirmed that these anti-CLN5 antibodies raised in rabbit 
were able to identify the ovine CLN5 sequence specifically. In addition, the other identified 
peptide sequences were found only in CLN5 sequences from cows and pigs, but not in any 
other proteins.  
It is not surprising that not all potential tryptic digest fragments were detected by mass 
spectrometry. Some of these peptides (Figure 3.8, T13, T14, T15, T20 and T21) contain 
asparagine residues, which are potential glycosylation sites. It is possible that the 
carbohydrate moieties interfere with the action of trypsin, therefore they are not being 
recognized (Leonard et al., 1990). Some others might be either too small to be identified (i.e. 
T17, FVLR) or likely to be extremely hydrophilic and poorly resolved from the salt fraction 
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during the digestion process (i.e. T12, STLTEK). The likelihood of insufficient amount of the 
protein sample also needs to be taken into account.   
CLN5 is a soluble lysosomal protein (Sleat et al., 2006a), synthesised as a pre-pro-protein 
with an N-terminal signal sequence, which translocates the precursor protein into the lumen 
of the ER. The signal peptide is removed and initial protein glycosylation takes place in the 
ER and Golgi apparatus. The mature protein is then recognized and bound by M6P receptors 
in the trans-Golgi network, and subsequently trafficked to lysosomes. The predicated mass 
of ovine CLN5 from online peptide analysis of ExPASy was 41.3 kDa. However, the peptide 
from the signal peptide of secreted CLN5 protein is not expected to be in the mature 
protein, so this part of the theoretical sequence (4.5 kDa, ProtParam tool, 
http://web.expasy.org/protparam/) should be excluded, and thus the mature CLN5 cDNA 
sequence mass reduces down to 36.8 kDa. The current study using sheep specific CLN5 
antibodies detected a band matched the observed molecular weight (60 kDa) in Western 
blot analysis (Figure 3.5). Treatment of the secreted CLN5 samples with PNGase F, which 
removes complex type oligosaccharides modified in the Golgi membranes, reduced the mass 
to around 35 kDa (Figure 3.7 c), close to the predicted mature CLN5 mass (36.8 kDa), 
confirming that sheep CLN5 is glycosylated. Deglycosylation studies on CLN5 from other 
species have produced similar results. A 60 kDa human CLN5 polypeptide reduced to 35 kDa 
after PNGase F digestion (Larkin et al., 2013). These results fit well with the third human ATG 
site being the initiation codon and cleavage of signal sequence. In contrast, Vesa and his 
colleagues (2002) observed one 47 kDa band from PNFase F treated CLN5 protein, as they 
used CLN5 antibodies which started from an incorrect codon. The deglycosylation study 
using Endo H treatment produced three bands of 46 kDa, 42 kDa and 38 kDa (Figure 3.7 c).  
The current deglycosylation study also found that the sheep CLN5 polypeptide contains eight 
predicted N-glycosylation sites, six of which (180, 205, 257, 273, 283 and 355) were 
confirmed, suggesting they function in CLN5 post-translation (Figure 3.8). A similar study on 
human CLN5 N-glycosylation sites determined seven of eight N residues were utilized in vivo 
(Vesa et al., 2002, Moharir et al., 2013), even though there was a confusion start on the 
human start codon. 
3.4.2.2 CLN6 
The mass spectrometry study using the rabbit anti-CLN6 antibodies identified 2 tryptic ovine 
CLN6 peptides out of the 12 peptide sequences predicted by online peptide analysis (Table 
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3.2 and Figure 3.9). It is clear that the abundance of expressed CLN6 on the gel is minimal 
(Figure 3.6), thus the amounts of trypsin digested CLN6 peptides were limited. Apart from 
ovine CLN6, a number of other co-migrating proteins were also present in that region 
(molecular weight of 27 kDa). When the CLN6 gel block was digested by trypsin, other co-
migrating proteins (including human peroxiredoxin 1 and several triosephosphate 
isomerases) were also digested and yielded fragments detected by mass spectrometry. 
Subsequently, the low level of trypsin digested CLN6 peptide fragments were difficult to 
identify by mass spectrometry analysis. However, a Blast search proved that one of the 
identified CLN6 fragments (HPGAAGGSGARPGASFLQAR) was unique to sheep, and the other 
identified peptide sequence was found only in CLN6 sequences from cow and pig, but not in 
any other proteins. Further, the raised sheep specific-CLN6 antibodies detected ovine CLN6 
even from such limited amounts of antigen on Western blotting.   
3.5 Conclusion 
In summary, recombinant ovine CLN5 and CLN6 protein expressions were obtained from use 
of lentiviral vectors containing the coding sequences in HEK293FT cell cultures. Adenovirally 
derived antibodies of ovine CLN5 and CLN6 specifically detected both native and denatured 
proteins.  
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Cellular and regional localisations of the ovine CLN5 and 
CLN6 proteins and characterisation of their interactions 
4.1 Introduction 
Correlations between locations and disease progression can give clues to the functions of 
proteins. The specificities of the full ovine CLN5 and CLN6 antibodies raised in rabbits in 
(described in Chapter 3) have been confirmed in overexpressed cells. The CLN5 and CLN6 
antibodies used previously in other studies are not generally as reliable as they were 
reported to be. The commercial antibodies were raised against CLN5 starting from an 
incorrect codon of human CLN5 sequence, and none of the reported CLN5 (Jules et al. 2015, 
2017; Silva et al., 2015; Vesa et al., 2002) and CLN6 (Heine et al., 2004; Mole et al., 2004) 
antibodies were able to detect the endogenous ovine CLN5 and CLN6 proteins. In this 
chapter, the adenoviral generated rabbit antibodies (Chapter 3) are used to visualise cellular 
and regional CLN5 and CLN6 protein expression in the ovine CNS, and to determine the 
correlation between the two proteins.  
Lysosome-associated membrane protein-1 (LAMP1) is a lysosomal marker, commonly used 
to study the localisation and function of lysosomal proteins (Falcón-Pérez et al., 2005; Saftig 
and Klumperman, 2009; Akasaki et al., 2014). It is a highly glycosylated lysosomal protein, 
synthesized in the ER, transported via a Golgi network, and delivered to lysosomes. 
Localisation of the human CLN5 protein to the lysosome has been confirmed by several 
studies using LAMP1 antibodies in cells overexpressing CLN5 (Vesa et al., 2002; Holmberg et 
al., 2004; Lyly et al, 2009). In the present study, a construct consisting of the human LAMP1, 
fused at its cytoplasmic carboxyl terminus to GFP, was transfected into 293FT LVMNDCLN5 
cells (3.2.1.1) to express LAMP1-GFP and CLN5 proteins. The rabbit anti-CLN5 antibodies 
(3.2.2) were then used to determine any co-localisation between ovine CLN5 protein 
expression and the lysosomes (LAMP1-GFP, visualised in green).  
Protein disulphide isomerase (PDI) is a resident enzyme of the endoplasmic reticulum (ER), 
and often used as an ER marker. Previously, the human CLN6 protein has been located as an 
ER resident protein using antibodies from the middle of CLN6 sequence (Mole et al., 2004; 
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Heine et al., 2007). In the present study, the rabbit anti-CLN6 antibodies (3.2.2) were used to 
determine co-localisation of the ovine CLN6 and PDI proteins.  
Previous studies have found CLN5 gene expression in neuronal cells and microglial cells in 
human and mouse brains (Holmberg et al., 2004). Northern blot analyses revealed CLN5 
mRNA expression in mouse brain and peripheral organs; liver, heart, kidney, lung, skeletal 
muscle, spleen and testis (Holmberg et al., 2004). Immunohistochemical staining of mouse 
brain sections detected CLN5 in Purkinje cells, hippocampal pyramidal cells and cortical 
neurons (Holmberg et al., 2004). One aim of the present work was to test the ability of the 
rabbit anti-CLN5 antibodies to detect endogenous CLN5 protein in sheep and human brain 
tissues by DAB staining.  
Neurons in the CNS are generally classified into primary sensory neurons and motor 
neurons. They can also be classified according to the cell shapes and patterns of dendrites 
into categories such as pyramidal cells, Purkinje cells and basket neurons. Most neurons in 
the CNS forming neuron-neuron connections are called interneurons (Kandel, 2000). 
Antibodies to the calcium binding ligands; calbindin, parvalbumin and calretinin are 
commonly used to identify specific γ-aminobutyric acid (GABAergic) interneuron subtypes. 
Co-localisation of GABAergic interneuron markers with other markers for specific neuronal 
cell types were studied in mice brain sections (Zhao et al., 2013; Molgaard et al., 2015). In 
the present work, the types of ovine neural cells which express CLN5 proteins were studied 
by double fluorescent labelling with the CLN5 antibodies (3.2.2) and GABAergic interneuron 
markers or a neuron-specific Nissl stain.  
Similar pathology and common symptoms shared by the NCL diseases have led to the theory 
that the NCL proteins do not function by themselves, but through interactions, and that they 
may operate via in a common pathway (Margraf et al., 1999). This study revealed that CLN2, 
CLN3 and CLN5 mRNAs were co-expressed during mouse brain development, and all three 
proteins are strongly expressed in the hippocampus of the postnatal brain (Fabritius et al., 
2014). A co-localisation study reported that CLN2, CLN5, CLN6 and CLN8 proteins co-
immunoprecipitate (Persaud-Sawin et al., 2007). A pull-down study suggested that CLN5 
possibly interacts with many other NCL proteins, including CLN1/PPT1, CLN2/TPP1, CLN3, 
CLN6 and CLN8 (Lyly et.al, 2009). Other studies concluded that CLN3 expression is reduced in 
CLN5 patients, and the expression of both CLN3 and CLN5 was reported to be down-
 97 
regulated in CLN2 deficient human patients (Bessa et al., 2006, 2008). Together, these 
findings suggest that CLN5 acts as a binding partner to the other NCL proteins.  
CLN5 is a lysosomal protein (Isosompii et al., 2002) and CLN6 an ER resident protein (Heine 
et al., 2004), however the functions of CLN5 and CLN6 are still unknown. Thus the possible 
mechanisms of these interactions remain unclear, but are likely to occur in the ER. The 
specific CLN5 and CLN6 antibodies generated in Chapter 3 have been used in 
immunohistochemical interaction studies that show reduced CLN5 expression in the CLN6 
affected South Hampshire and Merino sheep brains (Kristi McIntyre, personal 
communications and Russell, 2017). These data suggest a cross regulation of the expression 
of these two proteins. The present study also investigates potential interactions in the CLN5 
and CLN6 ovine models and any effects on protein expression by transduction with single 
lentiviral CLN5 (LV CLN5) or lentiviral CLN6 (LV CLN6) viruses, or both, in control and affected 
CLN5 and CLN6 secondary neural cells in vitro. 
4.2 Materials and Methods 
4.2.1 Co-localisation of CLN5 protein to the lysosome 
4.2.1.1 Isolation of LAMP1-GFP plasmid DNA 
A CMV pLAMP1-GFP plasmid DNA, encoding the complete open reading frame of human 
LAMP1 generated by Dr. Falcon-Perez, Department of Human Genetics, University of 
California, USA (Falcón-Pérez, 2005), was acquired by Dr Stephanie Hughes’s laboratory at 
the University of Otago. Top 10 competent E. coli cells (Invitrogen, NZ) were transformed 
with this plasmid and a glycerol stock prepared. The bacterial glycerol stock was used to 
inoculate 300 ml of LB medium (Sigma Aldrich, NZ) containing 50 µg/ml kanamycin. The 
culture was grown with vigorous shaking, 225 rpm, overnight, 37°C, until the OD600 ≥ 0.9. 
Cells were harvested by centrifugation, 1 min, 12,000 g, 4°C and the resultant pellets 
processed through Maxiprep Qiagen-tip 500 low-copy plasmid purification kits (Macherey 
GmbH, Germany) to isolate plasmid DNA. The concentration of plasmid DNA was 
determined using Nano Drop spectroscopy as described in section 2.2.2.1. 
4.2.1.2 Transfection with CMV LAMP1-GFP plasmid DNA  
293FT LVMNDCLN5 cells (3.2.1.3) were plated onto poly-L-lysine treated 24-well plates at 
5×104 cells/well and maintained until 60% confluence, then transfected with the LAMP1-GFP 
plasmid DNA at a ratio of Lipofectamine 2000 (Invitrogen, NZ): plasmid DNA = 3:1. Plasmid 
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DNA, 0.5 µg, was incubated with 1.5 µg of L2000 in 300 µl OptiMEM, 20 min. This plasmid-
L2000 transfection mixture was applied drop-wise onto cells containing OptiMEM media. Six 
hours post-transfection, media were refreshed with complete OptiMEM, and the cells 
cultured for a further 18 h. Untransfected HEK293FT cells were the negative control. 
4.2.1.3 Immunocytochemistry 
LAMP1-GFP transfected cells were fixed and blocked as described above (section 3.2.1.4).  
Cells were treated with the primary rabbit anti-CLN5 antibodies diluted 1:500 (3.2.2.1) in 
blocking buffer (PBS containing 0.2% Triton X-100 and 3% normal goat serum, NGS), 4°C, 
overnight. Cells were washed, with PBST, 3 × 30 min, before incubation with goat anti-rabbit 
Alexa 594 (red, A11012, Invitrogen, NZ) conjugated secondary antibody diluted 1:1000 in 
blocking buffer, 4 h. Cells were washed another 3 × 30 min with PBST and 1 × PB, mounted 
onto glass with ProLong Gold antifade, coverslipped, and images taken with a fluorescent 
microscope under the 40× objective as described above (section 3.2.1.4). 
4.2.2 Co-localisation of CLN6 protein and an ER marker by 
immunocytochemistry 
The general steps were the same as outlined above. 293FT LVMNDCLN6 cells (3.2.1.3) were 
plated onto a poly-L-lysine treated 24-well plate at 5×104 cells/well, maintained until 30% 
confluence and fixed with 4% PFA. To localise CLN6, co-immunocytochemistry was 
performed using rabbit anti-CLN6 (diluted 1 in 500, 3.2.2.1) and mouse anti-PDI (diluted 1: 
100, ab2792, Abcam, Australia) primary antibodies, and subsequent incubation with goat 
anti-rabbit Alexa 488 (green, A11008, Invitrogen, NZ) and goat anti-mouse Alexa 594 (red, 
A11005, Invitrogen, NZ) secondary antibodies respectively. The mounted cells were imaged 
under the 60× objective lens. 
4.2.3 Detection of endogenous ovine CLN5 by immunohistochemistry 
4.2.3.1 Ovine brain sections 
Sagittal sheep brain sections (50 µm) from level 5 (Figure 4.1 A) (Oswald et al., 2005), were 
obtained from 6 month old normal Coopworth and 9 month old affected Borderdale sheep. 
All the sections were prepared by Dr. Nadia Mitchell. A dorsal view of a whole sheep brain 
and a level 5 sagittal section are displayed in Figure 4.1. 
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Sections stored in 96-well plates containing cryoprotectant were thawed, washed in PBS (15 
ml/well), in 6-well plates on a rocking platform, 40 rpm, overnight, 4°C. On the following day 
sections were washed, 3 × 5 min, PBS, treated with 1% H2O2 in PBS for 30 min to quench 
endogenous peroxide activity, then incubated in 15% NGS in PBS, pH 7.4, containing 0.3% 
Triton X-100 (PBST), 2 h, to remove non-specific tissue antigens. All steps were followed by 3 
× 30 min washes in PBS. The sections were incubated with the primary antibodies rabbit 
anti-CLN5 (3.2.2.1), diluted 1:500 in PBST containing 10% NGS, overnight, 4°C. 
Immunoreactivity was detected using the secondary antibody, biotinylated goat anti-rabbit 
(B7389, Sigma Aldrich, NZ, diluted 1:1000 in PBST containing 10% NGS), 2 h. The sections 
were then stained in ExtrAvidin peroxidase solution (E2886, Sigma Aldrich, NZ, diluted 
1:1000 in PBS), 2 h. Immunoreactivity was detected by incubation with 0.05% (0.5mg/ml) 3, 
3’-diaminobenzadine (DAB, D5637, Sigma Aldrich, NZ) and 0.01% H2O2 in PBS for 10 min in 
the dark. DAB reactions were terminated by 4 × 5 min washes with ice-cold PBS. Sections 
were mounted onto glass slides, air dried, dehydrated in 50% ethanol, 10 min, 100% ethanol, 
10 min, cleared in xylene, 30 min and immediately coversliped in DPX (BDH, Poole, England). 
Images were captured with an Olympus IX71 microscope with an Olympus DP71 camera 
(Hilenski, Germany). Negative control sections in which the primary and secondary 
antibodies were omitted were also processed.  
Figure 4.1 Anatomical structure of a 
normal sheep brain 
 (A) Dorsal view. (B) A Level 5 sagittal 
section. CB = cerebellum, Cc = corpus 
callosum, CN = caudate nucleus, 
HC=hippocampus, Hyp = hypothalamus, 
IC = caudal colliculus, M = motor cortex, 
Med = medulla, S c= spinal cord, Th = 
thalamus, V = visual cortex (Modified 
from Oswald et al., 2005) 
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4.2.3.2 Chromogenic staining of paraffin-embedded human brain sections 
Wax-embedded sagittal blocks of normal human brain cortex, cerebellum and hippocampus 
were kindly provided by Professor Hans Goebel, Charité, Berlin, Germany and 3 µm sections 
were cut and mounted onto glass slides. Paraffin was removed with xylene soaking, 30 min, 
and a series of ethanol solutions from 100% progressing down to 50%, 10 min in each grade. 
All the tested slides were soaked in ddH2O, 10 min, and excess liquid drained off. A 
waterproof marker pen was used to draw a circle around the mounted tissues in order to 
make a hydrophobic barrier (Figure 4.2). 
 
              
 
The following processes were carried out in humid conditions to prevent sections drying out 
and without shaking. Endogenous peroxide activity was blocked with 300 µl/section of 1% 
H2O2 in PBS, 30 min, and nonspecific antibody binding blocked by incubation with 15% NGS 
in PBST, 300 µl/section, 2 h. Rabbit anti-CLN5 primary antibody (3.2.2.1) was diluted 1:500 in 
PBST containing 10% NGS and incubated on sections overnight, 4°C. Primary antibody was 
removed, followed by 3 × 30 min washes with PBST, before incubation in biotinylated goat 
anti-rabbit (1:1000 in PBST containing 10% NGS) followed by ExtrAvidin peroxidase (1:1000 
in PBS), 2 h. Sections were washed 3 × 30 min with PBS, and antibody binding detected with 
DAB, 5-10 min in the dark (see section 4.2.3.1). Sections were then rinsed, dehydrated, air-
dried, and cleared. Images were captured with an Olympus microscope and camera. 
Immunostainings of sections without primary or secondary antibodies provided negative 
controls.  
4.2.4 Immunohistochemical double fluorescent labelling of ovine brain 
sections 
Double-labelling was carried out on level 5 sagittal brain sections from a 6 month old normal 
Coopworth sheep. The brain sections (Table 4.1) were washed and blocked as described in 
Figure 4.2 DAB staining of paraffin-embedded human 
brain sections within a hydrophobic barrier formed by 
a waterproof marker pen 
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section 4.2.3.1. In preliminary studies calbindin stained the cortex, cerebellum, 
hippocampus, and brain stem; parvalbumin the cortex, thalamus, cerebellum, brain stem, 
and hippocampus; calretinin the cerebellum and hippocampus; and NeuN the cortex, 
cerebellum, and hippocampus. The following selected sections were used in a double 
labelling study following the best staining with one of the neural makers and the CLN5 
antibody. 
 
Table 4.1 Double-labelled primary and secondary antibodies 
  
Double primary antibody labelling was carried out with rabbit anti-CLN5 or mouse anti-CLN5, 
diluted 1:500 in 10% NGS in PBST, 48 h, 4°C. Sections were also co-labelled with one of the 
following neural markers (Table 4.1); mouse anti-NeuN (MAB3777, Millipore, USA), mouse 
anti-calbindin (D28K, Swant, Bellinzona, Switzerland), mouse anti-parvalbumin (PV235, 
Swant, Bellinzona, Switzerland), rabbit anti-calretinin (CR7697, Swant, Bellinzona, 
Switzerland), and mouse anti-GFAP (G3893, Sigma Aldrich, NZ). After 3 × 30 min washes in 
PBST, sections were incubated with secondary antibody mixes of either goat anti-rabbit 
Alexa 488 (green, A11008, Invitrogen, NZ) and goat anti-mouse Alexa 594 (red, A11005, 
Invitrogen, NZ), or goat anti-mouse Alexa 488 (green, A11001, Invitrogen, NZ) and goat anti-
rabbit Alexa 594 (red, A11012, Invitrogen, NZ) (Table 4.1). 
Reactions were carried out with secondary antibodies, diluted 1: 1000 in PBST, 4 h, room 
temperature. Sections were washed 3 × 30 min in PBST, followed by a 30 min PBS wash. Cell 
nuclei were stained with diamidino-2-phenylindole (DAPI, 1 mg/ml stock, Sigma Aldrich, NZ), 
diluted to 1:10,000 in PBS, 5 min, and washed with PBS. Sections were washed with 0.1 M PB 
before being mounted onto glass, and coverslips attached with ProLong Gold antifade 
Section parts Primary antibodies mix Secondary antibodies mix 
(1: 1000) 
1st label 2nd label 
Cortex Mouse anti-NeuN 
1:1000 
Rabbit anti-CLN5 
1:500  
Goat anti- rabbit Alex 488 
Goat anti- mouse Alex 594 
Cerebellum Mouse anti-Calbindin 
1:500 
Rabbit anti-CLN5 
1:500  
Goat anti- rabbit Alex 488 
Goat anti- mouse Alex 594 
Thalamus Mouse anti-Parvalbumin 
1:500 
Rabbit anti-CLN5 
1:500  
Goat anti- rabbit Alex 488 
Goat anti- mouse Alex 594 
Hippocampus Rabbit anti-Calretinin 
1:500 
Mouse anti-CLN5 
1:500  
Goat anti- mouse Alex 488 
Goat anti- rabbit Alex 594 
Cortex Mouse anti-GFAP 
1:500 
Rabbit anti-CLN5 
1:500  
Goat anti- rabbit Alex 488 
Goat anti- mouse Alex 594 
Cortex    
(negative control) 
None 
 
None Goat anti- rabbit Alex 488 
Goat anti- mouse Alex 594 
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reagent. Fluorescent images were taken on a Zeiss LSM 710 upright confocal microscope 
(Zeiss, Germany), merged and processed in Photoshop.  
4.2.5 Interactions of the CLN5 and CLN6 proteins 
4.2.5.1 Ovine primary neural cell cultures 
Approval for the use of sheep primary neural cells was obtained from EPA (approval 
#GMD002852). Frozen primary neural cells extracted from fetal sheep brains (Hughes et al., 
2014a) at Lincoln University, were thawed rapidly in a 37°C water bath and transferred into a 
50 ml tube containing 5 ml of neural culture media (DMEM, 10% FBS, 1% L-glutamine, 1% 
penicillin and streptomycin). After the cells were passed through a 40 µm cell strainer, they 
were pelleted, 1000 rpm, 5 min, in a Heraeus Multifuge3S centrifuge (Thermo Scientific, San 
Jose, CA). The supernatant was removed and the cell pellet re-suspended in 5 ml of neural 
culture media. The sheep primary neural cells were then plated onto poly-L-lysine treated 
24-well plates at a density of 1×105 cells/1 ml well, and the cells grown at 37°C in a 
humidified atmosphere containing 5% CO2. Half the neural culture media volumes were 
changed every three days. The neural cells were harvested at two weeks post plating.  
4.2.5.2 Generation of ovine neural cell lines (secondary neural cells) 
 
     Table 4.2 Generation of secondary neural cell lines 
Phenotype ID Generated by 
CLN5+/- F16P3 Janet Xu 
CLN5+/- F21P5 Dr. Hughes’s lab 
CLN5+/- F22P3 Janet Xu 
CLN5+/- F47P3 Dr. Hughes’s lab 
CLN5-/- F14P5 Dr. Hughes’s lab 
CLN5-/- F41P5 Dr. Hughes’s lab 
CLN5-/- F43P5 Dr. Hughes’s lab 
CLN5-/- F44P3 Janet Xu 
CLN6+/- F37P5 Dr. Hughes’s lab 
CLN6+/- F39P5 Dr. Hughes’s lab 
CLN6+/- F40P4 Dr. Hughes’s lab 
CLN6-/- F7P5 Dr. Hughes’s lab 
CLN6-/- F31P5 Dr. Hughes’s lab 
CLN6-/- F33P5 Dr. Hughes’s lab 
 
In this study, neural cell lines, referred to as secondary neural cells, were generated from 
ovine primary neural cells (Table 4.2). When the primary neural cells reached about 80% 
confluence, they were passaged and transferred to T25 flasks, until they again reached 
approximately 80% confluence. Cells were counted using Trypan blue, pelleted by 
centrifugation, and re-suspended in media for freezing. The cell suspensions were frozen as 
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1 ml samples at a density of 2×106 cells/ml at -80°C overnight then transferred to liquid 
nitrogen for long term storage. The control (+/-) and affected (-/-) CLN5 and CLN6 neural cell 
lines generated are shown in Table 4.2. 
4.2.5.3 CLN5 lentiviral transduction of neural cell lines 
Four sheep neural cell lines were used in this experiment; CLN5+/- F21, CLN5-/- F14, CLN6+/- F2 
and CLN6-/- F25 (Table 4.2). Vials of frozen sheep secondary neural cells were plated and 
cultured in neural culture media in poly-L-lysine treated 24-well plates at 7×104 cells/well (4 
wells/cell, 1ml/well) and refreshed with media (1ml/well) on the following day. Transduction 
was achieved by direct administration of LV CLN5 virus (1 µl/well, 1.1×1010 transducing 
units/ml, prepared by Dr. Stephanie Hughes’s laboratory) to the media by gentle mixing 
followed by a further 72 h incubation at 37°C. Neural cells were then incubated for 24 h in 
OptiMEM neural culture media (OptiMEM, 1% L-glutamine, 1% penicillin and streptomycin, 
300 µl/well). Untransduced sheep neural cell lines served as negative controls. A volume of 
1.2 ml of media from each neural cell line was collected and concentrated down to 10 µl for 
Western blotting as described above (section 3.2.1.5). Cells were washed briefly in 
Dulbecco's phosphate-buffered saline solution (dPBS, GIBCO, Invitrogen, NZ), and fixed in 4% 
PFA (see section 3.2.1.4).  
Western blots of CLN5 protein from transduced neural cells were processed as described in 
section 3.2.2.3.  Proteins in the concentrated cultured media (3 µl) were separated on 10% 
SDS gels, then transferred to PVDF membranes. The membranes were blocked and 
incubated in 1:500 primary rabbit anti-CLN5 antibodies overnight, then treated with the 
1:5000 secondary goat anti-rabbit HRP, 4 h and developed by ECL.  
CLN5 protein secreted from virally transduced neural cells was also detected by 
immunocytochemistry. To improve the clarity of rabbit anti-CLN5 staining, a short staining 
protocol was performed. The fixed cells were incubated with the primary rabbit anti-CLN5 
antibodies diluted 1:500 in blocking buffer with PBS, 2 h, then washed 3 × 5 min with PBST 
before incubation with secondary goat anti-rabbit Alexa 488 conjugated antibody diluted to 
1:1000 in blocking buffer, 30 min. After another 3 × 5 min washes with PBST, cells were 
refreshed in 0.1 M PB, cover-slipped and imaged by fluorescent microscopy.  
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4.2.5.4 CLN5 expression in virally transduced control and affected neural cells 
The experiment described here was aimed to detect any changes in CLN5 expression in 
neural cells transduced with LV CLN6 virus together with LV CLN5 virus. Four CLN5 control 
secondary neural cells (CLN5+/- F21, CLN5+/- F16, CLN5+/- F47, CLN5+/- F22) and four CLN5 
affected secondary neural cells (CLN5-/- F14, CLN5-/- F41, CLN5-/- F43 and CLN5-/- F44) were 
cultured in duplicate as described in section 4.2.5.3. One well of each neural cell line was 
transduced with 1 µl LV CLN5 virus, and the other well was transduced with 1 µl LV CLN5 and 
1 µl LV CLN6 viruses (8×109 transducing units/ml, prepared by Dr. Stephanie Hughes’s 
laboratory). At 72 h post-transduction, the neural culture media were replaced with 
OptiMEM media (300 µl/well), and the cells incubated for another 24 h, 37°C. The media 
from the neural cell cultures were collected and concentrated for Western blotting (as in 
section 3.2.1.5). Proteins in the concentrated media from overexpressed CLN5 cells (3 µl, 
positive control) and the concentrated media (20 µl) from the single LV CLN5 virus and 
double LV CLN5 and LV CLN6 virally transduced cells were separated on a 10% SDS gel, and 
then transferred to a PVDF membrane. The membrane was blotted with rabbit anti-CLN5 
and goat anti-rabbit HRP as described in section 3.2.2.3.  
Six CLN6 secondary neural cells, three controls (CLN6+/-F37, CLN6+/-F39 and CLN6+/-F40) and 
three affected (CLN6-/-F7, CLN6-/-F31 and CLN6-/-F33), transduced with LV CLN6 or LV CLN5 
plus LV CLN6 viruses, were also used to study changes of CLN5 expression. The processes 
were the same as described above. 
4.2.5.5 CLN6 expression in virally transduced control and affected neural cells 
An experiment was carried out to find any changes in CLN6 expression when LV CLN5 virus 
was transduced together with LV CLN6 into neural cells. Six CLN6 secondary neural cell lines 
(as in section 4.2.5.4), and four CLN5 secondary neural cell lines, two controls (CLN5+/- F21 
and CLN5+/- F47) and two affected (CLN5-/- F14 and CLN5-/- F41), were cultured and 
transduced as described in section 4.2.5.4. Culture media were discarded, the cells lysed and 
the proteins extracted as described in section 3.2.1.5. Western blotting was performed as 
outlined above. The proteins from lysed cells were separated (50 µg/well) on 10% SDS gels 
and then transferred to PVDF membranes, which were blotted with rabbit anti-CLN6 
(1:1000) and goat anti-rabbit HRP (1:10,000). Overexpressed CLN6 cells generated in section 
3.2.1.5, provided the positive control and neural cells without viral transduction acted as the 
negative control. 
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β-actin was used as the loading control to determine if equal amounts of protein had been 
loaded into each lane. The β-actin detection was carried out after rabbit anti-CLN6 detection 
without stripping the blot. The antibody treatment was as described above except a primary 
rabbit anti-actin antibody (1:2000, A5056, Sigma Aldrich, St. Louis, MO) was used instead of 
the rabbit anti-CLN6 antibody.  
4.2.5.6 Image analysis of Western blots 
The Image J program (Rasband, National Institutes of Health USA, http://imagej.nih.gov/ij/) 
was used to analyse the integrated density of the protein bands detected in control and 
affected cell cultures. Western blotting images showing the protein bands were imported 
into Image J and converted to 8-bit files. Backgrounds were subtracted by setting a rolling 
ball radius with 50 pixels, and densities of the selected protein bands were measured and 
recorded automatically. All the data were collected and exported to Microsoft Excel and 
normalised to the densities in reference overexpressed CLN5 or CLN6 neural cells. In the 
CLN6 expression study, the ratios of normalised integrated densities of CLN6 to actin 
(loading control) from every sample were also calculated.  
4.2.5.7 Statistical analysis 
Normalised integrated densities data were analysed in Genstat 18 (VSN International Ltd, 
Hempstead, UK). This examined the interaction of protein expression and lentivirus 
treatments using the General Linear Model function. Means were separated by the Least 
Significant Difference (P < 0.05).  
4.3 Results 
4.3.1 Co-localisation of the CLN5 protein and lysosome 
The subcellular localisation of the ovine CLN5 protein was studied by fluorescent microscopy 
after transfection of 293FT LVMNDCLN5 with LAMP1-GFP. LAMP was detected from the GFP 
tag as green fluorescence in the cells. Cells were labelled with the rabbit anti-CLN5 
antibodies and a red fluorescent antibody tag, goat anti-rabbit Alexa 594 (Figure 4.3). Yellow 
fluorescence indicated overlaps of the two proteins. This co-localisation indicates that the 
full CLN5 antibody was able to detect ovine CLN5 in lysosomes. Not all cells were double 
transfected, showing signals from either LAMP1-GFP or CLN5 alone. 
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Figure 4.3 Co-localisation of a LAMP1-GFP fusion and CLN5 protein expression 
Immunofluorescent images of LAMP1-GFP protein (green) and CLN5 protein (red) in the 293FT LVMNDCLN5 
cells. Cell images from top (i) and bottom (ii) panels were randomly selected. RαCLN5 refers to rabbit anti-CLN5 
antibodies staining. Yellow fluorescence indicates co-localisation. The scale bar represents 200 µm. 
 
4.3.2 Intracellular co-localisation of the CLN6 protein to the ER  
The 293FT LVMNDCLN6 cells were double labelled with rabbit anti-CLN6 and mouse anti-PDI 
antibodies. The mouse anti-PDI antibody was detected as a red signal and the CLN6 protein 
stained with anti-CLN6 gave a green signal. Yellow/orange fluorescence indicated co-
localisation of CLN6 protein and PDI, a marker for the ER. Double immunofluorescent 
microscopy images taken from three randomised sites (i, ii, and iii) all demonstrated the 
same typical patterns of staining for both the PDI and CLN6 proteins (Figure 4.4).   
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Figure 4.4 Immunofluorescent images of CLN6 and the ER marker PDI expression in 293FT LVMNDCLN6 
expressing cells 
293FT LVMNDCLN6 cells were fixed at 30% confluence and double-labelled with mouse anti-PDI (1:100, red) 
and rabbit anti-CLN6 (1:500, green). MαPDI refers to the mouse anti-PDI antibodies, RαCLN6 to the rabbit anti-
CLN6 antibodies. Merged yellow and orange images indicate co-localisation. The scale bar represents 100 µm. 
4.3.3 CLN5 antibodies detect endogenous protein in tissue 
Results of the study described in Chapter 3 confirmed that the specific polyclonal anti-CLN5 
antibody raised in rabbit detected over-expressed ovine CLN5 protein in transduced 
HEK293FT cells. The next step was to find out if it could detect endogenous CLN5 in ovine 
and human brain sections. Sections from the hippocampus, cerebellum and cortex of normal 
and CLN5 affected sheep, and normal human brains (obtained from Professor Hans Goebel, 
Berlin) were incubated with rabbit anti-CLN5. Positive staining was detected in brain sections 
from both sheep and humans (Figure 4.5 and Figure 4.6). 
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4.3.3.1 Endogenous sheep CLN5 protein expression 
Light microscopy revealed intense brown punctate DAB staining in all selected regions of the 
control sheep brain sections (Figure 4.5). The strongest specific CLN5 punctate staining was 
detected in the hippocampus (Figure 4.5 A and B), the hilus, granule cells (GCL) of the 
dentate gyrus, pyramidal cells, particularly in the CA3 and CA2 regions (Figure 4.5 A). 
CLN5 immunostaining was predominantly localised to the neuronal cell soma and along the 
neurites of some larger cells. Endogenous CLN5 expression was also observed in the Purkinje 
cells layer of the cerebellum (Figure 4.5 C). CLN5 positive cells were found evenly across the 
all cortical layers (Figure 4.5 E), and the granular cells of the motor cortex exhibited clear 
CLN5 staining (not shown). No expression was seen in any of the CLN5 affected sheep tissues 
with the CLN5 antibody (Figure 4.5 A, insert) or negative controls from which the primary 
antibody was omitted (Figure 4.5 D). These results confirm the specificity of the CLN5 
antibodies raised in rabbit and show that they detect endogenous CLN5 in normal sheep 
brains. 
4.3.3.2 Endogenous human CLN5 protein expression 
CLN5 protein was detected in the human brain, including the cerebellum, hippocampus and 
cortex (Figure 4.6). The strongest immunostaining was revealed in the cerebellar region. In 
particular, granular cells (small round cells) and Purkinje cell bodies and axons were 
noticeably stained (Figure 4.6 A and B, indicated with black arrows). This strong CLN5 
immunoreactivity of human granular cells contrasts with the weaker staining of granular 
cells in the sheep brain samples (Figure 4.6 C). Punctate CLN5 staining of cells was also 
clearly detected in granular cells of the visual cortex (Figure 4.6 C), pyramidal cells in the CA3 
(Figure 4.6 D) and hilus (Figure 4.6 E) of hippocampus. There was no DAB staining in sections 
in the absence of primary antibodies (Figure 4.6 F).  
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Figure 4.5 Expression of the endogenous CLN5 protein in the normal sheep brain 
Positive CLN5 immunostaining in hippocampus (A, B), cerebellum (C) and visual cortex (E). The hippocampus 
(D) is the negative control, from which the CLN5 antibody was omitted. The insert on B shows the lack of CLN5 
expression in the hippocampus of the affected brain. The scale bars represent 500 μm in A, 100 μm in B, C, E 
and 200 μm in D. 
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Figure 4.6 Immunohistochemistry of human brain sections 
Positive staining of CLN5 in the sections of cerebellum (A, B), visual cortex (C), and hippocampus (D, E) of 
normal human brain. The negative control (F) is the hippocampus without primary antibody. The scale bars 
represent 100 μm. 
4.3.4 Immunohistochemical double fluorescent labelling 
Ovine CLN5 expression was detected throughout the CNS (4.2.3.1). To visualise which neural 
cells express CLN5, sheep brain sections were co-stained with different red fluorescent 
markers, including NeuN and three GABAergic interneuron markers, calbindin, parvalbumin 
and calretinin. All the neural markers stained red, while the rabbit (or mouse) anti-CLN5 
fluorescence was green. Double labelled merged neural cells were yellow, and their nuclei 
were stained blue with DAPI (Figure 4.7). 
Calbindin staining co-localised with CLN5 positive Purkinje and basket cells in the cerebellum 
(Figure 4.7 A). Calbindin/CLN5 double labelling also clearly detected big motor neurons in 
the brain stem (Figure 4.7 B). Parvalbumin antibodies stained GABAergic interneurons in the 
nervous system, shown by specific positive CLN5 co-staining in reticular cells in the thalamus 
(Figure 4.7 C).  
Calretinin showed a similar expression pattern to CLN5 in the hippocampus, especially in the 
axons and dendrites of CA3 neurons, and neurons of the dentate gyrus and hilus (Figure 4.7 
D). Double-labelling revealed that the neurons determined via NeuN displayed a similar 
CLN5 positive expression pattern. The CLN5 signal was observed in big motor neurons in the  
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Figure 4.7 Confocal double fluorescent immunohistochemical labelling of neurons expressing CLN5 and 
neuron markers on ovine brain sections 
Green rabbit (or mouse) anti-CLN5 co-localised with the red neural markers, calbindin in the cerebellum and 
brain stem (A and B), parvalbumin in the thalamus (C), calretinin in the hippocampus (D), and NeuN in the brain 
stem and cortex (E and F). Anti-CLN5 did not co-localise with GFAP in the cortex (G). The scale bar represents 
200 µm for A, B and C and 100 µm for D, E, F and G. 
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brain stem (Figure 4.7 E) and pyramidal neurons in the cortex (Figure 4.7 F) by co-localisation 
with NeuN.  
Specific staining was confirmed by comparison with glial fibrillary acidic protein (GFAP), and 
the omission of primary antibodies (Appendix A.4, negative control). GFAP which is found in 
glial cells particularly astrocytes, did not co-stain with CLN5 in the cortex (Figure 4.7 G, 
negative control) indicating little CLN5 expression in astrocytes. Overall, key cellular 
expression of CLN5 was observed in Purkinje and granular neurons in the cerebellum, 
hippocampal interneurons, pyramidal neurons in the cortex and motor neurons in brain 
stem. 
4.3.5 Interactions of CLN5 and CLN6 proteins 
4.3.5.1 CLN5 in culture media from CLN5 in virally transduced neural cells 
Transduction of affected CLN5 and CLN6 cells with LV CLN5 was assessed by 
immunofluorescence and from the media by Western blotting to determine whether CLN5 
protein is restored and expressed in mutated cells in vitro. The CLN5 band was not 
detectable in any of the affected non-transduced cells (negative controls), or in the control 
non-transduced cells (Figure 4.8a). This indicates endogenous cellular CLN5 expression is 
below the threshold level of detection. However, CLN5 protein, 60 kDa, was detected in all 
the lanes of the Western blot containing media samples from LV CLN5 transduced control 
and affected CLN5 and CLN6 neural cells, as well as from overexpressing CLN5 cells (positive 
control, section 3.2.1.5) (Figure 4.8 a). This suggests that CLN5 expression can be restored 
and that CLN5 secretion from these cells is detectable.  
All the cells that received CLN5 viral-mediated treatment secreted CLN5 protein into the 
media. Immunofluorescence of LV CLN5 treated cells was carried out with the rabbit anti-
CLN5 antibodies in a short staining protocol to improve the staining clarity. Both control and 
affected CLN5 and CLN6 secondary neural cells revealed bright and clear punctate green 
staining with the rabbit anti-CLN5 antibodies after transduction with LVCLN5 (Figure 4.8 B). 
In particular a control CLN6+/- F2 contained a large star-like cell, spreading onto the bottom 
of the well, typical of a secondary neural cell (Figure 4.8 B-C). The major bodies of the cells 
were an intense green compared with edge of the cells, suggesting that LV CLN5 transduced 
cells were generating CLN5 in the ER close to nuclei and then trafficking it into lysosomes 
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close to the plasma membrane. These results suggest that even affected neural cells (for 
example CLN5-/- F14 and CLN6-/- F25) are able to express and process transduced LV CLN5.  
 
 
Figure 4.8 CLN5 is expressed in virally transduced CLN5 and CLN6 neural cells 
Secondary ovine neural cell cultures were plated and maintained following standard protocols. (a) The media 
were collected and concentrated for Western blotting, then 3 µl of each concentrated media sample and the 
media from overexpressing CLN5 cells (positive control) were separated on a 10% SDS-PAGE, transferred to a 
PVDF membrane and subsequently treated with 1:5000 goat anti-rabbit HRP. A pre-stained Precision Plus 
protein marker was used to determine molecular weights. (b) Immunocytochemistry images of CLN5 
transduced neural cells after fixing in 4% PFA: control CLN5+/- F21 (A), affected CLN5-/- F14 (B), control CLN6+/- 
F2 (C) and affected CLN6-/- F25 (D). CLN5 expression was detected with 1:500 rabbit anti-CLN5 and 1:1000 goat 
anti-rabbit Alexa 488 HRP. The scale bar represents 200 µm.  
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4.3.5.2 CLN5 expression in virally transduced control and affected neural cells 
This particular experiment aimed to determine any effect of viral-mediated co-expression of 
CLN5 on cultured cells. Media were collected from control and affected CLN5 or CLN6 neural 
cells, which were transduced with LV CLN5 alone or both LV CLN5 and LV CLN6 and probed 
by Western blotting with the rabbit anti-CLN5 antibodies. CLN5 was generated in all the cell 
samples, detected as a single protein band at 60 kDa in all lanes (Figure 4.9 a). Integrated 
densities of the CLN5 protein bands in neural cells on the Western blots were measured 
using Image J, normalised against reference over-expressed CLN5 cells and graphed with 
Excel (Figure 4.9 b). Induced CLN5 expression was twice that in the CLN5-/- cells transduced 
with both viruses (the orange column at the right) compared with the same cells transduced 
with LV CLN5 alone (the blue column at the right). No significant difference was found for 
CLN5 expression in the CLN5+/- cells virally transduced with CLN5 or CLN5 and CLN6 vectors. 
 
 
Figure 4.9 CLN5 expression in control and CLN5 affected neural cells transduced with LV CLN5 alone or both 
LV CLN5 and LV CLN6 virus. 
(a) Western blots of the concentrated secreted CLN5 cell media. The band densities represent CLN5 expression. 
(b) The bands in the Western blots were measured and the average normalised integrated density of the CLN5 
affected (CLN5-/-, n = 4) neural cells compared with the control (CLN5+/-, n = 4) neuronal cells. The blue columns 
refer to cells transduced with LV CLN5 alone, and the orange columns refer to cells transduced with both LV 
CLN5 and LV CLN6 viruses. CLN5 expression was induced 2-fold (* P < 0.05) in the CLN5-/- cells transduced with 
both viruses compared with the same cells transduced with LV CLN5 alone. The vertical error bars are + SEM. 
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Western blotting also revealed a single protein band at 60 kDa in all the CLN6 neural cells 
transduced with either LV CLN5 or both viruses (Figure 4.10 a), suggesting that with CLN6 
present, CLN5 expression was not blocked in CLN6 affected cells. The averaged normalised 
integrated densities of the protein bands showed CLN5 expression was not statistically 
different in affected cells (the blue column at the right) compared with controls after 
transduction with LV CLN5 alone (the blue column at the left) (Figure 4.10 b). 
Notwithstanding that CLN5 expression appeared to be higher in the CLN6-/- cells transduced 
with both LV CLN5 and LV CLN6 viruses (the orange column at the right) than those 
transduced with LV CLN5 alone (the blue column at the right). 
 
Figure 4.10 CLN5 expression in control and CLN6 affected cells transduced with LV CLN5 alone or both LV 
CLN5 and LV CLN6 viruses. 
(a) Western blots of the concentrated secreted CLN5 cell media. (b) The bands in the Western blots were 
measured and the average normalised integrated density of the affected (CLN6-/-, n = 3) neural cells compared 
with the control (CLN6+/-, n = 3) neuronal cells. The blue columns refer to cells transduced with LV CLN5 alone, 
the orange columns refer to cells transduced with both LV CLN5 and LV CLN6 viruses. The vertical error bars are 
+ SEM. 
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4.3.5.3 CLN6 expression in virally transduced control and affected neural cells 
This experiment aimed to determine the effect of viral-mediated co-expression of CLN6 on 
cultured cells. CLN5 and CLN6 affected neural cells transduced with LV CLN6 or LV CLN5 and 
LV CLN6 viruses, and the non-transduced controls were lysed for Western blotting with the 
rabbit anti-CLN6 antibody. CLN6 was present, as a protein band at 27 kDa in every lane 
(Figure 4.11 a and b). β-actin (42 kDa) was used as a loading control. No CLN6 band was 
detected in the blots of non-transduced cells. However, most of neural cells contained 
another band slightly bigger than 27 kDa, or an extra band slightly bigger than 42 kDa, while 
overexpressed cells showed only one band from the Western Blots. 
According to the averaged normalised integrated densities of the protein bands, CLN6 
protein expression was not statistically different between the affected cells (CLN6-/- and 
CLN5-/-) transduced with both viruses compared with those cells transduced with LV CLN6 
alone (Figure 4.11 c and d). However, expression appeared to be increased in the affected 
CLN6 cells transduced with both viruses (the orange column at the right) compared with the 
same cells transduced with LV CLN6 alone (the green column at the right) (Figure 4.11 c), 
and to be decreased in the affected cells (Figure 4.11 d).  
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Figure 4.11 CLN6 expression in control and affected neural cells transduced with LV CLN6 alone or both LV 
CLN5 and LV CLN6 viruses. 
(a, b) Western blots of the CLN6 expression in control, CLN6 and CLN5 affected cells. The band densities 
represent CLN6 expression. The averaged ratio of each normalised integrated density of CLN6 to its β-actin 
expression (loading control) was measured, in the CLN6 affected (CLN6-/-, n = 3) neural cells compared with the 
control (CLN6+/-, n = 3) neuronal cells (c) and the CLN5 affected (CLN5-/-, n = 2) neural cells compared with the 
control (CLN5+/-, n = 2) neuronal cells (d). The green columns refer to cells transduced with LV CLN6 alone, and 
the orange columns to cells transduced with both LV CLN5 and LV CLN6 viruses. The vertical error bars are + 
SEM. 
4.4 Discussion 
The subcellular localisation and endogenous expression of both ovine CLN5 and CLN6 
proteins are important for functional studies and required for understanding of the 
trafficking mechanisms. However, the availability and/or production of high quality 
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antibodies to the either protein has always been problematic. Promising specific CLN5 and 
CLN6 antibodies have been recently developed via adenoviral vectors (see Chapter 3). 
Western blotting and immunocytochemistry with these antibodies successfully detected 
these proteins in overexpressed cells (see Chapter 3). 
4.4.1 Characterisation of the cellular localisations of ovine CLN5 and CLN6 
The intracellular co-localisation of ovine CLN5 to lysosomes was revealed by specific CLN5 
antibody labelling of transfected 293FT LVMNDCLN5 cells, expressing the lysosomal protein 
LAMP 1-GFP (lysosomal associated membrane protein) (Figure 4.3). This correlated with 
similar findings in the mouse brain (Holmberg et al., 2004), where the mouse CLN5 protein 
also co-localised with LAMP 1. Other studies on overexpressed CLN5 protein, BHK21, COS1 
and HeLa cells also reported co-localisation to lysosomes (Isosomppi et al., 2002; Vesa et al., 
2002; Holmberg et al., 2004; Sleat et al., 2006a). In the present study, the cells with positive 
CLN5 signals did not always express LAMP 1-GFP proteins, presumably because not all cells 
were double transfected. The HEK293FT cells were first transduced with the full ovine CLN5 
DNA, and then with the LAMP 1-GFP DNA construct.  
Intracellular ovine CLN6 completely co-localised with the ER marker PDI in transfected 293FT 
LVMNDCLN6 cells (Figure 4.4). These data confirmed previous suggestions that the CLN6 
protein is localised to the ER (Mole et al., 2004; Heine et al., 2004; Kurze et al, 2010). An 
intracellular location of endogenous CLN6 was suggested by co-localisation of PDI and 
antibodies raised against synthesised peptides based on the human CLN6 sequence (Mole et 
al., 2004). However, this antibody was problematic and did not stain sheep sections (Dr. Lucy 
Barry, personal communication). Co-localisation of the CLN6 protein with PDI in BHK cells 
transfected with wild type CLN6 cDNA has been also reported previously (Heine et al., 2004).  
4.4.2 Characterisation of antibodies for endogenous CLN5 detection 
The CLN5 antibody specifically detected endogenous CLN5 expression throughout the 
normal sheep brain, most prominent expression being seen in the hippocampus, cortex and 
cerebellum, particularly in the CA3 and CA2 regions, the hilus and granule cells of the 
dentate gyrus (Figure 4.5). Similar CLN5 staining was seen in the mouse brain (Holmberg et 
al., 2004; Fabritius et al., 2014; Minye et al., 2016). Immunohistochemical staining of mouse 
brain sections detected CLN5 in Purkinje cells of cerebellum, hippocampal pyramidal cells 
and cortex (Holmberg et al., 2004). 
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Further analysis showed that CLN5 is expressed widely in neurons and interneurons in the 
normal ovine CNS (Figure 4.7). The most intense signals were detected in the Purkinje and 
basket cells of the cerebellum and pyramidal neurons in the hippocampus. The CLN5 protein 
was also expressed in some reticular cells in the thalamus and some interneurons in the 
striatum, frontal and visual cortices. All these data confirm earlier collaborative studies 
which showed that CLN5 immunoreactivity in healthy sheep brain sections co-localized with 
GABAergic interneuron markers and a neuronal marker (Kristina McIntyre, personal 
communication). The distribution of CLN5 positive cell types in the normal sheep brain is 
similar to the pattern reported in the normal mouse brain (Holmberg et al., 2004; Tepper et 
al. 2010; Minye et al., 2016). CLN5/parvalbumin and CLN5/calbindin double stainings of the 
normal mouse brain sections detected CLN5 in Purkinje cells of the cerebellum, hippocampal 
pyramidal cells and cortical neurons (Holmberg et al., 2004), while the GABAergic 
interneurons lost CLN5 signals in CLN5 affected cerebral cortex and cerebellum (Kopra et al., 
2004). Tepper and co-workers (2010) also used these three GABAergic interneuron markers 
to co-label CLN5 neurons in the mouse striatum. Strong co-expression of CLN5 and calbindin 
(or NeuN) was revealed in motor neurons in the brain stem (Figure 4.7 B and E), suggesting 
CLN5 was largely expressed in motor neurons. In the late stage of human CLN5 disease, 
cerebella Purkinje cells and thalamic neurons are lost, as are some cortical neurons (Tyynelä 
et al., 1997). The ovine CLN5 protein was not detected in GFAP positive astrocytes (Figure 
4.7 G), confirming a previous study showing that CLN5 and GFAP were not co-localised in 
sheep in situ (Kristina McIntyre, personal communication). On the other hand, a quantitative 
PCR study demonstrated murine CLN5 mRNA expression in glial cell cultures (Holmberg et 
al., 2004). 
The rabbit anti-CLN5 antibodies also detected CLN5 expression in the hippocampus, cortex 
and cerebellum of normal human brains (Figure 4.6). Human and sheep CLN5 share 84% 
amino acid identity (Figure 1.1), and the similarity is even higher (90%) for the mature 
protein without the signal sequence. Therefore, it is not surprising that rabbit anti-CLN5 is 
able to detect human CLN5. The granule cells and Purkinje cell bodies and axons of the 
human cerebellum (Figure 4.6 B) were strongly immunoreactive, compared with the slightly 
weaker positive signal from these cells in the sheep (Figure 4.5 C), when the same 
concentration of the antibodies was applied. This difference may be due to the age or 
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position of the samples selected. Different fixation and the dewaxed section thickness (50 
µm ovine, and 3 µm human) may also have affected the staining.  
Taken together, CLN5 protein shares a common distribution among sheep, human and 
mouse brains. In this study, CLN5 expression in sheep and human brains is concentrated in 
the hippocampal pyramidal cells, Purkinje cells of the cerebellum and pyramidal cells in the 
cortex, and this is also true for the mouse brain (Holmberg et al., 2004).  
4.4.3 Interactions of the CLN5 and CLN6 proteins 
Despite the very different genotypes and cellular localisation of the CLN5 and CLN6 proteins, 
defects in the progressive pathological changes during neurodegeneration and brain atrophy 
indicate that they interact closely in the CNS. An interaction between CLN5 and CLN6 was 
first suggested in a mouse NCL model by Lyly and co-workers (2009), but it has been difficult 
to substantiate, as no useful antibodies were available. 
In these studies, the potential interactions between the two proteins in the CLN5 and CLN6 
ovine models were examined in cultured virally transduced neural cell lines using the specific 
CLN5 or CLN6 antibodies. Results from Western blotting and immunofluorescence studies 
showed that both affected CLN5 and CLN6 cells transduced with LV CLN5 expressed CLN5 in 
vitro (Figure 4.8), indicating that the CLN5 transgene was expressed in these defective cells. 
It also suggested that CLN6 is not the key factor for CLN5 trafficking.  
The further studies compared the effect of viral-mediated co-expression of CLN5 and CLN6 
on affected CLN5 and CLN6 cells. Co-transduction of LV CLN6 with LV CLN5 significantly 
increased CLN5 expressions in the affected CLN5 cells transduced with both viruses 
compared with the cells transduced with LV CLN5 alone (Figure 4.9). These results suggest 
that CLN6 is involved in the correct processing of the CLN5 protein, and that CLN5 expression 
could be up-regulated by viral-mediated co-expression of CLN6 in CLN5 affected cells.  
The amounts of CLN5 protein in affected CLN6 cells appeared to be lower than in controls 
(Figure 4.10), consistent with other studies of CLN6 affected brain tissues from both South 
Hampshire and Merino affected sheep (Mitchell, 2016; Palmer et al., 2017; Russell, 2017; 
Kristina McIntyre, personal communication). Surprisingly there was very little CLN5 
expression in CLN6 affected sheep, and only intermediate staining in heterozygous CLN6 
sheep (Hughes et al., 2014b). Further quantitative PCR studies of brain samples also implied 
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an interaction between CLN5 and CLN6 expression (Palmer et al., 2017). Full length CLN5 
mRNA expression was increased 3-4 fold in CLN6 affected brains at 6-months of age 
compared with normal, thus there are sufficient amounts of CLN5 mRNA but this does not 
result in successful CLN5 expression. 
Co-transduction of LV CLN5 and LV CLN6 restored CLN6 expression in CLN6 affected cells, 
and whilst not statistically significant, the findings merit the case for further work with 
higher replication to test whether the CLN5 and CLN6 proteins and gene expression may be 
cross-regulated. In particular, this could examine whether increased CLN6 expression occurs 
in the affected CLN6 cells transduced with both viruses compared with the cells transduced 
with LV CLN6 alone (Figure 4.11 c), as well as whether co-expression of CLN5 decreases CLN6 
expression in the affected CLN5 cells (Figure 4.11 d). 
Furthermore, the extra bands from the Western blots that migrated slightly slower than 27 
kDa, or an extra band slightly slower than 42 kDa were detected in samples from most of the 
neural cells, but not from the overexpressed cells (Figure 4.11 a and b). The CLN6 proteins 
expressed from overexpressed cells and neural cells may be structurally different and/or 
artificial changing of the apparent band sizes could result from the large amount of samples 
loaded to the gels. 
4.5 Conclusion  
In summary, the newly generated specific CLN5 and CLN6 antibodies confirm that ovine 
CLN5 is localised to the lysosome and that ovine CLN6 is in the ER. The in situ study showed 
that endogenous CLN5 is predominantly present in Purkinje and basket cells of the 
cerebellum and pyramidal neurons in the hippocampus, some reticular cells in thalamus and 
some interneurons in the striatum, frontal and visual cortices, and motor neurons in the 
brain stem.  
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General Discussion 
5.1 Thesis summary  
The neuronal ceroid lipofuscinoses (NCLs, Batten disease) are a group of fatal 
neurodegenerative human lysosomal storage disorders that are caused by mutations in any 
of 13 different genes (Palmer et.al., 2015). Animal models of the human diseases provide 
valuable tools for determining the pathophysiology of disease and for developing effective 
therapeutic treatments (Linterman et al., 2011; Tecedor et al., 2013; Eaton and Wishart, 
2017). Two naturally occurring ovine forms, CLN5 in Borderdale (BD) and CLN6 in South 
Hampshire (SH) sheep, are in well-established flocks (Jolly et al., 2002; Tammen et al., 2006; 
Frugier et al., 2008). Mutations in CLN5 result in the dysfunction of a soluble mannose-6-
phosphate (M6P) tagged lysosomal protein (Holmberg et al., 2004; Sleat et al., 2005, 2006), 
which can be secreted from cells, and taken up by other cells via endocytosis. In contrast, 
CLN6 is considered to be an intracellular endoplasmic reticulum membrane associated 
protein (Gao et al., 2002; Wheeler et al., 2002; Heine et al., 2004). However, the functions of 
these two proteins are still unclear.   
This thesis aimed to look at different cell biology and biochemistry aspects of the ovine CLN5 
and CLN6 proteins, and possible interactions between them. Chapter 2 details the successful 
amplification of the full length ovine CLN5 gene sequence using a two-step PCR and ligation 
strategy with internal overhanging primers (Figure 2.7 and Figure 2.8). This method 
overcomes the difficulties arising from the disjunction in GC/AT ratios between exons 1 and 
2. An interesting finding is that ovine CLN5 exon 1 has an allelic variant, with three amino 
acid differences arising from two polymorphisms and one deletion (Figure 2.4 and Figure 
2.5), however this was not disease-associated. Unlike ovine CLN5, the human (Figure 2.16 
and Figure 2.17) and bovine CLN5 (Figure 2.15) genes do not contain variant sequences in 
their exon 1 region. Both full length ovine CLN5 and CLN6 sequences were cloned into 
expression vectors (e.g. pRUN vector or Gateway cloning vectors) for recombinant protein 
expression in Escherichia coli (E. coli). Unfortunately, all the CLN5 clones containing the 
target inserts showed random nucleotide base changes in the region from exon 2 to 4, most 
of which resulted in changes to two amino acids (Figure 2.10). These changes could arise 
because the ovine CLN5 sequences may be toxic to the host during E. coli replication, which 
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would result in mutated CLN5 sequences being selected instead of normal ones. 
Furthermore, none of the CLN5 and CLN6 clones could be used to express recombinant CLN5 
and CLN6 proteins in E. coli. prokaryotic systems. 
In Chapter 3, lentiviral vectors expressing the full length CLN5 and CLN6 coding sequences 
with or without C-terminal myc tags, under the control of the MND promoter were 
transduced into HEK293FT cells, and recombinant CLN5 and CLN6 proteins were successfully 
generated (Figure 3.1 and Figure 3.5). Adenoviral antibodies against ovine CLN5 and CLN6, 
produced by injection of adenoviral vectors expressing CLN5 and CLN6 proteins into rabbits 
and mice, were shown to recognise ovine CLN5 and CLN6 at high sensitivities. Western 
blotting with the rabbit anti-CLN5 antibodies specifically detected overexpressed ovine CLN5 
at an apparent molecular weight of 60 kDa (Figure 3.5), and a single PNGaseF deglycosylated 
CLN5 product at around 35 kDa (Figure 3.7). Mass spectrometry studies confirmed that 
these antibodies specifically identified the ovine CLN5 protein. All of the tryptic peptides 
identified were consistent with the ovine CLN5 sequence and one of them was unique to 
ovine CLN5 (Figure 3.8). The N-signal sequence from CLN5 exon 1 was not found in the CLN5 
protein fragment of the band recognised by the rabbit anti-CLN5 antibodies. It was likely 
removed during processing through the ER, consistent with other soluble proteins whose 
signal sequences are cleaved when they mature, and consistent with the molecular weight 
from the gel. The deglycosylation study confirmed that CLN5 is a soluble glycosylated 
protein, containing both high-mannose and complex types glycans, allowing it to be 
trafficked to the lysosome mainly via a mannose-6-phosphate (M6P)-dependent pathway as 
well as secreted via exocytosis. There are eight potential N-glycosylation consensus sites 
(Asn – X – Ser/Thr) present in the ovine CLN5 polypeptide and six of them, at positions N180, 
205, 257, 273, 283 and 355, have been confirmed (Figure 3.8). Similarly, the rabbit anti-CLN6 
antibodies specifically detected a band in overexpressed ovine CLN6 at an apparent 
molecular weight of 27 kDa on Western blotting (Figure 3.5). Mass spectroscopy of the 
trypsin digested CLN6 fragments identified included a single fragment unique to ovine CLN6 
(Figure 3.8). 
Chapter 4 details the cellular and regional localisations of ovine CLN5 and CLN6 and the 
interactions between the proteins. Lysosomal localisation of ovine CLN5 was confirmed by 
double-labelling of transfected 293FT LVMNDCLN5 cells with rabbit anti-CLN5 antibodies and 
the lysosomal associated membrane protein, LAMP1 (Figure 4.3). Similarly, the ER 
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intracellular localisation of ovine CLN6 was revealed by co-staining with rabbit anti-CLN6 
antibodies and the ER marker PDI in transfected 293FT LVMNDCLN6 cells (Figure 4.4).  
The anti-CLN5 antibodies detected endogenous CLN5 expression throughout the normal 
sheep brain, most prominently in pyramidal cells of the cerebral cortex, Purkinje and basket 
cells of the cerebellum as well as the hilus, granule cells of the dentate gyrus and the 
pyramidal cells, particularly in the CA3 and CA2 regions of the normal sheep hippocampus 
(Figure 4.5). The ovine CLN5 protein was also found in motor neurons, some reticular cells in 
the thalamus and some interneurons in the striatum, frontal and occipital cortices. 
Furthermore, rabbit anti-CLN5 antibodies also detected CLN5 protein expression in normal 
human brain sections in the hippocampus, cortex and particularly the granule cells, Purkinje 
cell bodies and axons of the human cerebellum (Figure 4.6). The second part of this chapter 
provided evidence for the hypothesis that interactions between CLN5 and CLN6 proteins 
exist, using the rabbit anti-CLN5 and rabbit anti-CLN6 antibodies in cultured and virally 
transduced neural cell lines. Transducing CLN6 affected cells with a CLN5-containing 
lentivirus (LV CLN5) restored CLN5 expression (Figure 4.8), indicating that CLN6 is not a vital 
component of the transport of CLN5. Co-transduction of LV CLN6 and LV CLN5 restored CLN5 
expression in CLN6 affected cells (Figure 4.10), and dramatically increased CLN5 expression 
in affected CLN5 cells transduced with both viruses compared with the cells transduced with 
LV CLN5 alone (Figure 4.9).  
5.2 Overall discussion 
5.2.1 Generation of the full ovine CLN5 
Amplification of GC-rich sequences by PCR has been an irritant for scientists for decades and 
amplification of the full length ovine CLN5 cDNA in one PCR reaction has not yet been 
achieved. Previous studies relied on several pairs of primers which amplified the exons and 
introns separately to produce the ovine CLN5 sequence (Frugier et al, 2008). All mutation 
studies of CLN5 in other species, including humans (Bessa et al., 2006), cattle (Houweling et 
al, 2006), and dogs (Melville et al, 2005), also used several short PCR reactions to produce 
the sequence data. 
These difficulties are caused by the disjunction in GC/AT ratios, with a much higher 
percentage of G/C bases (around 80%) in the ovine CLN5 exon 1 sequence compared with 
exons 2-4 (39%). GC-rich containing DNA sequences are more stable for PCR than sequences 
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with a low GC content; the higher the GC content, the higher the melting point of the DNA. 
The most common approach to overcome this problem is to increase the melting 
temperature, but this results in lower product yields, especially for whole coding sequence 
amplifications, as the Taq enzyme denatures more rapidly after several PCR cycles at higher 
temperature (Jensen et al., 2010). Substitution of dimethyl sulphoxide (DMSO) into PCR 
reaction mix could reduce the annealing temperature, but this also inhibits the Taq enzyme 
(Jurišić et al., 2016). 
In this study, a two-step PCR and ligation strategy was developed to generate full length 
ovine CLN5 (chapter 2). The key was to design pairs of complementary internal overhanging 
primers, which were 38 bp and 34 bp in length (at least 10 base pairs longer than standard 
PCR primers), so as to assist annealing. Each of the primers contained sequences with 
complementary ends of 5’ or 3’ sequences, so that the two separate CLN5 exon 1 and exons 
2-4 amplicons contained complementary sequences at the 3’ end of the exon 1 fragment 
and the 5’ end of the exons 2-4 fragment (Figure 2.7). This resulted in successful 
amplification of the full length coding sequence in the second PCR reaction. Doronina (2012) 
has also suggested increasing primers length by 10 bp as well as moving the primers 20-30 
bp upstream or downstream for better annealing of difficult PCRs with GC rich substrates. 
5.2.2 Failure of prokaryotic systems to express recombinant proteins 
All attempts to express the ovine CLN5 and CLN6 recombinant proteins in prokaryotic 
systems failed, probably because of the toxicity of the target proteins, which may even cause 
bacterial cell death.  
Expression vectors for many membrane proteins, as well as for other toxic proteins, can kill 
the host bacterium (Miroux and Walker, 1996). A modified C43 (DE3) strain was used in this 
study as it has been known to improve the stability of plasmids in cloning and culture during 
the expression of toxic proteins (Miroux and Walker, 1996), but only a few colonies were 
produced on the agar plates, and no recombinant CLN6 proteins was expressed by the 
clones. Similarly, only small amounts of F-ATPase b and c subunits (toxic proteins) were 
expressed using strain C43 (DE3), suggesting that removal of the toxic effects of an 
expression plasmid cannot automatically guarantee that the protein is generated in large 
amounts (Miroux and Walker, 1996). Based on these facts, it may be necessary to remove 
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the unnecessary features in the coding sequence that inhibit translation, or to prevent 
proteolytic degradation (Kane, 1995; Miroux and Walker, 1996).   
Only a few CLN5 clones were produced in E.coli, and all contained mutant CLN5 sequences 
(Figure 2.10), indicating that the highly toxic nature of the CLN5 mRNA inhibited replication 
of any hosts containing normal CLN5 sequences. Instead, only hosts containing mutated 
CLN5 sequences were amplified. As explained above, the CLN5 toxicity may be due to the 
recombinant protein performing an unnecessary function, which interferes with the normal 
proliferation and homeostasis of the host and results in a slower growth rate and cell death 
(Dong et al., 1995).  
In addition, many mammalian proteins are glycosylated, but CLN5 could not be glycosylated 
properly in E. coli, the N-terminal signal sequence not cleaved, and the protein may even be 
incapable of folding correctly without ER processing (Getty and Pearce, 2011). For example, 
a mouse CLN5-cDNA lacking the suggested signal sequence (aa 26-341) and fused with N-
terminal GST tag construct was reportedly able to be expressed in E. coli (Lyly et al., 2009). 
However, the expressed GST-mCLN5 fusion protein was incubated with cultured cells for GST 
pull-down assays, but was not purified and detected by SDS-PAGE via traditional methods. 
Therefore whether or not enough mouse CLN5 was expressed with the correct molecular 
weight is not clear. Expressing a highly modified protein like CLN5 in E. coli does not 
necessarily produce a native CLN5 protein (Getty and Pearce, 2011). 
5.2.3 Adenoviral derived anti-CLN5 and anti-CLN6 antibodies 
Good antibodies are required for many biological analyses and clinical diagnostics. However, 
published research-generated or commercially available antibodies against CLN5 and CLN6 
were not always as reliable as they were reported to be. This is specially so for antibodies 
against ovine CLN5 and CLN6. In the present studies, adenoviral antibodies against ovine 
CLN5 and CLN6, produced by injection of adenoviral vectors expressing CLN5 and CLN6 
proteins into rabbits and mice, were shown to recognise ovine CLN5 and CLN6 at a high 
sensitivity. Generating antibodies using recombinant adenoviral vectors was straightforward. 
It required cloning of the full length CLN5 and CLN6 sequences into an adenoviral plasmid, 
packaging and purification of adenoviral particles and direct injection of the vectors into host 
animals, e.g. rabbits. This technique eliminated the need for purification of the protein 
antigens and re-administration of the antigen to enhance immune responses. 
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5.2.3.1 Adenoviral derived anti-CLN5 antibodies 
Like most soluble lysosomal proteins, ovine CLN5 is N-glycosylated, and most of the 
overexpressed glycosylated CLN5 was secreted into the culture medium (Figure 3.5), 
indicating that it is a soluble protein. This confirmed previous reports of human CLN5 being a 
soluble glycoprotein based on the fact that it is secreted (Isosompppi et al., 2002; Sleat et al., 
2006a; Palmer et al., 2015). Mouse CLN5 has also been identified as a soluble lysosomal 
glycoprotein with prominent homology to human CLN5 (Holmberg et al., 2004). In addition, 
ovine CLN5 contains an N-terminal sequence, which undergoes proteolysis to become the 
mature form (Figure 3.8). Cleavage of the N-terminal signal peptides is also a characteristic 
feature of soluble lysosomal proteins. Therefore, taken together, all of the cross-species 
results imply that CLN5 is a soluble lysosomal glycoprotein, not a transmembrane-spanning 
protein as has been reported before (Savukoski et al., 1998). 
When CLN5 was first discovered in a Finnish variant late infantile NCL, it was predicted to be 
a membrane bound protein, containing two type II transmembrane domains and 
cytoplasmic N and C termini (Savukoski et al., 1998). This later changed to having one 
transmembrane domain with a cytoplasmic N-terminal domain and an amphipathic helix 
(Mole et al., 2005; Larkin et al., 2013). These predictions were based on the results of the 
TMpred transmembrane prediction program. However, studies have shown that most of the 
transmembrane prediction programs perform poorly in distinguishing transmembrane 
proteins from soluble proteins, and the error rate for TMpred was shown to be 55% 
(Isosomppi et al., 2002; Moller et al., 2001). Another group also suggested that human CLN5 
is a type II transmembrane protein (Jule et al., 2015, 2017) and their statements were based 
on the first methionine being the initiator sites of human CLN5. However, the true initiator 
site of human CLN5 has been confirmed as being the third ATG (Frugier et al., 2008). This 
correct initiation site of human CLN5 aligned perfectly with ovine CLN5 sequences and those 
from all the other species (Figure 2.18). 
As mentioned before, the rabbit anti-CLN5 antibodies identified the mature glycosylated 
ovine CLN5 form with a molecular weight of 60 kDa and 35 kDa when unglycosylated by 
PNGase F. These results are consistent with the anticipated mass of the ovine CLN5myc 
protein, recognized by C-myc antibodies (Sleat et al., 2006b; Hughes et al., 2014) and the 
mass of the human CLN5 protein, detected by human CLN5 peptide antibodies (raised 
against aa 393-407) (Schmiedt et al., 2010). Another peptide antibody raised against human 
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CLN5 aa 258–273 also detected a mature protein in a human CLN5 expression study in BHK 
cells, and revealed a 60 kDa CLN5 band and a 38 kDa CLN5 polypeptide after PNGase F 
deglycosylation (Isosomppi 2002). A reported mouse peptide antibody recognized 
overexpressed mouse CLN5, detecting two bands of 48 and 50 kDa from CLN5 transfected 
cells and a reduced 34 kDa band after PNGase F treatment (Holmberg et al., 2004), indicating 
mouse CLN5 is slightly smaller than the CLN5 of sheep and human.  
In contrast, some other reported human CLN5 antibodies, either commercially available or 
raised to include the N-terminal sequence detected protein bands of different molecular 
weights. A monoclonal CLN5 synthetic peptide antibody (abcam, ab170899), raised against 
human CLN5 aa 150-250, identified an endogenous 56 kDa proprotein and a mature form 
(De Silva et al., 2015). However, a search of this 100 aa peptide sequence against the 
universal data base (protein blast software, 
https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins) revealed that it also aligns 100% 
with two unnamed human protein products (NCBI, BAG64918 and BAG52069), so this 
antibody may select pick out proteins other than CLN5. Similarly, commercial polyclonal anti-
CLN5 antibodies (sc-49928, Santa Cruz Biotechnology, Santa Cruz, CA), derived from the 
internal region of human CLN5 at aa 140-220, detected a soluble mature 50 kDa protein 
(Jules et al. 2017). This peptide sequence also aligns 100% with an unnamed human protein 
product (BAG64918), thus these antibodies may also select a different protein indicating that 
they are not specific to CLN5. In addition, an N-terminal peptide antibody (corresponding to 
human CLN5 aa 1-75, Figure 1.1) detected an apparently uncleaved CLN5 proprotein with a 
molecular weight of 47 kDa (Vesa et al., 2002). This is unlikely to be CLN5 because of the 
usage of a CLN5 antibody which started from an incorrect codon. 
5.2.3.2 Adenoviral derived anti-CLN6 antibodies 
The rabbit anti-CLN6 antibodies detected ovine CLN6 from the overexpressed CLN6 cells at a 
molecular weight of 27 kDa on Western blotting, consistent with the anticipated mass of 
human and mouse CLN6 proteins, recognized by a human CLN6 or a mouse CLN6 peptide 
antibodies (Heine et al., 2004, 2007; More et all, 2004). However, CLN6 has also been 
reported to form a homodimer (60 kDa) in cell extracts (Heine et al., 2007), but was found by 
SDS-PAGE of overexpressing cells (Figure 3.5).  
Polyclonal CLN6 synthetic peptide antibodies (Eurogentech, Seraing, Belgium, Germany), 
raised against human CLN6 aa 155-168 and 281-293, revealed a single prominent 
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immunoreactive band of 27 kDa in cell extracts of CLN6 transfected BHK21 cells (Heine et al., 
2004). However, these peptide antibodies are not specific to CLN6 alone, because 
comparison of the two peptide sequences against the universal database revealed that both 
align 100% with the integrin alpha-11 protein of the Chinese hamster (NCBI, EGW04330) and 
also an unnamed human protein product (NCBI, BAG56737.1). In addition, these antibodies 
detected a CLN6 band in both CLN6 affected and control sheep, indicating that they are not 
specific for ovine CLN6 (Dr. Lucy Barry, personal communication).  
Similar results can be seen with another transmembrane NCL protein. Immunoblot 
experiments showed that all available anti-CLN3 antibodies lack specificity, as they detect 
the same protein bands in controls and CLN3 affected mouse tissues, the latter of which 
should not contain CLN3 proteins (Nelson et al., 2017). These data provide evidence that 
immunization against a transmembrane protein with a low to medium expression level does 
not necessarily generate specific antibodies because of the possible cross-reactivity with 
other proteins. Another two polyclonal anti-CLN6 antibodies (Eurogentech, Seraing, Belgium, 
Germany), produced by immunizing rabbits with synthetic polypeptides corresponding to aa 
1-15 and 28-39 of human CLN6, detected a protein band of approximately 30 kDa in HEK293 
cells and human fibroblasts by Western blotting (Mole et al., 2004). Consequently, human 
CLN6 was suggested to form a homodimer with a molecular weight of 60 kDa (Heine et al., 
2004; Mole et al., 2004). However, these peptide antibodies are not specific to CLN6, 
because comparison of the two peptide sequences against the universal database revealed 
that both aligned 100% with an unnamed human protein product (NCBI, BAG55226.1), and 
not with CLN6.  
5.2.4 Lysosomal trafficking of the CLN5 protein 
Western  blotting analysis described in Chapter 3 detected CLN5 bands in both solubilised 
CLN5 overexpressing cells and cell media (Figure 3.2 and Figure 3.5), and the secreted 
glycosylated CLN5 in cell media containing both high-mannose and complex type glycans, 
allowing CLN5 to be trafficked to lysosomes mainly via a mannose-6-phosphate (M6P)-
dependent pathway (Hughes et al., 2014; Sleat et al., 2005, 2007) and to be secreted via 
exocytosis. 
As soon as a CLN5 polypeptide is synthesized in the ER, the N-terminal signal peptide is 
cleaved, and the polypeptide receives oligosaccharide side chains which undergo a series of 
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post-translational modifications for proper folding and trafficking. The study described in 
Chapter 3 found eight N-glycosylation consensus sites (Asn – X – Ser/Thr) are present and 
confirmed that six Asn sites are N-glycosylated, at positions N180, 205, 257, 273, 283 and 
355. Whether or not the other two Asn residues, at positions N132 and 145, are real N-
glycosylation sites and function in CLN5 post-translation modification is still not clear (Figure 
3.8). In vivo studies have determined that all eight human CLN5 Asn residues are utilized for 
N-glycosylation, and seven of eight sites are conserved among mammalian species (Moharir 
et al., 2013; Sleat et al., 2005, 2006, 2007). The five residues on human CLN5, corresponding 
to N132, 205, 257, 273 and 283 of ovine CLN5, are essential for proper protein folding 
(Isosomppi et al., 2002; Lebrun et al., 2009; Moharir et al., 2013). Loss of these N-
glycosylation specific sites on human CLN5 leads to mis-localisation of CLN5 to the Golgi 
membranes. The two residues on human CLN5 corresponding to N145 and 180 of ovine 
CLN5 have been suggested to be crucial for functionality of the CLN5 protein in lysosomes 
(Moharir et al., 2013). The last human CLN5 glycosylation site, corresponding to N355 of 
ovine CLN5, is not present in the mouse protein (Moharir et al., 2013). However, this special 
N355 glycosylation site is essential for lysosomal localisation of human CLN5. Without it, 
CLN5 accumulates in the Golgi and is then secreted into the media. Therefore, the M6P 
modification on N355 is a major determinant marking human CLN5 to the M6P lysosomal 
trafficking pathway and six of the confirmed N-glycosylation sites on ovine CLN5 are likely 
have similar functions to the corresponding sites on human CLN5. 
The properly folded CLN5 is translocated from the ER to the cis- and trans-Golgi complex 
where different types of glycans are generated, containing both high mannose-type and 
complex-type oligosaccharides bound to Asn residues (Figure 1.4 and Figure 5.1). The 
deglycosylation study of secreted ovine CLN5 revealed that both high mannose-type and 
complex-type oligosaccharides of CLN5 are present in both cell media (Figure 3.7) and cells 
(Hughes et al., 2014). These results are in agreement with previous N-deglycosylation studies 
of human and mouse CLN5 (Lyly et al., 2008; Sleat et al., 2005, 2006, 2007). As mentioned 
before, CLN5 contains multiple glycosylation binding sites, some for high mannose-type 
oligosaccharides and some complex-type oligosaccharides.  
Glycosylated CLN5 with high mannose-type sugars, sensitive to Endo H, is trafficked via the 
M6P-dependent pathway (Figure 5.1, indicated in black solid arrows). The glycans are 
phosphorylated to form M6P which bind to M6P receptors, are then sorted and moved on to 
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the late endosome, where the M6P receptors disassociate as the pH reduces from 6.5 to 5.5 
(Beck, 2007).  Next the CLN5 molecules are dephosphorylated and transported to lysosomes, 
while the M6P receptors are recycled to the trans-Golgi network or to the plasma 
membrane (Ghosh et al., 2003). A fraction of phosphorylated CLN5 that misses intracellular 
M6PRs in the Golgi apparatus is enclosed into secreted protein budding vesicles, and 
secreted into the media via exocytosis (Figure 5.1, indicated in black dashed arrows). These 
secreted CLN5 molecules can be taken up into the cells by binding to plasma membrane M6P 
receptors, transported to the early and late endosomes and finally to lysosomes (Futerman 
and van Meer, 2004, Hughes et al., 2014a). 
All CLN5 proteins are likely to contain both Endo H sensitive high mannose and PNGase F 
sensitive complex sugars (Figure 3.9). Transient expression may exceed the capacity of the 
phosphotransferase and oligosaccharides may be processed further to complex forms which 
are resistant to Endo H, but sensitive to PNGase F (Isosomppi et al., 2002). 
5.2.5 The cellular and regional localisations of ovine CLN5 and CLN6 
Evidence for the lysosomal intracellular localisation of ovine CLN5 was obtained by co-
localisation of CLN5 and the lysosomal associated membrane protein LAMP1 in transfected 
293FT LVMNDCLN5 cells (Figure 4.3). This is in the agreement with reports that mouse CLN5 
protein co-localised with LAMP1 and overexpressed human CLN5 protein co-localised to 
lysosomes in transfected cells (Isosomppi et al., 2002; Vesa et al., 2002; Holmberg et al., 
2004; De Silva et al., 2015).  
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Figure 5.1 The predicated trafficking process of CLN5 
The signal peptide is removed from the pre-proform of CLN5 in the ER and high mannose-type residues are 
added. CLN5 is transported to the Golgi apparatus where complex-type sugars are added and some mannose 
residues are phosphorylated at carbon 6. CLN5 is then transported through the early endosome and trafficked 
to lysosomes via the M6P-dependent pathway (indicated by solid black arrows). A small amount of CLN5 
protein also joins the secretory pathway (indicated by solid blue arrows) and is secreted into the media via 
exocytosis. It can be taken up via M6P receptor-mediated endocytosis and transported to the early and late 
endosomes and finally to the lysosomes (indicated by dashed black arrows). 
 
None of the published human or mouse antibodies detected endogenous human CLN5 
(Isosomppi 2002; Holmberg et al., 2004; Schmiedt et al., 2010), however the rabbit anti-
CLN5 antibodies were detected endogenous CLN5 expression throughout the sheep brain. 
The most prominent expression detected in pyramidal cells of the cerebral cortex, Purkinje 
and basket cells of the cerebellum as well as the hilus, granule cells of the dentate gyrus and 
the pyramidal cells of the normal sheep hippocampus, particularly in the CA3 and CA2 
regions (Figure 4.5). In late stage human CLN5 disease, cerebellar Purkinje cells and thalamic 
neurons are nearly all lost, and some cerebral cortical neurons are obliterated (Tyynelä J et 
al., 1997; Kopra et al., 2004). The rabbit anti-CLN5 antibodies also detected CLN5 expression 
in normal human brain sections, in the hippocampus, cortex and cerebellum (Figure 4.6), 
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particularly in the granule cells and Purkinje cell bodies and axons of the human cerebellum 
(Figure 4.6 B). CLN5 immunostaining of the hippocampal pyramidal cells, Purkinje cells of 
cerebellum and pyramidal cells in the cortex in sheep and human brains is similar to that 
recorded in the mouse brain (Holmberg et al., 2004; Fabritius et al., 2014; Minye et al., 
2016). The ovine CLN5 protein was also expressed in some reticular cells in the thalamus and 
some interneurons in the striatum, frontal and visual cortices. Tepper and co-workers (2010) 
also used three GABAergic interneuron markers to co-label CLN5 neurons in the mouse 
striatum. A large amount of CLN5 mRNA was detected in qPCR studies of the normal sheep 
hippocampus, and some in the thalamus, frontal and occipital cortex (Tepper et al., 2010), 
consistent with these observations.  
Evidence for the ER intracellular localisation of ovine CLN6 was revealed by co-staining with 
the rabbit anti-CLN6 antibodies and the ER marker PDI in transfected 293FT LVMNDCLN6 
cells (Figure 4.4), supporting previous suggestions which implied that the CLN6 protein is 
localized to the ER (Mole et al., 2004; Heine et al., 2004; Kurze et al, 2010). Endogenous 
CLN6 expression has been studied by Dr. Nadia Mitchell using the rabbit anti-CLN6 
antibodies on ovine brain tissues for immunohistochemistry. These antibodies detected 
CLN6 throughout the normal sheep brain, predominantly in the hippocampus, 
hypothalamus, cerebral cortex and cerebellum, but this required lower serum dilution than 
that used for CLN5 (Mitchell, 2016). Control CLN6 expression was 10 fold less than CLN5 
expression in qPCR studies of sheep brains suggesting an extremely low level of CLN6 
expression in sheep brains not easily detected by the CLN6 antibodies (Palmer et al., 2017). 
The small amounts of trypsin digested CLN6 peptide fragments in the gel band identified by 
rabbit anti-CLN6 antibodies and detected by mass spectrometry (Chapter 3, Table 3.2 and 
Figure 3.9) fits with this observation. 
5.2.6 Interactions between NCL gene products 
NCL patients with diseases caused by mutations in different genes have similar clinical, 
pathological and biochemical phenotypes. Many NCL proteins are trafficked through the ER-
Golgi network and located in lysosomes, suggesting that they may share common cross-
linked pathways, where different dysfunctions resulted in similar pathologies (Lyly et al., 
2009; Getty and Pearce 2011; Palmer et al., 2015). NCL protein interactions have been 
described in a number of in vitro experiments, which suggest that the mutated growth of 
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patient cell lines were reversed by transfecting functional NCL proteins (Vesa et al., 2002; 
Persaud-Sawin et al., 2007; Lyly et al, 2009).  
    
CLN5, a lysosomal protein, may have a central role. It has been suggested to interact with 
several other NCL proteins in vitro, including PPT1/CLN1, TPP1/CLN2, CLN3, CLN6 and CLN8 
(Vesa et al., 2002; Lyly et al., 2009; von Schantz et al., 2009; Getty and Pearce 2011; Palmer 
et al., 2015). Interactions between CLN5 and CLN2 have been reported to occur after the 
proteins have left the ER (von Schantz, 2009), possibly in lysosomes or late endosomes (Vesa 
et al., 2002). CLN5 and CLN1 were suggested to share the same pathway, from the ER to the 
lysosome, in the CLN5 and CLN1 knockout mice brains (von Schantz et al., 2008; Lyly et al., 
2009). Lyly and the co-workers (2009) found that co-expression of CLN1/PPT1 in cell culture 
could restore CLN5 in the overexpressed COS cells transfected with mutated mouse CLN5. 
Trafficking of CLN3 was partially affected by the simultaneous expression of mutated CLN5, 
possibly suggesting that CLN5 and CLN3 proteins interact in the ER (von Schantz, 2009). CLN5 
and CLN8 have also been suggested to be related (Haddad et al., 2012).  
CLN6, resident in the ER, has been suggested to play a role in protein trafficking pathways 
(Heine et al., 2004), especially in a network involving other NCL associated proteins (Figure 
5.2). An investigation has tested whether mutated ovine CLN6 affected the activity of CLN1, 
CLN2 and CLN10 proteins (Palmer et al., 2015, 2017). This study indicated that the CLN6 
mutation did not disrupt the trafficking of CLN1/PPT1 and CLN2/TPP1 to the lysosome, but 
CLN10/Cathepsin D enzyme activity in lysosomes was decreased.  
Some studies have suggested that CLN5 and CLN6 are likely to interact in the CNS (Lyly et al., 
2009; Warrier et al., 2013). Despite having mutations in different genes and having different 
cellular localisations, the development of clinical and neuropathological disease in CLN5 and 
Figure 5.2 Schema of potential 
NCL protein-protein interactions 
Arrows indicate reported CLN5 
interactions (Lyly et al., 2009; Vesa 
et al., 2002; von Schantz et al., 
2009) and CLN6 interactions (this 
study; Palmer et al., 2015).  
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CLN6 affected sheep is very similar. They both result in the accumulation of lysosome-
derived storage bodies containing large amounts of the c subunit of ATP synthase, retinal 
degeneration, seizures and pre-mature death, and follow a similar time-course. Affected 
sheep brains of both genotypes appear to be normally developed at birth. The masses of 
CLN5 and CLN6 affected sheep brains peak at 4 months of age, falling behind normal 
controls at this stage by 11% and 19% respectively, marking the start of progressive brain 
atrophy (Mitchell, 2016). This similarity is unexpected as the CLN5 and CLN6 genes and 
mutations are different and unrelated. CLN5 disease is caused by an intronic splice-site 
mutation resulting in deletion of exon 3 from the mRNA for a soluble lysosomal protein, 
while CLN6 defects result from a 5’UTR-exon 1 deletion from the gene for an ER membrane 
bound protein.   
Gene therapies provided to small and large animals have shown persistent transgene 
expression (Jarraya et al., 2009; Lattanzi et al., 2010; Palmer et al., 2015). Affected soluble 
lysosomal proteins, such as CLN1, CLN2, CLN5 and CLN10, are considered potentially 
amenable to viral-mediated gene therapy by “cross-correction” when secreted proteins are 
taken up by adjacent or distal protein-deficient cells (Fratantoni et al., 1968). Promising 
results achieved from Western blotting and immunofluorescent studies showed that 
affected CLN5 foetal neural cells transduced with LV CLN5 expressed CLN5 in vitro (see 
Chapter 4, Figure 4.8). This is in agreement with the studies of in vivo AAV/lentiviral 
injections expressing CLN5 into CLN5 affected Borderdate sheep (Mitchell, 2016). Two years 
post-injection, the treated CLN5 affected sheep remained disease-free at 27 months of age, 
with the exception of delayed visual deficits. Compared with untreated animals, they 
benefited from an improvement in the quality of life, preservation of neurological function, 
and normalisation of brain structure and volume. Similarly, in vivo viral injections expressing 
CLN6 into CLN6 affected South Hampshire sheep were studied, but only 1 out of 6 treated 
animals had inhibited NCL neurobehavioural dysfunction and a normal brain structure at 27 
months of age (Mitchell, 2016). The different outcomes to similar treatment by the CLN5 
and CLN6 affected animals is likely due to the differences in the proteins. As mentioned 
before, CLN6 is an intracellular membrane protein that is not secreted like CLN5, and thus is 
unlikely benefit from extracellular cross-correction.  
Co-transduction of LV CLN6 and LV CLN5 restored CLN5 expression in CLN6  affected cells 
(Figure 4.10), and increased CLN5 expression was seen in the CLN5 affected cells transduced 
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with both viruses compared with the cells transduced with LV CLN5 alone (Figure 4.9). These 
results could arise if CLN6 dysfunction caused ER associated protein degradation, therefore 
impeding the system of folding and glycosylation of CLN5 and preventing CLN5 from being 
exported out of the ER, or entering the CLN5 M6P trafficking pathway from the ER to 
lysosomes. Lack of CLN6 could also limit the endocytic pathway returning secreted CLN5 to 
cells, in agreement with the effect on the endocytic pathway of an exogenous protein, 
arylsulfatase A (ASA), in CLN6 affected cells (Heine et al., 2004).  
Other studies are in agreement with these findings. Antibodies specific for the ovine CLN5 
protein revealed very little CLN5 expression in CLN6 affected sheep and only intermediate 
staining in heterozygous CLN6 sheep (Mitchell, 2016). A further quantitative PCR study of 
brain samples revealed that full length CLN5 mRNA expression was upregulated 3-4 fold in 
CLN6 affected brains of both South Hampshire and Merino sheep in previous studies, but 
this does not result in successful CLN5 protein expression (McIntyre, 2014; Palmer et al., 
2017). These results indicate that the CLN5 and CLN6 protein and gene expressions may be 
cross-regulated. If CLN6 is required for the correct processing of the CLN5 protein, then it 
may be that the majority of the CLN5 protein may not reach the lysosome in its fully 
modified and folded mature form in CLN6 affected sheep, thus these CLN5 isoforms cannot 
function, and their related enzyme activity may be greatly reduced, resulting in an induced 
lysosomal CLN5 deficiency disease.  
5.3 Final remarks 
This thesis provided some promising methodology for overcoming the difficulties associated 
with amplification of the full length ovine CLN5 gene sequence, which contains a large 
percentage of G/C bases in the exon 1 region. The studies have established methodology for 
lentiviral-mediated expression of CLN5 and CLN6 proteins in eukaryotic mammalian cells and 
proved the reliability of the generated adenoviral CLN5 and CLN6 antibodies.  
These adenoviral CLN5 and CLN6 antibodies will be useful to further studies of the biological 
function of these two proteins and their trafficking as well. Further work to test the co-
expression of CLN2, CLN3 and CLN5 in CLN6-/- cells, or co-expression of CLN2, CLN3 and CLN6 
in CLN5-/- cells and to investigate whether CLN2 and CLN3 together with CLN5 and CLN6 
could help restore or enhance CLN5 or CLN6 expression in affected cells, should be 
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considered. These studies will increase the possibility for therapies for human CLN5 and 
CLN6 patients. 
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Appendix A 
 
A.1 Primers designed for the ovine CLN5 genomic sequence 
 
 
 
A.2 Ovine CLN5 cloning into the pCR4-TOPO vector 
5.3.1 A.2.1 pCR4-TOPO with the full CLN5 insert (5153bp) 
 Full length CLN5 CDS  (plus 109bp of 3’UTR insert, 1199 bp, red) without myc epitope  
 The PCR product was A-tailed and then inserted between two EcoR I cut sites (underlined) for easy sub-
cloning 
 Start and stop codons in bold  
 Plasmid DNA produced after ligation and confirmed by sequencing 
 
AGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCCGACAGGTTTCCCGA
CTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCCACTCATTAGGCACCCCAGGCTTTACACTTT
ATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGAT
TACGCCAAGCTCAGAATTAACCCTCACTAAAGGGACTAGTCCTGCAGGTTTAAACGAATTCGCCCTT 
CACCATGGCGCAGGCGGGGGGTGCCGGTGCGGGGGCCTGGGGTCGGCGGGGCGCGGGCGCAGGTGCGGGCCCGGA
GCGGGCGCCTTGGCGCTGGGCCCCCGCACTGCTCTGGCTGGCGGCGGCGACGGCGGCGGCGGCGGCGGCGGGCGA
CCCCTCCCGGCGCCAGTGGCCGGTGCCCTACAAACGCTTCTCCTTCCGTCCGGAACCAGATCCTTATTGTCAAGC
TAAATATACTTTCTGTCCCACTGGCTCCCCTATCCCGGTGATGAAGGATGACGATGTCATTGAAGTCTTTCGATT
ACAAGCCCCAGTGTGGGAATTTAAATATGGAGACCTCCTGGGACACTTGAAAATCATGCATGATGCCATTGGATT
CAGGAGTACTTTAACGGAGAAGAACTACACGATGGAATGGTATGAACTCTTCCAACTTGGAAACTGCACGTTTCC
CCATCTCCGACCTGAAATGAATGCCCCTTTCTGGTGTAATCAAGGAGCTGCCTGCTTTTTTGAAGGGATTGATGA
TAATCACTGGAAGGAAAATGGGACGTTAGTTCTAGTAGCAACCATATCAGGAGGCATGTTTAACAAAATGGCAAA
GTGGGTAAAACAGGACAATGAAACAGGGATTTATTATGAGACATGGACTGTCCAAGCCAGCCCGAAAAAGGAGGC
AGAGAAATGGTTTGAATCCTACGACTGCTCCAAATTTGTGTTAAGGACCTATGAGAAATTGGCTGAACTTGGAGC
AGACTTCAAGAAGATAGAAACCAACTATACAAGGATATTTCTTTACAGTGGAGAACCTACTTATCTGGGAAATGA
AACATCTGTTTTTGGGCCAACAGGAAACAAGACTCTTGCTTTAGCTATAAAAAAATTTTATTACCCTTTCAAACC
ACATTTGTCAACTAAAGAATTTCTGTTGAGTCTCTTGCAAATTTTTGATGCAGTGGTTATACACAGAGAGTTCTA
TTTGTTTTATAATTTTGAATATTGGTTTTTACCTATGAAATCCCCTTTTATTAAAATAACATATGAAGAAATCCC
TTTACCTAACAGAAAAAACAGAACACTCTCTGGTTTATAAAACCTTAATTCTACTGCTTTTCTTTCTACCAGCAC
ATCAGTTTTTCAGGGAGTGGTTTTACAAGTGTGGGATTTCTTAGGCCTTTCTTCCTTGGGGCAGAAAGCTAACA 
AAGGGCGAATTCGCGGCCGCTAAATTCAATTCGCCCTATAGTGAGTCGTATTACAATTCACTGGCCGTCGTTTTA
CAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGG
CGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTATACGTACGGCAGTTTAAGGTT
TACACCTATAAAAGAGAGAGCCGTTATCGTCTGTTTGTGGATGTACAGAGTGATATTATTGACACGCCGGGGCGA
CGGATGGTGATCCCCCTGGCCAGTGCACGTCTGCTGTCAGATAAAGTCTCCCGTGAACTTTACCCGGTGGTGCAT
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ATCGGGGATGAAAGCTGGCGCATGATGACCACCGATATGGCCAGTGTGCCGGTCTCCGTTATCGGGGAAGAAGTG
GCTGATCTCAGCCACCGCGAAAATGACATCAAAAACGCCATTAACCTGATGTTCTGGGGAATATAAATGTCAGGC
ATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTCACGTAGAAAGCCAGTCCGCAGAAACGGTGCTGACCC
CGGATGAATGTCAGCTACTGGGCTATCTGGACAAGGGAAAACGCAAGCGCAAAGAGAAAGCAGGTAGCTTGCAGT
GGGCTTACATGGCGATAGCTAGACTGGGCGGTTTTATGGACAGCAAGCGAACCGGAATTGCCAGCTGGGGCGCCC
TCTGGTAAGGTTGGGAAGCCCTGCAAAGTAAACTGGATGGCTTTCTTGCCGCCAAGGATCTGATGGCGCAGGGGA
TCAAGCTCTGATCAAGAGACAGGATGAGGATCGTTTCGCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCG
GCCGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTC
CGGCTGTCAGCGCAGGGGCGCCCGGTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAAGAC
GAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAAGCG
GGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAA
GTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGCG
AAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGAGCAT
CAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGAGCATGCCCGACGGCGAGGATCTCGTCGTGACC
CATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTGGCCGGCTG
GGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCT
GACCGCTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAG
TTCTTCTGAATTATTAACGCTTACAATTTCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACAC
CGCATCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATAT
GTATCCGCTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAAT
CTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTG
TCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGG
CCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGG
AAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAG
AGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTC
GTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAA
AGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGC
AGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTC
ATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAG
CAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAG
ATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTG
AGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTT
CCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTT
CCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTG
CTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAA
GGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAA
GAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTC
GTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTG
CACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCAC
GCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCT
TCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTG
ATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTG
GCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGC
TGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAG 
 
 
5.3.2 A.2.2 pCR4-TOPO with the full CLN5myc insert (5074bp) 
 Full length CLN5 CDS (minus the CLN5 stop codon) with myc epitope and new stop codon (1120 bp) 
 The PCR product was A-tailed and then inserted between two EcoR I cut sites (underlined) for easy sub-
cloning 
 Start and stop codons in bold and the two restriction enzymes underlined 
 Plasmid DNA produced after ligation and confirmed by sequencing: 
 
AGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCCGACAGGTTTCCCGA
CTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCCACTCATTAGGCACCCCAGGCTTTACACTTT
ATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGAT
TACGCCAAGCTCAGAATTAACCCTCACTAAAGGGACTAGTCCTGCAGGTTTAAACGAATTCGCCCTT 
CACCATGGCGCAGGCGGGGGGTGCCGGTGCGGGGGCCTGGGGTCGGCGGGGCGCGGGCGCAGGTGCGGGCCCGGA
GCGGGCGCCTTGGCGCTGGGCCCCCGCACTGCTCTGGCTGGCGGCGGCGACGGCGGCGGCGGCGGCGGCGGGCGA
 140 
CCCCTCCCGGCGCCAGTGGCCGGTGCCCTACAAACGCTTCTCCTTCCGTCCGGAACCAGATCCTTATTGTCAAGC
TAAATATACTTTCTGTCCCACTGGCTCCCCTATCCCGGTGATGAAGGATGACGATGTCATTGAAGTCTTTCGATT
ACAAGCCCCAGTGTGGGAATTTAAATATGGAGACCTCCTGGGACACTTGAAAATCATGCATGATGCCATTGGATT
CAGGAGTACTTTAACGGAGAAGAACTACACGATGGAATGGTATGAACTCTTCCAACTTGGAAACTGCACGTTTCC
CCATCTCCGACCTGAAATGAATGCCCCTTTCTGGTGTAATCAAGGAGCTGCCTGCTTTTTTGAAGGGATTGATGA
TAATCACTGGAAGGAAAATGGGACGTTAGTTCTAGTAGCAACCATATCAGGAGGCATGTTTAACAAAATGGCAAA
GTGGGTAAAACAGGACAATGAAACAGGGATTTATTATGAGACATGGACTGTCCAAGCCAGCCCGAAAAAGGAGGC
AGAGAAATGGTTTGAATCCTACGACTGCTCCAAATTTGTGTTAAGGACCTATGAGAAATTGGCTGAACTTGGAGC
AGACTTCAAGAAGATAGAAACCAACTATACAAGGATATTTCTTTACAGTGGAGAACCTACTTATCTGGGAAATGA
AACATCTGTTTTTGGGCCAACAGGAAACAAGACTCTTGCTTTAGCTATAAAAAAATTTTATTACCCTTTCAAACC
ACATTTGTCAACTAAAGAATTTCTGTTGAGTCTCTTGCAAATTTTTGATGCAGTGGTTATACACAGAGAGTTCTA
TTTGTTTTATAATTTTGAATATTGGTTTTTACCTATGAAATCCCCTTTTATTAAAATAACATATGAAGAAATCCC
TTTACCTAACAGAAAAAACAGAACACTCTCTGGTTTAGAACAAAAACTCATCTCAGAAGAGGATCTGTGA 
AAGGGCGAATTCGCGGCCGCTAAATTCAATTCGCCCTATAGTGAGTCGTATTACAATTCACTGGCCGTCGTTTTA
CAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGG
CGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTATACGTACGGCAGTTTAAGGTT
TACACCTATAAAAGAGAGAGCCGTTATCGTCTGTTTGTGGATGTACAGAGTGATATTATTGACACGCCGGGGCGA
CGGATGGTGATCCCCCTGGCCAGTGCACGTCTGCTGTCAGATAAAGTCTCCCGTGAACTTTACCCGGTGGTGCAT
ATCGGGGATGAAAGCTGGCGCATGATGACCACCGATATGGCCAGTGTGCCGGTCTCCGTTATCGGGGAAGAAGTG
GCTGATCTCAGCCACCGCGAAAATGACATCAAAAACGCCATTAACCTGATGTTCTGGGGAATATAAATGTCAGGC
ATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTCACGTAGAAAGCCAGTCCGCAGAAACGGTGCTGACCC
CGGATGAATGTCAGCTACTGGGCTATCTGGACAAGGGAAAACGCAAGCGCAAAGAGAAAGCAGGTAGCTTGCAGT
GGGCTTACATGGCGATAGCTAGACTGGGCGGTTTTATGGACAGCAAGCGAACCGGAATTGCCAGCTGGGGCGCCC
TCTGGTAAGGTTGGGAAGCCCTGCAAAGTAAACTGGATGGCTTTCTTGCCGCCAAGGATCTGATGGCGCAGGGGA
TCAAGCTCTGATCAAGAGACAGGATGAGGATCGTTTCGCATGATTGAACAAGATGGATTGCACGCAGGTTCTCCG
GCCGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTC
CGGCTGTCAGCGCAGGGGCGCCCGGTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAAGAC
GAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAAGCG
GGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAA
GTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGCG
AAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGAGCAT
CAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGAGCATGCCCGACGGCGAGGATCTCGTCGTGACC
CATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTGGCCGGCTG
GGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCT
GACCGCTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAG
TTCTTCTGAATTATTAACGCTTACAATTTCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACAC
CGCATCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATAT
GTATCCGCTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAAT
CTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTG
TCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGG
CCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGG
AAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAG
AGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTC
GTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAA
AGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGC
AGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTC
ATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAG
CAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAG
ATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTG
AGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTT
CCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTT
CCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTG
CTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAA
GGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAA
GAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTC
GTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTG
CACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCAC
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GCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCT
TCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTG
ATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTG
GCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGC
TGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAG 
 
 
A.3 Expression of ovine CLN5 and CLN6 recombinant proteins  
5.3.3 A.3.1 Attempted expression of CLN5 and CLN6 proteins with pRUN 
vectors 
 
5.3.4 A.3.2 Attempted expression of CLN5 peptides by the Gateway system 
 
  
 
 
SDS-PAGE gel analysis of recombinant 
(a) CLN5 and (b) CLN6. Each protein 
sample, 30 μg, was run on 12% 
polyacrylamide gels which were 
stained with Commassie blue. C43 
(DE3) cells containing CLN5 or CLN6 
protein expression constructs 
pRUNCLN5his exons 2-4 and 
pRUNCLN6his were grown at 37°C and 
then induced with 0.5 mM or 1 mM 
IPTG and incubated at 25°C, 30°C or 
37°C for 5.5 h. The samples for analysis 
were collected just before the 
induction and 5.5 h post-induction 
incubation. CLN5 soluble fractions and 
CLN6 insoluble fractions for collected 
samples were analysed. MW refers to 
Precision plus protein standard. 
 
LDS-PAGE gel analysis of 
recombinant CLN5 polypeptides. 
30 μg, was run on a 15% 
polyacrylamide gel. C43 (DE3) cells 
containing CLN5 protein expression 
constructs pDEST17 CLN5151-207 and 
pDEST17 CLN5656-717 were grown at 
37°C, induced with 1 mM IPTG, 
incubated at 37°C for 5 h. The 
samples for analysis were collected 
just before the induction, 2 h and 
5.5 h post-induction incubation.  
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A.4 Immunocytochemical optimisation CLN5 and CLN6 antibodies 
generated from adenoviral vectors 
 
293FT LVMNDCLN5 and LVMNDCLN6 cells were fixed at a confluence of 70% and labelled with (i) rabbit anti-
CLN5 (red, RαCLN5), (ii) rabbit anti-CLN6 (red, RαCLN6), (i) mouse anti-CLN5 (green, MαCLN5), and (iv) rabbit 
anti-CLN6 (green, MαCLN6) primary antibodies at concentrations of 1:500 and 1:1000. The scale bar represents 
200 µM. 
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